US20230381292A1 - Vaccines Comprising Mycobacterium Leprae Polypeptides for the Prevention, Treatment, and Diagnosis of Leprosy - Google Patents
Vaccines Comprising Mycobacterium Leprae Polypeptides for the Prevention, Treatment, and Diagnosis of Leprosy Download PDFInfo
- Publication number
- US20230381292A1 US20230381292A1 US18/190,934 US202318190934A US2023381292A1 US 20230381292 A1 US20230381292 A1 US 20230381292A1 US 202318190934 A US202318190934 A US 202318190934A US 2023381292 A1 US2023381292 A1 US 2023381292A1
- Authority
- US
- United States
- Prior art keywords
- leprae
- mammal
- mycobacterium
- polypeptide
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 361
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 350
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 349
- 241000186362 Mycobacterium leprae Species 0.000 title claims abstract description 260
- 206010024229 Leprosy Diseases 0.000 title abstract description 59
- 229960005486 vaccine Drugs 0.000 title description 31
- 238000011282 treatment Methods 0.000 title description 18
- 238000003745 diagnosis Methods 0.000 title description 3
- 230000002265 prevention Effects 0.000 title description 3
- 239000000427 antigen Substances 0.000 claims abstract description 205
- 102000036639 antigens Human genes 0.000 claims abstract description 205
- 108091007433 antigens Proteins 0.000 claims abstract description 205
- 238000000034 method Methods 0.000 claims abstract description 134
- 239000000203 mixture Substances 0.000 claims abstract description 114
- 230000004927 fusion Effects 0.000 claims description 176
- 241000124008 Mammalia Species 0.000 claims description 95
- 208000015181 infectious disease Diseases 0.000 claims description 57
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 43
- 230000028993 immune response Effects 0.000 claims description 27
- 230000003308 immunostimulating effect Effects 0.000 claims description 23
- 239000012472 biological sample Substances 0.000 claims description 21
- 241000282414 Homo sapiens Species 0.000 claims description 18
- 229960001438 immunostimulant agent Drugs 0.000 claims description 17
- 239000003022 immunostimulating agent Substances 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 16
- 229940127089 cytotoxic agent Drugs 0.000 claims description 16
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims description 15
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims description 14
- 238000002512 chemotherapy Methods 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 7
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 6
- 229960001225 rifampicin Drugs 0.000 claims description 6
- ZLHZLMOSPGACSZ-NSHDSACASA-N (6s)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O([C@H]1CN2C=C(N=C2OC1)[N+](=O)[O-])CC1=CC=C(OC(F)(F)F)C=C1 ZLHZLMOSPGACSZ-NSHDSACASA-N 0.000 claims description 4
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 4
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 4
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 4
- 229960004287 clofazimine Drugs 0.000 claims description 4
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 4
- 229960000860 dapsone Drugs 0.000 claims description 4
- 229960003923 gatifloxacin Drugs 0.000 claims description 4
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 4
- 229960003907 linezolid Drugs 0.000 claims description 4
- 229960004023 minocycline Drugs 0.000 claims description 4
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 4
- 229960001699 ofloxacin Drugs 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 abstract description 62
- 102000040430 polynucleotide Human genes 0.000 abstract description 62
- 239000002157 polynucleotide Substances 0.000 abstract description 62
- 108090000623 proteins and genes Proteins 0.000 description 183
- 102000004169 proteins and genes Human genes 0.000 description 167
- 235000018102 proteins Nutrition 0.000 description 164
- 235000001014 amino acid Nutrition 0.000 description 73
- 229940024606 amino acid Drugs 0.000 description 71
- 150000001413 amino acids Chemical class 0.000 description 71
- 210000004027 cell Anatomy 0.000 description 68
- 230000002163 immunogen Effects 0.000 description 54
- 241000187488 Mycobacterium sp. Species 0.000 description 48
- 230000003053 immunization Effects 0.000 description 48
- 238000002649 immunization Methods 0.000 description 47
- 239000002671 adjuvant Substances 0.000 description 46
- 230000028327 secretion Effects 0.000 description 35
- UPAZUDUZKTYFBG-HNPUZVNISA-N azane [(2S,3R,4R,5S,6R)-2,5-dihydroxy-6-[[(2R,3R,4R,5S,6R)-6-(hydroxymethyl)-5-phosphonooxy-3-[[(3R)-3-tetradecanoyloxytetradecanoyl]amino]-4-[(3R)-3-tetradecanoyloxytetradecanoyl]oxyoxan-2-yl]oxymethyl]-3-[[(3R)-3-hydroxytetradecanoyl]amino]oxan-4-yl] (3R)-3-hydroxytetradecanoate Chemical compound [NH4+].CCCCCCCCCCCCCC(=O)O[C@H](CCCCCCCCCCC)CC(=O)N[C@H]1[C@H](OC[C@H]2O[C@H](O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]2O)O[C@H](CO)[C@@H](OP(O)([O-])=O)[C@@H]1OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC UPAZUDUZKTYFBG-HNPUZVNISA-N 0.000 description 34
- 239000000523 sample Substances 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 31
- 239000012634 fragment Substances 0.000 description 31
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 30
- 230000004044 response Effects 0.000 description 29
- 102000004127 Cytokines Human genes 0.000 description 28
- 108090000695 Cytokines Proteins 0.000 description 28
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 description 27
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 description 27
- 210000001744 T-lymphocyte Anatomy 0.000 description 27
- 238000003556 assay Methods 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 description 26
- 239000003153 chemical reaction reagent Substances 0.000 description 24
- 241000289632 Dasypodidae Species 0.000 description 23
- OPGTXAUDXWCGFI-UHFFFAOYSA-N [1-[[6-[[3-(3-dodecanoyloxytetradecanoylamino)-6-(hydroxymethyl)-5-phosphonooxy-4-(3-tetradecanoyloxytetradecanoyloxy)oxan-2-yl]oxymethyl]-2,4,5-trihydroxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] hexadecanoate Chemical compound OC1C(O)C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(O)OC1COC1C(NC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)C(OC(=O)CC(CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(OP(O)(O)=O)C(CO)O1 OPGTXAUDXWCGFI-UHFFFAOYSA-N 0.000 description 23
- 238000001514 detection method Methods 0.000 description 23
- 108020001507 fusion proteins Proteins 0.000 description 22
- 102000037865 fusion proteins Human genes 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- 108091034117 Oligonucleotide Proteins 0.000 description 19
- 230000001580 bacterial effect Effects 0.000 description 19
- 239000013604 expression vector Substances 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 18
- -1 ML2380 Proteins 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 18
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 18
- 239000013598 vector Substances 0.000 description 18
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 16
- 238000007792 addition Methods 0.000 description 16
- 125000006853 reporter group Chemical group 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 15
- 101710088335 Diacylglycerol acyltransferase/mycolyltransferase Ag85A Proteins 0.000 description 15
- 102000002689 Toll-like receptor Human genes 0.000 description 15
- 108020000411 Toll-like receptor Proteins 0.000 description 15
- 230000000890 antigenic effect Effects 0.000 description 15
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 14
- 241000186359 Mycobacterium Species 0.000 description 14
- 229960003767 alanine Drugs 0.000 description 14
- 235000004279 alanine Nutrition 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
- 230000027455 binding Effects 0.000 description 13
- 241000304886 Bacilli Species 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 12
- 239000000556 agonist Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 150000007523 nucleic acids Chemical group 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000006735 deficit Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 230000014616 translation Effects 0.000 description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 9
- 102000013462 Interleukin-12 Human genes 0.000 description 9
- 108010065805 Interleukin-12 Proteins 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000005847 immunogenicity Effects 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 9
- 208000015521 paucibacillary leprosy Diseases 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000013519 translation Methods 0.000 description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 208000015305 multibacillary leprosy Diseases 0.000 description 8
- 210000005036 nerve Anatomy 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 238000013389 whole blood assay Methods 0.000 description 8
- 125000006538 C11 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 101710180814 ESAT-6-like protein EsxH Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 description 7
- 101150080488 apa gene Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 230000002459 sustained effect Effects 0.000 description 7
- 201000008827 tuberculosis Diseases 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- 206010024227 Lepromatous leprosy Diseases 0.000 description 6
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 6
- 208000028389 Nerve injury Diseases 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000007830 nerve conduction Effects 0.000 description 6
- 230000008764 nerve damage Effects 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 206010040882 skin lesion Diseases 0.000 description 6
- 231100000444 skin lesion Toxicity 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 210000004989 spleen cell Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 5
- 238000009007 Diagnostic Kit Methods 0.000 description 5
- 102000005720 Glutathione transferase Human genes 0.000 description 5
- 108010070675 Glutathione transferase Proteins 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 230000024932 T cell mediated immunity Effects 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 235000009582 asparagine Nutrition 0.000 description 5
- 238000002820 assay format Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 201000006382 tuberculoid leprosy Diseases 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 4
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 241000187474 Mycobacterium asiaticum Species 0.000 description 4
- 241001312372 Mycobacterium canettii Species 0.000 description 4
- 241001147828 Mycobacterium haemophilum Species 0.000 description 4
- 241000178382 Mycobacterium lepromatosis Species 0.000 description 4
- 241000187492 Mycobacterium marinum Species 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 230000003292 diminished effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229940117681 interleukin-12 Drugs 0.000 description 4
- 229940028885 interleukin-4 Drugs 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 4
- 239000007764 o/w emulsion Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101710102499 Alanine and proline-rich secreted protein Apa Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000289661 Dasypus novemcinctus Species 0.000 description 3
- 101710180803 ESAT-6-like protein EsxR Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000419175 Mycobacterium colombiense Species 0.000 description 3
- 241000187484 Mycobacterium gordonae Species 0.000 description 3
- 241000187490 Mycobacterium scrofulaceum Species 0.000 description 3
- 241001414632 Mycobacterium ulcerans Agy99 Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 101710182846 Polyhedrin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 229940124613 TLR 7/8 agonist Drugs 0.000 description 3
- 241000723873 Tobacco mosaic virus Species 0.000 description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 3
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 3
- 241000255985 Trichoplusia Species 0.000 description 3
- 206010054094 Tumour necrosis Diseases 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical group [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000008073 immune recognition Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 230000019734 interleukin-12 production Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003970 toll like receptor agonist Substances 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- FHJATBIERQTCTN-UHFFFAOYSA-N 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC=CC2=C(N(C(CNCC)=N3)CC(C)(C)O)C3=C(N)N=C21 FHJATBIERQTCTN-UHFFFAOYSA-N 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 108700023418 Amidases Proteins 0.000 description 2
- 239000004254 Ammonium phosphate Substances 0.000 description 2
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010065839 Capreomycin Proteins 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 2
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 108010040721 Flagellin Proteins 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 101150046735 LEPR gene Proteins 0.000 description 2
- 101150063827 LEPROT gene Proteins 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- 241001467553 Mycobacterium africanum Species 0.000 description 2
- 241000186367 Mycobacterium avium Species 0.000 description 2
- 241000400730 Mycobacterium bohemicum DSM 44277 Species 0.000 description 2
- 241000186366 Mycobacterium bovis Species 0.000 description 2
- 241000187485 Mycobacterium gastri Species 0.000 description 2
- 241000187910 Mycobacterium gilvum Species 0.000 description 2
- 241001467535 Mycobacterium interjectum Species 0.000 description 2
- 241001166087 Mycobacterium iranicum Species 0.000 description 2
- 241000186363 Mycobacterium kansasii Species 0.000 description 2
- 241000557009 Mycobacterium mucogenicum Species 0.000 description 2
- 241001013798 Mycobacterium nebraskense Species 0.000 description 2
- 241000187496 Mycobacterium szulgai Species 0.000 description 2
- 241001646722 Mycobacterium tuberculosis CDC1551 Species 0.000 description 2
- 241000297783 Mycobacterium ulcerans subsp. shinshuense Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 229930189077 Rifamycin Natural products 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 2
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229940024545 aluminum hydroxide Drugs 0.000 description 2
- 102000005922 amidase Human genes 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960004909 aminosalicylic acid Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229960000106 biosimilars Drugs 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000006386 borderline leprosy Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960004602 capreomycin Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- QUWFSKKBMDKAHK-SBOJBMMISA-A chembl2103793 Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 QUWFSKKBMDKAHK-SBOJBMMISA-A 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 229960003077 cycloserine Drugs 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229940011399 escin Drugs 0.000 description 2
- 229960000285 ethambutol Drugs 0.000 description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 2
- 229960002001 ethionamide Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 229940124307 fluoroquinolone Drugs 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229940124670 gardiquimod Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229960002751 imiquimod Drugs 0.000 description 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000012125 lateral flow test Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 208000037837 multi-bacillary leprosy Diseases 0.000 description 2
- 231100000878 neurological injury Toxicity 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960005206 pyrazinamide Drugs 0.000 description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 229950010550 resiquimod Drugs 0.000 description 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229960000885 rifabutin Drugs 0.000 description 2
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 2
- 229940081192 rifamycins Drugs 0.000 description 2
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 2
- 229960002599 rifapentine Drugs 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940038774 squalene oil Drugs 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000006433 tumor necrosis factor production Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- FBFJOZZTIXSPPR-UHFFFAOYSA-N 1-(4-aminobutyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCCCN)C3=C(N)N=C21 FBFJOZZTIXSPPR-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZRENMMRSMYBZRN-UHFFFAOYSA-N 2-(2H-quinolin-1-yl)ethanol hydrate Chemical compound O.N1(CC=CC2=CC=CC=C12)CCO ZRENMMRSMYBZRN-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- PCLFEHAPITXKJL-UHFFFAOYSA-N 5,8-dihydroxy-2-[2-(4-methoxyphenyl)ethyl]chromen-4-one Chemical compound C1=CC(OC)=CC=C1CCC1=CC(=O)C2=C(O)C=CC(O)=C2O1 PCLFEHAPITXKJL-UHFFFAOYSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 241000272478 Aquila Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- 235000015493 Chenopodium quinoa Nutrition 0.000 description 1
- 239000005496 Chlorsulfuron Substances 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 101710177832 Co-chaperonin GroES Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- CEXINUGNTZFNRY-BYPYZUCNSA-N Gly-Cys-Gly Chemical compound [NH3+]CC(=O)N[C@@H](CS)C(=O)NCC([O-])=O CEXINUGNTZFNRY-BYPYZUCNSA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241001316290 Gypsophila Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229940124872 Hepatitis B virus vaccine Drugs 0.000 description 1
- 101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
- 241000204795 Muraena helena Species 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 241001318887 Mycobacterium aromaticivorans Species 0.000 description 1
- 241000187473 Mycobacterium aurum Species 0.000 description 1
- 241001532520 Mycobacterium austroafricanum Species 0.000 description 1
- 241001002976 Mycobacterium avium 104 Species 0.000 description 1
- 241000513886 Mycobacterium avium complex (MAC) Species 0.000 description 1
- 241001134667 Mycobacterium celatum Species 0.000 description 1
- 241001524108 Mycobacterium chlorophenolicum Species 0.000 description 1
- 241000187913 Mycobacterium chubuense Species 0.000 description 1
- 241000252261 Mycobacterium europaeum Species 0.000 description 1
- 241001509451 Mycobacterium genavense Species 0.000 description 1
- 241000142650 Mycobacterium heckeshornense Species 0.000 description 1
- 241000673373 Mycobacterium heraklionense Species 0.000 description 1
- 241001494992 Mycobacterium indicus pranii Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000982191 Mycobacterium kansasii 662 Species 0.000 description 1
- 241000272747 Mycobacterium kyorinense Species 0.000 description 1
- 241000035554 Mycobacterium liflandii Species 0.000 description 1
- 241000755466 Mycobacterium llatzerense Species 0.000 description 1
- 241000187469 Mycobacterium neoaurum Species 0.000 description 1
- 241001318886 Mycobacterium rufum Species 0.000 description 1
- 241000187489 Mycobacterium simiae Species 0.000 description 1
- 241000383305 Mycobacterium sinense Species 0.000 description 1
- 241000164881 Mycobacterium sp. djl-10 Species 0.000 description 1
- 241000218972 Mycobacterium triplex Species 0.000 description 1
- 241000772736 Mycobacterium tuberculosis GuangZ0019 Species 0.000 description 1
- 241000959055 Mycobacterium tuberculosis SUMu010 Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 241000187644 Mycobacterium vaccae Species 0.000 description 1
- 241000142559 Mycobacterium vanbaalenii Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 description 1
- KTHDTJVBEPMMGL-UHFFFAOYSA-N N-acetyl-L-alanine Natural products OC(=O)C(C)NC(C)=O KTHDTJVBEPMMGL-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000026681 Paratuberculosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 241000508269 Psidium Species 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 229940124614 TLR 8 agonist Drugs 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YGPZYYDTPXVBRA-RTDBHSBRSA-N [(2r,3s,4r,5r,6s)-2-[[(2r,3r,4r,5s,6r)-3-[[(3r)-3-dodecanoyloxytetradecanoyl]amino]-6-(hydroxymethyl)-5-phosphonooxy-4-[(3r)-3-tetradecanoyloxytetradecanoyl]oxyoxan-2-yl]oxymethyl]-3,6-dihydroxy-5-[[(3r)-3-hydroxytetradecanoyl]amino]oxan-4-yl] (3r)-3-hydr Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](O)O1 YGPZYYDTPXVBRA-RTDBHSBRSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000009118 appropriate response Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- VJYIFXVZLXQVHO-UHFFFAOYSA-N chlorsulfuron Chemical compound COC1=NC(C)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)Cl)=N1 VJYIFXVZLXQVHO-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229930186222 escin Natural products 0.000 description 1
- 101150069551 esxH gene Proteins 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 101150113423 hisD gene Proteins 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 231100000191 repeated dose toxicity Toxicity 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 101150081616 trpB gene Proteins 0.000 description 1
- 101150111232 trpB-1 gene Proteins 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- QAOHCFGKCWTBGC-QHOAOGIMSA-N wybutosine Chemical compound C1=NC=2C(=O)N3C(CC[C@H](NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O QAOHCFGKCWTBGC-QHOAOGIMSA-N 0.000 description 1
- QAOHCFGKCWTBGC-UHFFFAOYSA-N wybutosine Natural products C1=NC=2C(=O)N3C(CCC(NC(=O)OC)C(=O)OC)=C(C)N=C3N(C)C=2N1C1OC(CO)C(O)C1O QAOHCFGKCWTBGC-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
- 229910052725 zinc Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/464817—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present disclosure relates generally to compositions and methods for preventing, treating and detecting leprosy in patients. More particularly, the disclosure relates to compositions and methods comprising Mycobacterium leprae antigens and fusion polypeptides, as well as polynucleotides encoding such antigens and fusion polypeptides.
- Leprosy (Hansen's disease) is an infectious peripheral neurological disorder caused by Mycobacterium leprae . Nerve involvement in leprosy patients can present as sensory and/or motor neuron damage and can advance to cause disability and disfigurement. Nerve damage likely involves a complicated interplay of both host immunity and mycobacterial infection-mediated events (1, 2). Although bacterial cure can be achieved by multidrug therapy (MDT), which the World Health Organization (WHO) provides free of charge for registered leprosy patients, leprosy remains as a public health problem in many regions. Declines in global incidence prompted by the introduction of MDT and drive toward ‘elimination’ as a global health problem by the year 2000 have now levelled off. More worryingly, it is widely believed that a large number of cases go unreported (Smith, 2015 #4604). Recent new case incidence rates indicate that transmission continues and the disease is slowly re-emerging in many regions that previously reported elimination.
- MDT multidrug therapy
- WHO World Health Organization
- a vaccine By promoting a lasting adaptive immune response, a vaccine, unlike drug treatment, has the potential to provide active and sustained protection.
- the current standard—and only administered-vaccine against M. leprae is the BCG vaccine, originally developed for use in tuberculosis.
- the persistence of leprosy in countries where BCG is implemented suggests its effectiveness is limited. (Goulart I M, Clin Vaccine Immunol 2008; 15(1): 101-5.)
- the degree of protection afforded by BCG against leprosy has varied dramatically between studies. Systematic meta-analyses indicate that BCG has a wide-ranging protective efficacy with an average around 50% and protection appears to be better against the MB than PB forms.
- M. leprae itself as an immunogen has been assessed in various trials, often to see if it can add to the protective effect of BCG.
- Large-scale studies in Venezuela, Malawi and India testing the use of killed M. leprae in combination with BCG have been largely inconclusive, with wide discrepancies in results. (Convit J et al., Lancet 1992; 339(8791): 446-50; Karonga Prevention Trial Group, Lancet 1996; 348(9019): 17-24)
- production of a vaccine using killed M. leprae would be enormously constrained by the difficulties associated with mass production.
- compositions and vaccines that can effectively prevent, treat and/or diagnose leprosy in humans and other mammals.
- present disclosure fulfills these needs and offers other related advantages.
- compositions, kits and methods for preventing, treating and detecting leprosy are provided.
- compositions comprising at least two Mycobacterium leprae ( M. leprae ) antigens selected from the group consisting of ML2028, ML2055, and ML2380, or at least two M. leprae antigens each having at least 90% amino acid sequence identity to ML2028, ML2055, or ML2380.
- the composition comprises ML2028 and ML2055; or an M. leprae antigen having at least 90% amino acid identity to ML2028 and an M. leprae antigen having at least 90% amino acid identity to ML2055.
- the composition comprises ML2028 and ML2380; or an M.
- the composition comprises ML2055 and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2055 and an M. leprae antigen having at least 90% amino acid identity to ML2380.
- the composition comprises ML2028, ML2055, and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2028, an M. leprae antigen having at least 90% amino acid identity to ML2055, and an M. leprae antigen having at least 90% amino acid identity to ML2380.
- the composition further comprises ML2531 or a M. leprae antigen having at least 90% amino acid sequence identity to ML2531.
- the disclosure provides fusion polypeptides comprising at least two Mycobacterium leprae ( M. leprae ) antigens selected from the group consisting of ML2028, ML2055, and ML2380, or at least two M. leprae antigens each having at least 90% amino acid sequence identity to ML2028, ML2055, or ML2380.
- M. leprae Mycobacterium leprae
- the fusion polypeptide comprises ML2028 and ML2055; or an M. leprae antigen having at least 90% amino acid identity to ML2028 and an M. leprae antigen having at least 90% amino acid identity to ML2055.
- the fusion polypeptide comprises ML2028 and ML2380; or an M.
- the fusion polypeptide comprises ML2055 and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2055 and an M. leprae antigen having at least 90% amino acid identity to ML2380.
- the fusion polypeptide comprises ML2028, ML2055, and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2028, an M. leprae antigen having at least 90% amino acid identity to ML2055, and an M.
- the fusion polypeptide further comprises M. leprae antigen ML2531. In some embodiments, the fusion polypeptide comprises the sequence of SEQ ID NO: 12, or a sequence having 90% sequence identity thereto.
- the disclosure provides isolated polynucleotides encoding the fusion polypeptides of the disclosure.
- compositions comprising a fusion polypeptide of the disclosure.
- ML2028 comprises the sequence of SEQ ID NO: 2. In some embodiments, ML2028 comprises the sequence of SEQ ID NO: 4. In some embodiments, ML2055 comprises the sequence of SEQ ID NO: 6. In some embodiments, ML2380 comprises the sequence of SEQ ID NO: 8. In some embodiments, ML2531 comprises the sequence of SEQ ID NO: 10.
- the composition further includes an immunostimulant.
- the immunostimulant is selected from the group consisting of a CpG-containing oligonucleotide, synthetic lipid A, MPLTM, 3D-MPLTM, saponins, saponin mimetics, AGPs, Toll-like receptor agonists, or a combination thereof.
- the immunostimulant is selected from the group consisting of a TLR4 agonist, a TLR7/8 agonist and a TLR9 agonist.
- the immunostimulant is selected from the group consisting of GLA, CpG-containing oligonucleotide, imiquimod, gardiquimod and resiquimod.
- the immunostimulant is GLA, having the following structure:
- R 1 , R 3 , R 5 and R 6 are C 11 -C 20 alkyl; and R 2 and R 4 are C 9 -C 20 alkyl.
- R 1 , R 3 , R 5 and W 6 are C 11-14 alkyl; and R 2 and R 4 are C 12-15 alkyl.
- R 1 , R 3 , W 5 and W 6 are C 11 alkyl; and R 2 and W 4 are C 13 alkyl.
- R 1 , R 3 , R 5 and R 6 are C 11 alkyl; and R 2 and R 14 are C 9 alkyl.
- the immunostimulant has the following structure:
- the immunostimulant has the following structure:
- the disclosure provides methods for stimulating an immune response against M. leprae in a mammal comprising administering to a mammal in need thereof a composition of the disclosure.
- the method further comprises administering to the mammal M. bovis BCG vaccine.
- M. bovis BCG vaccine was previously administered to the mammal.
- the mammal has not been exposed to M. leprae .
- the mammal has been exposed to M. leprae .
- the mammal is a human healthy household contact of a human identified as being infected with M. leprae .
- the mammal has been infected by M. leprae .
- the mammal exhibits signs or symptoms of infection by M. leprae.
- the disclosure provides methods for stimulating an immune response against a tuberculosis-causing mycobacterium in a mammal comprising administering to a mammal in need thereof a composition of the disclosure.
- the disclosure provides methods for treating an M. leprae infection in a mammal, the method comprising administering to a mammal having an M. leprae infection a composition of the disclosure.
- the method further comprises administering to the mammal one or more chemotherapeutic agents.
- the one or more chemotherapeutic agents comprise one or more agents selected from the group consisting of dapsone, rifampicin, clofazimine, ofloxacin, minocycline, gatifloxacin, linezolid, and PA 824.
- the mammal is first administered one or more chemotherapeutic agents over a period of time and subsequently administered the composition.
- the mammal is first administered the composition and subsequently administered one or more chemotherapeutic agents over a period of time. In some embodiments, administration of the one or more chemotherapeutic agents and the composition is concurrent. In some embodiments, the method further comprises administering the composition to the mammal one or more subsequent times. In some embodiments, the method further comprises administering to the mammal M. bovis BCG vaccine. In some embodiments, M. bovis BCG vaccine was previously administered to the mammal. In some embodiments, the mammal does not exhibit signs or symptoms of infection by M. leprae . In some embodiments, the mammal has indeterminate or tuberculoid presentation. In some embodiments, the mammal has paucibacillary leprosy.
- the mammal has multibacillary leprosy. In some embodiments, the mammal has lepromatous leprosy. In some embodiments, the mammal has borderline lepromatous leprosy. In some embodiments, the mammal has mid-borderline leprosy. In some embodiments, the mammal has borderline tuberculoid leprosy. In some embodiments, the mammal has tuberculoid leprosy. In some embodiments, the mammal is infected with a multidrug resistant M. leprae.
- the disclosure provides methods for reducing the time course of chemotherapy against an M. leprae infection, the method comprising administering to a mammal having an M. leprae infection a composition of the disclosure in conjunction with the chemotherapy, where the composition induces an immune response against M. leprae , thereby providing for a reduced time course of the chemotherapy against an M. leprae infection.
- the time course of chemotherapy is shortened to no more than about 3 months, about 5 months, or about 7 months.
- the mammal is a human.
- the disclosure provides a method for detecting M. leprae infection in a biological sample, comprising: (a) contacting a biological sample with a polypeptide (including a fusion polypeptide) as described herein; and (b) detecting in the biological sample the presence of antibodies that bind to the fusion polypeptide, thereby detecting M. leprae infection in a biological sample.
- a polypeptide including a fusion polypeptide
- Any suitable biological sample type may be analyzed by the method, illustrative examples of which may include, for example, sera, blood, saliva, skin, and nasal secretion.
- the polypeptide (including a fusion polypeptide) is bound to a solid support. Accordingly, the present disclosure further provides diagnostic reagents comprising a polypeptide (including a fusion polypeptide) as described herein, immobilized on a solid support.
- kits for detecting M. leprae infection in a biological sample are also provided, generally comprising a polypeptide (including a fusion polypeptide) as described herein and a detection reagent.
- the kit may employ a polypeptide (including a fusion polypeptide) of the disclosure in any of a variety of assay formats known in the art, including, for example, a lateral flow test strip assay, a dual path platform (DPP) assay and an ELISA assay.
- DPP dual path platform
- kits and compositions of the disclosure can offer valuable point of care diagnostic information.
- the kits and compositions can also be advantageously used as test-of-cure kits for monitoring the status of infection in an infected individual over time and/or in response to treatment.
- Treatment kits for treating an M. leprae infection in a mammal are also provided, generally comprising a composition of the disclosure.
- FIG. 1 A shows the antigens, ML2028, ML2055 and ML2380, administered individually compared to the sham treatment and heat-killed M. leprae .
- FIG. 1 B shows the results of administering the antigens in combination.
- FIG. 1 C shows the negative results from immunization with the antigens ML0276 and ML46F.
- FIG. 2 Immunological recognition of each component is retained in chimeric fusion protein ML89. Mice were injected s.c. with antigens/GLA-SE at biweekly intervals, for a total of 3 immunizations. Serum and spleens were collected one month after the third immunization.
- antigen-specific serum IgG, IgG1 and IgG2a titers in response to ML89 immunization were determined by ELISA for ML89 ( FIG. 2 A ), ML2028 ( FIG. 2 B ), ML2055 ( FIG. 2 C ), and ML2380 ( FIG. 2 D ).
- FIG. 3 Prior BCG priming does not alter the induction of anti- M. leprae responses by ML89 immunization.
- ML89 FIG. 3 A
- BCG lysate FIG. 3 B
- PPD purified protein derivative
- FIG. 5 Immunization with ML89/GLA-SE delays M. leprae -induced nerve damage.
- FIG. 5 A shows that untreated armadillos demonstrated early onset of defects, while onset in ML89-immunized armadillos was comparatively delayed.
- FIG. 5 B shows that ML89-immunized armadillos had lower incidence of sustained nerve conduction defects, whereas BCG-immunized armadillos developed more rapid onset of severe damage relative to both control and ML-89 treated animals.
- FIG. 5 C shows the proportion of animals displaying normal, borderline, and abnormal nerve conduction in control, BCG, and LepVax-treated armadillos.
- SEQ ID NO: 1 is a nucleic acid sequence encoding the ML2028 antigen polypeptide of SEQ ID NO: 2.
- SEQ ID NO: 2 is an amino acid sequence of Mycobacterium leprae ML2028 antigen (diacylglycerol acyltransferase; NCBI Reference Sequence: WP_010908679.1).
- SEQ ID NO: 3 is a nucleic acid sequence encoding the ML202839-327 polypeptide of SEQ ID NO: 4.
- SEQ ID NO: 4 is an amino acid sequence of the mature chain without signal sequence of ML2028 antigen from Mycobacterium leprae (ML202839-327).
- SEQ ID NO: 5 is a nucleic acid sequence encoding the ML2055 antigen polypeptide of SEQ ID NO: 6.
- SEQ ID NO: 6 is an amino acid sequence of ML2055 antigen from Mycobacterium leprae (alanine and proline-rich secreted protein Apa; NCBI Reference Sequence: WP_010908692.1).
- SEQ ID NO: 7 is a nucleic acid sequence encoding the ML2380 antigen polypeptide of SEQ ID NO: 8.
- SEQ ID NO: 8 is an amino acid sequence of ML2380 antigen from Mycobacterium leprae (hypothetical protein; NCBI Reference Sequence: WP_010908863.1).
- SEQ ID NO: 9 is a nucleic acid sequence encoding the ML2531 antigen polypeptide of SEQ ID NO: 10.
- SEQ ID NO: 10 is an amino acid sequence of ML2531 antigen from Mycobacterium leprae (ESAT-6-like protein EsxR: NCBI Reference Sequence: WP_010908945.1).
- SEQ ID NO: 11 is a nucleic acid sequence encoding the LEP-F1 fusion polypeptide of SEQ ID NO: 12.
- SEQ ID NO: 12 is an amino acid sequence of the LEP-F1 fusion polypeptide.
- compositions of the disclosure include, for example, polypeptides including fusion polypeptides that comprise various immunogenic portions of Mycobacterium leprae ( M. leprae ) proteins, wherein the portions and variants preferably retain substantially the same or similar immunogenic properties as a corresponding full length M. leprae protein.
- Immunization strategies using compositions of the disclosure can be applied to the in vivo protection against, for example, infection by M. leprae , which is the causative agent of leprosy in humans and armadillos.
- the present disclosure also contemplates, in other embodiments, using the polypeptides including fusion polypeptides described herein in methods of treating mammals having an M. leprae infection.
- the present disclosure also contemplates, in other embodiments, using the polypeptides including fusion polypeptides described herein in diagnostic applications, including, but not limited to, diagnosis and whole blood assays, preferably in a format amenable to providing rapid, point of care diagnostic results, such as a lateral flow assay or a dual path platform assay.
- the present disclosure provides M. leprae antigens, as described herein, including fusion polypeptides and compositions containing the same.
- the disclosure provides compositions comprising at least two Mycobacterium leprae ( M. leprae ) antigens selected from the group consisting of ML2028, ML2055, and ML2380, or at least two M. leprae antigens each having at least 90% amino acid sequence identity to ML2028, ML2055, or ML2380.
- the composition comprises ML2028 and ML2055; or an M. leprae antigen having at least 90% amino acid identity to ML2028 and an M. leprae antigen having at least 90% amino acid identity to ML2055.
- the composition comprises ML2028 and ML2380; or an M.
- the composition comprises ML2055 and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2055 and an M. leprae antigen having at least 90% amino acid identity to ML2380.
- the composition comprises ML2028, ML2055, and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2028, an M. leprae antigen having at least 90% amino acid identity to ML2055, and an M. leprae antigen having at least 90% amino acid identity to ML2380.
- the composition further comprises ML2531 or an M. leprae antigen having at least 90% amino acid sequence identity to ML2531.
- the disclosure provides fusion polypeptides comprising at least two Mycobacterium leprae ( M. leprae ) antigens selected from the group consisting of ML2028, ML2055, and ML2380, or at least two M. leprae antigens each having at least 90% amino acid sequence identity to ML2028, ML2055, or ML2380.
- M. leprae Mycobacterium leprae
- the fusion polypeptide comprises ML2028 and ML2055; or an M. leprae antigen having at least 90% amino acid identity to ML2028 and an M. leprae antigen having at least 90% amino acid identity to ML2055.
- the fusion polypeptide comprises ML2028 and ML2380; or an M.
- the fusion polypeptide comprises ML2055 and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2055 and an M. leprae antigen having at least 90% amino acid identity to ML2380.
- the fusion polypeptide comprises ML2028. ML2055, and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2028, an M. leprae antigen having at least 90% amino acid identity to ML2055, and an M.
- the fusion polypeptide further comprises M. leprae antigen ML2531. In some embodiments, the fusion polypeptide comprises the sequence of SEQ ID NO: 12, or a sequence having 90% sequence identity thereto.
- compositions comprising antigens and fusion polypeptides described herein can generate an immune response or an effective immune response to M. leprae .
- the immune response may have one or more of the following characteristics: 1) a reduction in bacterial burden in immunized hosts upon challenge with an M. leprae infection; 2) secretion of IFN ⁇ in vitro spleen cell cultures from mice immunized with the compositions of the disclosure upon incubation with the matched fusion polypeptide or individual antigens of the fusion polypeptide; 3) IFN ⁇ secretion in vitro spleen cell cultures from mice immunized with the compositions of the disclosure following incubation with crude M.
- Th1 cells for example CD4 T cells that produce multiple cytokines indicative of a Th1 phenotype such as the combined production of IFN ⁇ , TNF and IL-2 or IFN ⁇ and TNF; or 5) improvement or enhancement of the immune recognition of one or more antigen(s), when presented in the context of a fusion polypeptide, as measured for example by the secretion of cytokines such ⁇ IFN, or the titer of presence of antibodies or cellular responses to the antigen.
- Methods for testing one or more of the above immune responses are known in the art and are described in detail in Examples.
- Different M. leprae antigens in the fusion polypeptides may be arranged in the fusion polypeptide in any order.
- any particular polypeptide of the fusion polypeptide may be located towards the C-terminal end of the fusion polypeptide or the N-terminal end of the polypeptide or in the center of the fusion polypeptide ⁇ i.e., located in between at least two other polypeptides in the fusion polypeptide).
- Different M. leprae antigens may be linked by a linker sequence of any length (e.g., 2-20 amino acids).
- the fusion polypeptide consists of four M. leprae antigens: ML2531 (ESAT-6-like protein EsxR), ML2380 (hypothetical protein), ML2055 (cell surface protein associated with virulence), and ML202839-327 (antigen 85B, mature chain without signal sequence).
- ML2531 ESAT-6-like protein EsxR
- ML2380 hyperthetical protein
- ML2055 cell surface protein associated with virulence
- ML202839-327 antigen 85B, mature chain without signal sequence.
- the full native sequence of ML2531, ML2380, ML2055 are present, while ML202839-327 represents the mature chain without the signal sequence residues 1 through 38.
- the resulting 831 amino acid fusion protein has a predicted molecular weight of 89,062 Da.
- the polynucleotide sequence encoding the fusion polypeptide is SEQ ID NO: 11, and the amino acid sequence of the fusion polypeptide is SEQ ID NO: 12.
- Such fusion polypeptide may be referred to as LEP-F1, ML89, or LepVax.
- a schematic of one embodiment of the fusion polypeptide is below.
- polypeptide or “protein” encompasses amino acid chains of any length, including full length proteins, wherein the amino acid residues are linked by covalent bonds.
- An antigen is a polypeptide comprising an immunogenic portion of a M. leprae polypeptide or protein and may consist solely of an immunogenic portion, may contain two or more immunogenic portions and/or may contain additional sequences. The additional sequences may be derived from a native M. leprae polypeptide or protein or may be heterologous, and such heterologous sequences may (but need not) be immunogenic.
- isolated polypeptide is one that is removed from its original environment.
- a naturally-occurring protein is isolated if it is separated from some or all of the coexisting materials in the natural system.
- polypeptides are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99% pure.
- antigenic polypeptide fragments could also be obtained from those already available in the art.
- Polypeptides of the disclosure, antigenic/immunogenic fragments thereof, and other variants may be prepared using conventional recombinant and/or synthetic techniques.
- the M. leprae antigens used in a fusion polypeptide of the present disclosure can be full length, substantially full length polypeptides, or variants thereof as described herein.
- a fusion polypeptide or composition of the disclosure can comprise or consist of immunogenic portions or fragments of a full length M. leprae polypeptide, or variants thereof.
- an immunogenic portion of a M. leprae polypeptide is a portion that is capable of eliciting an immune response (i.e., cellular and/or humoral) in a presently or previously M. leprae -infected patient (such as a human or a mammal (e.g., an armadillo)) and/or in cultures of spleen cells, lymph node cells or peripheral blood mononuclear cells (PBMC) isolated from presently or previously M. leprae -infected individuals.
- an immune response i.e., cellular and/or humoral
- a presently or previously M. leprae -infected patient such as a human or a mammal (e.g., an armadillo)
- PBMC peripheral blood mononuclear cells
- the cells in which a response is elicited may comprise a mixture of cell types or may contain isolated component cells (including, but not limited to, T-cells, NK cells, macrophages, monocytes and/or B cells).
- immunogenic portions of a fusion polypeptide of the disclosure are capable of inducing T-cell proliferation and/or a predominantly Th1-type cytokine response (e.g., IL-2, IFN- ⁇ , and/or TNF ⁇ production by T-cells and/or NK cells, and/or IL-12 production by monocytes, macrophages and/or B cells).
- Immunogenic portions of the polypeptides described herein may generally be identified using techniques known to those of ordinary skill in the art, including the representative methods summarized in Paul, Fundamental Immunology, 5th ed., Lippincott Williams & Wilkins, 2003 and references cited therein. Such techniques include screening fusion polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T cell lines or clones.
- antisera and antibodies are “antigen-specific” if they specifically bind to an antigen (i.e., they react with the protein in an immunoassay, and do not react detectably with unrelated proteins).
- antisera and antibodies may be prepared as described herein and using well-known techniques.
- Immunogenic portions of an M. leprae polypeptide can be essentially any length; provided they retain one or more of the immunogenic regions that are responsible for or contribute to the in vivo protection provided against leprosy by one or more antigens of fusion polypeptides of the disclosure, as disclosed herein.
- the ability of an immunogenic portion to react with antigen-specific antisera may be enhanced or unchanged, relative to the native protein, or may be diminished by less than 50%, and preferably less than 20%, relative to the native protein.
- Illustrative portions will generally be at least 10, 15, 25, 50, 150, 200, 250, 300, or 350 amino acids in length, or more, up to and including full length M. leprae polypeptide.
- a M. leprae antigen described herein includes ML2028, ML2055, ML2380, and ML2531. In some embodiments, these M. leprae antigens include any naturally occurring variants.
- composition of the disclosure may also comprise one or more polypeptides that are immunologically reactive with T cells and/or antibodies generated against a polypeptide of the disclosure, particularly a polypeptide having an amino acid sequence disclosed herein, or to an immunogenic fragment or variant thereof.
- the polypeptide is a fusion polypeptide, as described herein.
- fusion polypeptides generally comprise at least an immunogenic portion or variant of the M. leprae polypeptides described herein.
- preferred immunogenic portions will be identified that have a level of immunogenic activity greater than that of the corresponding full-length polypeptide, e.g., having greater than about 100% or 150% or more immunogenic activity.
- the immunogenicity of the fill-length fusion polypeptide will have additive, or greater than additive immunogenicity contributed by of each of the antigenic/immunogenic portions contained therein.
- fusion polypeptides of the present disclosure may contain multiple copies of polypeptide fragments, repeats of polypeptide fragments, or multimeric polypeptide fragments, including antigenic/immunogenic fragments, such as M. leprae polypeptides comprising at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more contiguous fragments of aM leprae polypeptide, in any order, and including all lengths of a polypeptide composition set forth herein, or those encoded by a polynucleotide sequence set forth herein.
- antigenic/immunogenic fragments such as M. leprae polypeptides comprising at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more contiguous fragments of aM leprae polypeptide, in any order, and including all lengths of a polypeptide composition set forth herein, or those encoded by a polynucleotide sequence set forth herein.
- the ML2028 antigen comprises the sequence of SEQ ID NO: 2 or SEQ ID NO: 4, or a sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) to SEQ ID NO: 2 or to SEQ ID NO: 4.
- the ML2055 antigen comprises the sequence of SEQ ID NO: 6, or a sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) to SEQ ID NO: 6.
- the ML2380 antigen comprises the sequence of SEQ ID NO: 8, or a sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) to SEQ ID NO: 8.
- the ML2531 antigen comprises the sequence of SEQ ID NO: 10, or a sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) to SEQ ID NO: 10.
- the disclosure provides a fusion polypeptide comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO: 12, or a sequence having at least 90% identity thereto (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto).
- the present disclosure provides fusion polypeptides comprising one or more variants of the M. leprae antigens described herein.
- Polypeptide variants generally encompassed by the present disclosure will typically exhibit at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more identity (determined as described below), along its length, to a polypeptide sequence set forth herein.
- a polypeptide “variant,” includes polypeptides that differ from a native protein in one or more substitutions, deletions, additions and/or insertions, such that the desired immunogenicity of the variant polypeptide is not substantially diminished relative to a native polypeptide.
- certain variants of the disclosure include polypeptides of the disclosure that have been modified to replace one or more cysteine residues with alternative residues.
- Such polypeptides are referred to hereinafter as cysteine-modified polypeptides or cysteine-modified fusion polypeptides.
- the modified polypeptides retain substantially the same or similar immunogenic properties as the corresponding unmodified polypeptides.
- cysteine residues are replaced with serine residues because of the similarity in the spatial arrangement of their respective side chains.
- any amino acid that is incapable of interchain or intrachain disulfide bond formation can be used as a replacement for cysteine.
- the resulting cysteine-modified variant may be less prone to aggregation and thus easier to purify, more homogeneous, and/or obtainable in higher yields following purification.
- the ability of a variant to react with antigen-specific antisera may be enhanced or unchanged, relative to the native protein, or may be diminished by less than 50%, and preferably less than 20%, relative to a corresponding native or control polypeptide.
- a variant of an M. leprae polypeptide is one capable of providing protection against M. leprae infection.
- a fusion polypeptide of the present disclosure comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 or more substitutions, deletions, additions and/or insertions within a M. leprae polypeptide, where the fusion polypeptide is capable of providing protection against an M. leprae infection.
- a fusion polypeptide of the present disclosure comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 or more substitutions, deletions, additions and/or insertions within a M. leprae polypeptide, where the fusion polypeptide is capable of serodiagnosis of M. leprae.
- a variant will contain conservative substitutions.
- a “conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged.
- modifications may be made in the structure of the polynucleotides and polypeptides of the present disclosure and still obtain a functional molecule that encodes a variant or derivative polypeptide with desirable characteristics, e.g., with immunogenic characteristics.
- amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences which encode said peptides without appreciable loss of their biological utility or activity.
- the hydropathic index of amino acids may be considered.
- the importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982, incorporated herein by reference). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like.
- Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics (Kyte and Doolittle, 1982).
- hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 ⁇ 1); glutamate (+3.0 ⁇ 1) serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine ( ⁇ 0.4); proline ( ⁇ 0.5 ⁇ 1); alanine ( ⁇ 0.5); histidine ( ⁇ 0.5); cysteine ( ⁇ 1.0); methionine ( ⁇ 1.3); valine ( ⁇ 1.5); leucine ( ⁇ 1.8); isoleucine ( ⁇ 1.8); tyrosine ( ⁇ 2.3); phenylalanine ( ⁇ 2.5); tryptophan ( ⁇ 3.4).
- an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein.
- substitution of amino acids whose hydrophilicity values are within ⁇ 2 is preferred, those within ⁇ 1 are particularly preferred, and those within ⁇ 0.5 are even more particularly preferred.
- amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like.
- Exemplary substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.
- Amino acid substitutions may further be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues.
- negatively charged amino acids include aspartic acid and glutamic acid
- positively charged amino acids include lysine and arginine
- amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine: glycine and alanine: asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine.
- variant polypeptides differ from a native sequence by substitution, deletion or addition of five amino acids or fewer.
- Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydropathic nature of the polypeptide.
- polypeptides may comprise a signal (or leader) sequence at the N-terminal end of the protein, which co-translationally or post-translationally directs transfer of the protein.
- the polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-Histidine tag (6XHis), GST, MBP, TAP/TAG, FLAG epitope, MYC epitope, V5 epitope, VSV-G epitope, etc.), or to enhance binding of the polypeptide to a solid support.
- a polypeptide may be conjugated to an immunoglobulin Fc region.
- two sequences are said to be “identical” if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity.
- a “comparison window” as used herein refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.
- Alignment of sequences for comparison may be conducted using, for example, the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters.
- This program embodies several alignment schemes described in the following references: Dayhoff, M. O. (1978) A model of evolutionary change in proteins—Matrices for detecting distant relationships. In Dayhoff, M. O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358: Hein J. (1990) Unified Approach to Alignment and Phylogenes pp. 626-′′645 Methods in Enzymology vol.
- alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) Add. APL. Math 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) J. MoL Biol. 48:443, by the search for similarity methods of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.
- BLAST and BLAST 2.0 are described in Altschul et al. (1977) Nucl. Acids Res. 25:3389-3402 and Altschul ct al. (1990) J. Mol. Biol. 215:403-410, respectively.
- BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the disclosure.
- Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
- cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always ⁇ 0).
- M forward score for a pair of matching residues; always >0
- N penalty score for mismatching residues; always ⁇ 0
- a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
- the BLAST algorithm parameters W. T and X determine the sensitivity and speed of the alignment.
- the “percentage of sequence identity” is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences.
- additions or deletions i.e., gaps
- the percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size) and multiplying the results by 100 to yield the percentage of sequence identity.
- the present disclosure encompasses polynucleotide and polypeptide sequences having substantial identity to the sequences disclosed herein, for example those comprising at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence identity compared to a polynucleotide or polypeptide sequence of this disclosure (e.g., as set out in SEQ ID NOs: 1-12) using the methods described herein, (e.g., BLAST analysis using standard parameters, as described below).
- fusion polypeptides of the present disclosure may comprise at least 2, at least 3, or at least 4 or more antigenic/immunogenic portions or fragments of a polypeptide comprising at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence identity to a M. leprae polypeptide that is capable of providing protection against M. leprae infection, or serodiagnosis of M. leprae.
- fusion polypeptides comprise at least an immunogenic portion of a polypeptide and further comprise a heterologous fusion partner, as well as polynucleotides encoding such fusion polypeptides.
- a fusion polypeptide comprises one or more immunogenic portions or fragments of a M. leprae polypeptide and one or more additional immunogenic M. leprae sequences, which are joined via a peptide linkage into a single amino acid chain.
- a fusion polypeptide may comprise multiple M. leprae antigenic portions.
- at least one of the portions in the fusion polypeptide is from ML2028, ML2055, or ML2380.
- an immunogenic portion is a portion of an antigen that reacts with blood samples from M. leprae -infected individuals (i.e. an epitope is specifically bound by one or more antibodies and/or T-cells present in such blood samples.
- a fusion polypeptide may further comprise at least one heterologous fusion partner having a sequence that assists in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or that assists in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein.
- an immunological fusion partner preferably T helper epitopes recognized by humans, or that assists in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein.
- Certain preferred fusion partners include both immunological and expression-enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the protein or to enable the protein to be targeted to desired intracellular compartments.
- Still further fusion partners include affinity tags, such as V5, 6XHIS, MYC, FLAG, and GST, which facilitate purification of the protein.
- an immunological fusion partner comprises an amino acid sequence derived from the protein known as LYTA, or a portion thereof (preferably a C-terminal portion).
- LYTA is derived from Streptococcus pneumoniae , which synthesizes an N-acetyl-L-alanine amidase known as amidase LYTA (encoded by the LytA gene; Gene 43:265-292 (1986)).
- LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone.
- the C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of E. coli C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (see Biotechnology 10:795-798 (1992)). Within a particular embodiment, a repeat portion of LYTA may be incorporated into a fusion protein. A repeat portion is found in the C-terminal region starting at residue 178. A more particular repeat portion incorporates residues 188-305.
- Fusion sequences may be joined directly (i.e., with no intervening amino acids) or may be joined by way of a linker sequence (e.g., Gly-Cys-Gly) that does not significantly diminish the immunogenic properties of the component polypeptides.
- the polypeptides forming the fusion protein are typically linked C-terminus to N-terminus, although they can also be linked C-terminus to C-terminus, N-terminus to N-terminus, or N-terminus to C-terminus.
- the polypeptides of the fusion protein can be in any order. Fusion polypeptides or fusion proteins can also include conservatively modified variants, polymorphic variants, alleles, mutants, subsequences, interspecies homologs, and immunogenic fragments of the antigens that make up the fusion protein.
- Fusion polypeptides may generally be prepared using standard techniques, including recombinant technology, chemical conjugation and the like. For example, DNA sequences encoding the polypeptide components of a fusion may be assembled separately, and ligated into an appropriate expression vector. The 3′ end of the DNA sequence encoding one polypeptide component is ligated, with or without a peptide linker, to the 5′ end of a DNA sequence encoding the second polypeptide component so that the reading frames of the sequences are in frame. This permits translation into a single fusion polypeptide that retains or in some cases exceeds the biological activity of the component polypeptides.
- a peptide linker sequence may be employed to separate the fusion components by a distance sufficient to ensure that each polypeptide folds into its desired secondary and/or tertiary structures.
- Such a peptide linker sequence may be incorporated into the fusion polypeptide using standard techniques well known in the art.
- Suitable peptide linker sequences may be chosen, for example, based on one or more of the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes.
- Certain preferred peptide linker sequences contain Gly. Asn and Ser residues.
- linker sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258-8262, 1986; U.S. Pat. Nos. 4,935,233 and 4,751,180.
- the linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.
- the ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements.
- the regulatory elements responsible for expression of DNA are located only 5′ to the DNA sequence encoding the first polypeptides.
- stop codons required to end translation and transcription termination signals are only present 3′ to the DNA sequence encoding the second polypeptide.
- M. leprae polypeptides, immunogenic portions, variants and fusions thereof may be generated by synthetic or recombinant means.
- Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids may be generated using techniques well known to those of ordinary skill in the art.
- such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain (Merrifield, J. Am. Chem. Soc. 85:2149-2146, 1963).
- Recombinant polypeptides containing portions and/or variants of a native M. leprae polypeptide may be readily prepared from a DNA sequence encoding the antigen, using well known and established techniques.
- a fusion polypeptide comprising M. leprae antigens may be readily prepared from a DNA sequence encoding the cloned fused antigens.
- supematants from suitable host/vector systems which secrete recombinant protein into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix, a size exclusion chromatography matrix or an ion exchange resin.
- any of a variety of expression vectors known to those of ordinary skill in the art may be employed to express recombinant polypeptides of this disclosure.
- Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a polynucleotide that encodes a recombinant polypeptide.
- the host cells are E. coli , yeast, an insect cell line (such as Spodoptera or Trichoplusia ) or a mammalian cell line, including (but not limited to) CHO, COS, HEK-293T and NS-1.
- the DNA sequences expressed in this manner may encode naturally occurring proteins, and fusion proteins comprising M.
- Expressed fusion polypeptides of this disclosure are generally isolated in substantially pure form.
- the fusion polypeptides are isolated to a purity of at least 80% by weight, more preferably, to a purity of at least 95% by weight, and most preferably to a purity of at least 99% by weight.
- purification may be achieved using, for example, the standard techniques of ammonium sulfate fractionation. SDS-PAGE electrophoresis, and affinity chromatography.
- the polypeptides or fusion polypeptides produced as described above are preferably immunogenic.
- the polypeptides (or immunogenic portions thereof) are capable of eliciting an immune response in cultures of lymph node cells and/or peripheral blood mononuclear cells (PBMC) isolated from presently or previously M. leprae —infected individuals.
- PBMC peripheral blood mononuclear cells
- the antigens, and immunogenic portions thereof have the ability to induce T-cell proliferation and/or to elicit a dominantly Th1-type cytokine response (e.g., IL-2, IFN- ⁇ , and/or TNF- ⁇ production by T-cells and/or NK cells; and/or IL-12 production by monocytes, macrophages and/or B cells) in cells isolated from presently or previously M. leprae -infected individuals.
- a dominantly Th1-type cytokine response e.g., IL-2, IFN- ⁇ , and/or TNF- ⁇ production by T-cells and/or NK cells; and/or IL-12 production by monocytes, macrophages and/or B cells
- leprae -infected individual may be afflicted with a form of leprosy (such as paucibacillary (PB), multibacillary (MB), lepromatous leprosy (LL), borderline lepromatous (BL), mid-borderline (BB), borderline tuberculoid (BT), or tuberculoid leprosy (Ti)) or may be asymptomatic.
- leprosy such as paucibacillary (PB), multibacillary (MB), lepromatous leprosy (LL), borderline lepromatous (BL), mid-borderline (BB), borderline tuberculoid (BT), or tuberculoid leprosy (Ti)
- PB paucibacillary
- MB multibacillary
- LL lepromatous leprosy
- BL borderline lepromatous
- BB mid-borderline
- BT borderline tuberculoid
- Ti tuberculoid leprosy
- Asymptomatic individuals are infected individuals who have
- PBMC which refers to a preparation of nucleated cells consisting primarily of lymphocytes and monocytes that are present in peripheral blood, encompasses both mixtures of cells and preparations of one or more purified cell types.
- PBMC may be isolated by methods known to those in the art. For example, PBMC may be isolated by density centrifugation through, for example, FicollTM (Winthrop Laboratories, New York). Lymph node cultures may generally be prepared by immunizing BALB/c mice (e.g., in the rear foot pad) with M. leprae promastigotes emulsified in complete Freund's adjuvant.
- the draining lymph nodes may be excised following immunization and T-cells may be purified in an anti-mouse Ig column to remove the B cells, followed by a passage through a Sephadex G10 column to remove the macrophages.
- lymph node cells may be isolated from a human following biopsy or surgical removal of a lymph node.
- the ability of a fusion polypeptide of the disclosure to induce a response in PBMC or lymph node cell cultures may be evaluated, for example, by contacting the cells with the polypeptide and measuring a suitable response.
- the amount of polypeptide that is sufficient for the evaluation of about 2 ⁇ 10 5 cells ranges from about 10 ng to about 100 ug or 100 ng to about 50 ug, and preferably is about 1 ug, to 10 ug.
- the incubation of polypeptide (e.g., a fusion polypeptide) with cells is typically performed at 37° C. for about 1-3 days. Following incubation with polypeptide, the cells are assayed for an appropriate response.
- the response is a proliferative response
- any of a variety of techniques well known to those of ordinary skill in the art may be employed.
- the cells may be exposed to a pulse of radioactive thymidine and the incorporation of label into cellular DNA measured.
- a polypeptide that results in at least a three fold increase in proliferation above background i.e., the proliferation observed for cells cultured without polypeptide is considered to be able to induce proliferation.
- the response to be measured may be the secretion of one or more cytokines (such as interferon-y (IFN- ⁇ ), interleukin-4 (IL-4), interleukin-12 (p70 and/or p40), interleukin-2 (IL-2) and/or tumor necrosis factor-a (TNF- ⁇ )) or the change in the level of mRNA encoding one or more specific cytokines.
- cytokines such as interferon-y (IFN- ⁇ ), interleukin-4 (IL-4), interleukin-12 (p70 and/or p40), interleukin-2 (IL-2) and/or tumor necrosis factor-a (TNF- ⁇ )
- the secretion of interferon-y, interleukin-2, tumor necrosis factor-a and/or interleukin-12 is indicative of a Th1 response, which contributes to the protective effect against M. leprae .
- Assays for any of the above cytokines may generally be performed using methods known to those of ordinary skill in the art, such as an enzyme-linked immunosorbent assay (ELISA).
- ELISA enzyme-linked immunosorbent assay
- Suitable antibodies for use in such assays may be obtained from a variety of sources such as Chemicon, Temucula, CA and PharMingen, San Diego, CA, and may generally be used according to the manufacturer's instructions.
- the level of mRNA encoding one or more specific cytokines may be evaluated by, for example, amplification by polymerase chain reaction (PCR).
- a polypeptide that is able to induce, in a preparation of about 1-3 ⁇ 10 5 cells, the production of 30 pg/mL of IL-12, IL-4, IFN- ⁇ , TNF- ⁇ or IL-12 p40, or 10 pg/mL of IL-12 p70, is considered able to stimulate production of a cytokine.
- the present disclosure also provides isolated polynucleotides, particularly those encoding the polypeptide combinations and/or fusion polypeptides of the disclosure, as well as compositions comprising such polynucleotides.
- DNA and “polynucleotide” and “nucleic acid” refer to a DNA molecule that has been isolated free of total genomic DNA of a particular species. Therefore, a DNA segment encoding a polypeptide refers to a DNA segment that contains one or more coding sequences yet is substantially isolated away from, or purified free from, total genomic DNA of the species from which the DNA segment is obtained.
- DNA segment and “polynucleotide” are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phagemids, phage, viruses, and the like.
- polynucleotide sequences of this disclosure can include genomic sequences, extra-genomic and plasmid-encoded sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, fusion polypeptides, peptides and the like. Such segments may be naturally isolated, recombinant, or modified synthetically by the hand of man.
- polynucleotides may be single-stranded (coding or anti sense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. Any polynucleotide may be further modified to increase stability in vivo.
- flanking sequences at the 5′ and/or 3′ ends Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends; the use of phosphorothioate or 2′ 0-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl- methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present disclosure, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.
- Polynucleotides may comprise a native sequence (i.e., an endogenous sequence that encodes a M. leprae antigen or a portion thereof) or may comprise a variant, or a biological or antigenic functional equivalent of such a sequence.
- polynucleotides may encode for two or more antigenic/immunogenic portions, fragments, or variants derived from the M. leprae antigens described herein.
- polynucleotides of the present disclosure comprise a sequence encoding any of the immunogenic portions described herein.
- the polynucleotide comprises the sequence of SEQ ID NO: 1, 3, 5, 7, 9, or 11.
- portions of these sequences and variant sequences sharing identity to these sequences may also be employed (e.g., those having at least about any of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% thereto).
- Polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions, as further described below, preferably such that the immunogenicity of the encoded polypeptide is not diminished, relative to the native protein.
- the effect on the immunogenicity of the encoded polypeptide may generally be assessed as described herein.
- variants of the disclosure include cysteine-modified polynucleotides in which the cysteine-encoding codons are replaced with codons encoding other amino acids not capable of forming intrachain or interchain disulfide bonds.
- some or all of the replacement codons encode serine because of the spatial similarity of the serine sidechain to the cysteine sidechain in the resulting polypeptide.
- some or all of the replacement codons encode alanine.
- Illustrative methods of replacing cysteine and other codons within a polynucleotide are well known (e.g., U.S. Pat. No. 4,816,566, the contents of which are incorporated herein by reference, and Proc Natl Acad Sci 97 (15): 8530, 2000).
- variants also encompasses homologous genes of xenogenic origin.
- isolated polynucleotides of the present disclosure comprise various lengths of contiguous stretches of sequence identical to or complementary to the sequence encoding M. leprae polypeptides, such as those sequences disclosed herein.
- polynucleotides are provided by this disclosure that comprise at least about 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous nucleotides of two or more of the sequences disclosed herein as well as all intermediate lengths there between.
- intermediate lengths means any length between the quoted values, such as 16, 17, 18, 19, etc.; 21, 22, 23, etc.; 30, 31, 32, etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103, etc.; 150, 151, 152, 153, etc.; including all integers through 200-500; 500-1,000, and the like.
- polynucleotides of the present disclosure may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a polynucleotide fragment of almost any length may be employed; with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol.
- nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present disclosure, for example polynucleotides that are optimized for human and/or primate codon selection. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present disclosure.
- Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions and/or substitutions of nucleotides.
- the resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison).
- M. leprae polynucleotides and fusions thereof may be prepared, manipulated and/or expressed using any of a variety of well established techniques known and available in the art.
- fusions comprise two or more polynucleotide sequences encoding M. leprae polypeptides.
- polynucleotide sequences or fragments thereof which encode polypeptides of the disclosure, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of a polypeptide in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences that encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express a given polypeptide of the present disclosure.
- codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.
- polynucleotide sequences of the present disclosure can be engineered using methods generally known in the art in order to alter fusion polypeptide encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, expression and/or immunogenicity of the gene product.
- a nucleotide sequence encoding the fusion polypeptide, or a functional equivalent may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.
- appropriate expression vector i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.
- a variety of expression vector/host systems are known and may be utilized to contain and express polynucleotide sequences. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast (such as Saccharomyces or Pichia ) transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.
- microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors
- yeast such as Saccharomyces or Pichia transformed with yeast expression vectors
- insect cell systems infected with virus expression vectors e.g., bac
- control elements or “regulatory sequences” present in an expression vector are those non-translated regions of the vector-enhancers, promoters, 5′ and 3′ untranslated regions—which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the PBLUESCRIPT phagemid (Stratagene, La Jolla, Calif.) or PSPORTI plasmid (Gibco BRL, Gaithersburg, Md.) and the like may be used.
- inducible promoters such as the hybrid lacZ promoter of the PBLUESCRIPT phagemid (Stratagene, La Jolla, Calif.) or PSPORTI plasmid (Gibco BRL, Gaithersburg, Md.)
- promoters from mammalian genes or from mammalian viruses are generally preferred. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding a polypeptide, vectors based on SV40 or EBV may be advantageously used with an appropriate selectable marker.
- a number of expression vectors may be selected depending upon the use intended for the expressed polypeptide. For example, when large quantities are needed, vectors which direct high level expression of fusion proteins that are readily purified may be used.
- Such vectors include, but are not limited to, the multifunctional E. coli cloning and expression vectors such as PBLUESCRIPT (Stratagene), in which the sequence encoding the polypeptide of interest may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of B-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke & Schuster, J. Biol. Chem.
- pGEX Vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST).
- GST glutathione S-transferase
- fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione.
- Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.
- yeast Saccharomyces cerevisiae
- a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used.
- constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH
- sequences encoding polypeptides may be driven by any of a number of promoters.
- viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, EMBO J. 3:1671-1680 (1984); Broglie et al., Science 224:838-843 (1984); and Winter et al., Results Probl. Cell Differ. 17:85-105 (1991)).
- constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, e.g., Hobbs in McGraw Hill, Yearbook of Science and Technology, pp. 191-196 (1992)).
- An insect system may also be used to express a polypeptide of interest.
- Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae.
- the sequences encoding the polypeptide may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the polypeptide-encoding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein.
- the recombinant viruses may then be used to infect, for example, S.
- sequences encoding a polypeptide of the present disclosure may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing the polypeptide in infected host cells (Logan & Shenk, Proc. Natl. Acad. Sci. U.S.A. 81:3655-3659 (1984)).
- transcription enhancers such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.
- RSV Rous sarcoma virus
- Specific initiation signals may also be used to achieve more efficient translation of sequences encoding a fusion polypeptide of interest. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding the polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, et al., Results ProbL Cell Differ. 20:125-162 (1994)).
- a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed fusion protein in the desired fashion.
- modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation.
- Post-translational processing which cleaves a “prepro” form of the protein may also be used to facilitate correct insertion, folding and/or function.
- Different host cells such as CHO, HeLa, MDCK, HEK293, and W138, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.
- cell lines which stably express a fusion polynucleotide of the present disclosure may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media.
- the purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences.
- Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.
- any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223-232 (1977)) and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817-823 (1990)) genes which can be employed in tk- or aprt- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler et al., Proc. Natl. Acad. Sci. U.S.A.
- npt which confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin et al., J. Mol. Biol. 150:1-14 (1981)); and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, Proc. Natl. Acad. Sci. U.S.A.
- Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide.
- sequences, or any portions thereof may be cloned into a vector for the production of an mRNA probe.
- a vector for the production of an mRNA probe Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits.
- Suitable reporter molecules or labels include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.
- Host cells transformed with a polynucleotide sequence of interest may be cultured under conditions suitable for the expression and recovery of the protein from cell culture.
- the protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used.
- expression vectors containing polynucleotides of the disclosure may be designed to contain signal sequences which direct secretion of the encoded polypeptide through a prokaryotic or eukaryotic cell membrane.
- Other recombinant constructions may be used to join sequences encoding a polypeptide of interest to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins.
- fusion polypeptides of the disclosure may be produced by direct peptide synthesis using solid-phase techniques (Merrifield, J. Am. Chem. Soc. 85:2149-2154 (1%3)). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431 A Peptide Synthesizer (Perkin Elmer). Alternatively, various fragments, for example, immunogenic fragments from M. leprae polypeptides, may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.
- polypeptides, antigens, polynucleotides, portions, variants, fusion polypeptides, etc., as described herein are incorporated into pharmaceutical compositions or vaccines.
- Pharmaceutical compositions generally comprise one or more polypeptides, antigens, polynucleotides, portions, variants, fusion polypeptides, etc., as described herein, in combination with a physiologically acceptable carrier.
- Vaccines also referred to as immunogenic compositions, generally comprise one or more of the polypeptides, antigens, polynucleotides, portions, variants, fusion proteins, etc., as described herein, in combination with an immunostimulant, such as an adjuvant.
- compositions comprise fusion polypeptides containing M. leprae antigens (or portions or variants thereof) that are capable of providing protection against M. leprae .
- compositions comprise fusion polypeptides containing M. leprae antigens (or portions or variants thereof) that are capable of providing protection against a tuberculosis-causing Mycobacterium.
- An immunostimulant may be any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen.
- immunostimulants include adjuvants, biodegradable microspheres (e.g., polylactic galactide) and liposomes (into which the compound is incorporated; see, e.g., Fullerton, U.S. Pat. No. 4,235,877).
- Vaccine preparation is generally described in, for example. Powell & Newman, eds., Vaccine Design (the subunit and adjuvant approach) (1995).
- immunostimulants may be employed in the vaccines of this disclosure.
- an adjuvant may be included.
- Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A (natural or synthetic), Bordatella pertussis or Mycobacterium species or Mycobacterium -derived proteins.
- Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.); AS-2 and derivatives thereof (GlaxoSmithKline Beecham, Philadelphia, Pa.); CWS, TDM, LeIF, aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quit A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, may also be used as adjuvants.
- Cytokines such as GM-CSF or interleukin-2, -7, or -12, may
- compositions of the disclosure contemplate vaccine and pharmaceutical compositions that include one or more toll-like receptor agonists (TLR agonist).
- TLR agonist toll-like receptor agonists
- the compositions of the disclosure include Toll-like receptor agonists, such as TLR7 agonists and TLR7/8 agonists.
- the TLR agonist is capable of delivering a biological signal by interacting with at least one TLR that is selected from TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8 and TLR-9.
- TLR Toll-like receptors
- TLR Toll-like receptors
- innate immune system that confer early-phase recognition capability to host cells for a variety of conserved microbial molecular structures such as may be present in or on a large number of infectious pathogens, (e.g., Armant et al., 2002 Genome Biol. 3(8): reviews 3011.1-3011.6; Fearon et al., 1996 Science 272:50; Medzhitov et al., 1997 Curr. Opin. Immunol. 9:4; Luster 2002 Curr. Opin. Immunol. 14:129; Lien et al. 2003 Nat. Immunol. 4:1162; Medzhitov, 2001 Nat. Rev. Immunol.
- TLR agonists which engage cell surface TLR or cytoplasmic TLR.
- lipopolysaccharide may be a TLR agonist through TLR2 or TLR4 (Tsan et al., 2004 J. Leuk. Biol. 76:514; Tsan et al., 2004 Am. J. Physiol. Cell Phsiol.
- poly(inosine-cytidine) may be a TLR agonist through TLR3 (Salem et al., 2006 Vaccine 24:5119); CpG sequences (oligodeoxynucleotides containing unmethylated cytosine-guanosine or “CpG” dinucleotide motifs, e.g., CpG 7909, Cooper et al., 2005 AIDS 19:1473; CpG 10101 Bayes et al. Methods Find Exp Clin Pharnacol 27:193; Vollmer et al.
- TLR agonists may be TLR9 (Andaloussi et a., 2006 Glia 54:526; Chen et al., 2006 J. Immunol. 177:2373); peptidoglycans may be TLR2 and/or TLR6 agonists (Soboll et al., 2006 Biol. Reprod. 75:131; Nakao et al., 2005 J. Immunol.
- 3M003 (4-amino-2-(ethoxymethyl)-a,a-dimethyl-617,8,9-tetrahydro-IH-imidazo[4,5] quinoline-1-ethanol hydrate, Mol. Wt. 318 Da from 3M Pharmaceuticals, St. Paul, MN, which is also a source of the related compounds 3M001 and 3M002; Gorden et al., 2005 J. Immunol. 174:1259) may be a TLR7 agonist (Johansen 2005 Clin. Exp. Allerg.
- TLR8 agonist 35:1591
- flagellin may be a TLR5 agonist
- hepatitis C antigens may act as TLR agonists through TLR7 and/or TLR9 (Lee et al., 2006 Proc. Nat. Acad. Sci. USA 103:1828; Horsmans et al., 2005 Hepatol. 42:724).
- Other TLR agonists are known (e.g., Schirmbeck et al., 2003 J. Immunol. 171:5198) and may be used according to certain of the presently described embodiments.
- CpG immunostimulatory oligonucleotides containing unmethylated CpG dinucleotides
- CpG immunostimulatory oligonucleotides containing unmethylated CpG dinucleotides
- the central role of the CG motif in immunostimulation was elucidated by Krieg, Nature 374, p546 1995. Detailed analysis has shown that the CG motif has to be in a certain sequence context, and that such sequences are common in bacterial DNA but are rare in vertebrate DNA.
- the immunostimulatory sequence is often: Purine. Purine, C, G, pyrimidine, pyrimidine: wherein the dinucleotide CG motif is not methylated, but other unmethylated CpG sequences are known to be immunostimulatory and may be used in certain embodiments of the present disclosure.
- CpG when formulated into vaccines may be administered in free solution together with free antigen (WO 96/02555; McCluskie and Davis, supra) or covalently conjugated to an antigen (PCT Publication No. WO 98/16247), or formulated with a carrier such as aluminium hydroxide (e.g., Davis et al. supra, Brazolot-Millan et al., Proc.NatLAcad.Sci., USA, 1998, 95(26), 15553-8).
- a carrier such as aluminium hydroxide
- oligonucleotides for use in compositions of the present disclosure will often contain two or more dinucleotide CpG motifs separated by at least three, more preferably at least six or more nucleotides.
- the oligonucleotides of the present disclosure are typically deoxynucleotides.
- the internucleotide in the oligonucleotide is phosphorodithioate, or more preferably a phosphorothioate bond, although phosphodiester and other intemucleotide bonds are within the scope of the disclosure including oligonucleotides with mixed internucleotide linkages.
- Methods for producing phosphorothioate oligonucleotides or phosphorodithioate are described in U.S. Pat. Nos. 5,666,153, 5,278,302 and WO95/26204.
- oligonucleotides have sequences that are disclosed in the following publications; for certain herein disclosed embodiments the sequences preferably contain phosphorothioate modified intemucleotide linkages: CPG 7909: Cooper et al., “CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.” AIDS, 2005 Sep. 23; 19(14): 1473-9.
- CpG 10101 Bayes et al., “Gateways to clinical trials.” Methods Find. Exp. Clin.
- Alternative CpG oligonucleotides may comprise variants of the preferred sequences described in the above-cited publications that differ in that they have inconsequential nucleotide sequence substitutions, insertions, deletions and/or additions thereto.
- the CpG oligonucleotides utilized in certain embodiments of the present disclosure may be synthesized by any method known in the art (e.g., EP 468520). Conveniently, such oligonucleotides may be synthesized utilizing an automated synthesizer.
- the oligonucleotides are typically deoxynucleotides.
- the intemucleotide bond in the oligonucleotide is phosphorodithioate, or more preferably phosphorothioate bond, although phosphodiesters are also within the scope of the presently contemplated embodiments.
- Oligonucleotides comprising different internucleotide linkages are also contemplated, e.g., mixed phosphorothioate phophodiesters.
- Other internucleotide bonds which stabilize the oligonucleotide may also be used.
- the TLR agonist is selected from lipopolysaccharide, peptidoglycan, polyl: C, CpG, 3M003, flagellin, M. leprae homolog of eukaryotic ribosomal elongation and initiation factor 4a (LeIF) and at least one hepatitis C antigen.
- LeIF leprae homolog of eukaryotic ribosomal elongation and initiation factor 4a
- adjuvants include imiquimod, gardiquimod and resiquimod (all available from Invivogen), and related compounds, which are known to act as TLR7/8 agonists.
- imiquimod gardiquimod and resiquimod (all available from Invivogen)
- related compounds which are known to act as TLR7/8 agonists.
- a compendium of adjuvants that may be useful in vaccines is provided by Vogel et al., Pharm Biotechnol 6:141 (1995), which is herein incorporated by reference.
- compositions of the disclosure may also employ adjuvant systems designed to induce an immune response predominantly of the Th1 type.
- High levels of Th1-type cytokines e.g., IFN- ⁇ , TNF-a, IL-2 and IL-12
- Th2-type cytokines e.g., IL-4, IL-5, IL-6 and IL-10
- a patient will support an immune response that includes Th1- and Th2-type responses.
- the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines.
- the levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mossman & Coffman, Ann. Rev. Immunol. 7:145-173 (1989).
- Certain adjuvants for use in eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPLTM), together with an aluminum salt (U.S. Pat. Nos. 4,436,727; 4,877,611; 4,866,034; and 4,912,094).
- CpG-containing oligonucleotides in which the CpG dinucleotide is unmethylated also induce a predominantly Th1 response.
- Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Pat. Nos.
- Another illustrative adjuvant comprises a saponin, such as Quil A, or derivatives thereof, including QS21 and QS7 (Aquila Biopharmaceuticals Inc., Framingham, Mass.); Escin; Digitonin; or Gypsophila or Chenopodium quinoa saponins.
- Other illustrative formulations include more than one saponin in the adjuvant combinations of the present disclosure, for example combinations of at least two of the following group comprising QS21, QS7, Quil A, 0-escin, or digitonin.
- the adjuvant system includes the combination of a monophosphoryl lipid A and a saponin derivative, such as the combination of QS21 and 3D-MPLTM adjuvant, as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739.
- Other formulations comprise an oil-in-water emulsion and tocopherol.
- Another adjuvant formulation employing QS21, 3D-MPLTM adjuvant and tocopherol in an oil-in-water emulsion is described in WO 95/17210.
- the adjuvant used in the present disclosure is a glucopyranosyl lipid A (GLA) adjuvant, as described in U.S. Patent Application Publication No. 20080131466, the disclosure of which is incorporated herein by reference in its entirety.
- GLA adjuvant used in the context of the present disclosure has the following structure:
- R 1 , R 3 , R 5 and R 6 are C 11 -C 20 alkyl, and R 2 and R 4 are C 9 -C 20 alkyl.
- the GLA has the formula set forth above wherein R 1 , R 3 , R 5 and R 6 are C 11-14 alkyl, and R 2 and R 4 are C 12-15 alkyl.
- the GLA has the formula set forth above wherein R 1 , R 3 , R 5 and R 6 are C 11 alkyl; and R 2 and R 4 are C 13 alkyl.
- the GLA has the formula set forth above wherein R 1 , R 3 , R 5 and R 6 are C 11 alkyl; and R 2 and R 4 are C 9 alkyl.
- the adjuvant is a GLA adjuvant (e.g., synthetic) having the following structure:
- R 1 , R 3 , R 5 and R 6 are C 11 -C 20 alkyl; and R 2 and R 4 are C 9 -C 20 alkyl. In certain embodiments, R 1 , R 3 , R 5 and R 6 are C 11 alkyl; and R 2 and R 4 are C 9 alkyl.
- the adjuvant is a synthetic GLA adjuvant having the following structure:
- R 1 , R 3 , R 5 and R 6 are C 11 -C 20 alkyl; and R 2 and R 4 are C 9 -C 20 alkyl. In certain embodiments. R 1 , R 3 , R 5 and R 6 are C 11 alkyl; and R 2 and R 4 are C 9 alkyl.
- the adjuvant is a synthetic GLA adjuvant having the following structure:
- R 1 , R 3 , R 5 and R 6 are C 11 -C 20 alkyl; and R 2 and R 4 are C 11 -C 20 alkyl. In certain embodiments. R 1 , R 3 , R 5 and R 6 are C 11 alkyl; and R 2 and R 4 are C 9 alkyl.
- the adjuvant is a synthetic GLA adjuvant having the following structure:
- the adjuvant is a synthetic GLA adjuvant having the following structure:
- the adjuvant is a synthetic GLA adjuvant having the following structure:
- the adjuvant is GLA-SE having the following structure:
- the adjuvant is GLA-SE having the following structure:
- the GLA adjuvant may be in a salt form, e.g., an ammonium salt.
- GLA-SE refers to a stable oil-in-water emulsion comprising GLA formulated in squalene oil and other excipients including, for example, dimyristoyl phosphatidyl choline (DPMC). In some preferred embodiments, 20 ug/ml GLA is formulated in 4% squalene oil.
- Methods of making GLA-SE are known in the art, see for example, Misquith et al., Colloids and Surfaces B: Biointerfaces 113(2014) 312-319; Fox et al., Vaccine 31(2013) 1633-1640, Van Hoeven et al., Nature Scientific Reports 7:46426.
- Another enhanced adjuvant system involves the combination of a CpG-containing oligonucleotide and a saponin derivative as disclosed in WO 00/09159.
- illustrative adjuvants include Montanide ISA 720 (Seppic, France), SAF (Chiron, Calif, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (e.g., SBAS-2, AS2′, AS2,′′ SBAS-4, or SBAS6, available from SmithKline Beecham, Rixensart, Belgium), Detox, RC-529 (Corixa, Hamilton, Mont.) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. patent application Ser. Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties, and polyoxyethylene ether adjuvants such as those described in WO 99/52549A1.
- SBAS series of adjuvants e.g., SBAS-2, AS2′, AS2,′′ SBAS-4, or SBAS6, available from SmithKline Beecham
- the vaccine and pharmaceutical compositions of the disclosure may be formulated using any of a variety of well known procedures.
- the vaccine or pharmaceutical compositions are prepared as stable emulsions (e.g., oil-in-water emulsions) or as aqueous solutions.
- compositions of the disclosure may also, or alternatively, comprise T cells specific for fusion polypeptide comprising immunogenic/antigenic portions or fragments of M. leprae antigens or variants thereof, described herein.
- T cells may generally be prepared in vitro or ex vivo, using standard procedures.
- T cells may be isolated from bone marrow, peripheral blood, or a fraction of bone marrow or peripheral blood of a patient.
- T cells may be derived from related or unrelated humans, non-human mammals, cell lines or cultures.
- T cells may be stimulated with a fusion polypeptide comprising M. leprae polypeptides or immunogenic portions or variants thereof, polynucleotide encoding such a fusion polypeptide, and/or an antigen presenting cell (APC) that expresses such a fusion polypeptide.
- APC antigen presenting cell
- Such stimulation is performed under conditions and for a time sufficient to permit the generation of T cells that are specific for the polypeptide.
- the polypeptide or polynucleotide is present within a delivery vehicle, such as a microsphere, to facilitate the generation of specific T cells.
- T cells are considered to be specific for a fusion polypeptide of the disclosure if the T cells specifically proliferate, secrete cytokines or kill target cells coated with the fusion polypeptide or expressing a gene encoding the fusion polypeptide.
- T cell specificity may be evaluated using any of a variety of standard techniques. For example, within a chromium release assay or proliferation assay, a stimulation index of more than two fold increase in lysis and/or proliferation, compared to negative controls, indicates T cell specificity. Such assays may be performed, for example, as described in Chen et al., Cancer Res. 54:1065-1070 (1994)).
- T cell proliferation can be detected by measuring an increased rate of DNA synthesis (e.g., by pulse-labeling cultures of T cells with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into DNA).
- a polypeptide of the disclosure 100 ng/ml-1001.1 g/ml, preferably 200 ng/ml-251.1 g/ml
- T cells that have been activated in response to a polypeptide, polynucleotide or polypeptide-expressing APC may be CD4+ and/or CD8+.
- Protein-specific T cells may be expanded using standard techniques.
- the T cells are derived from a patient, a related donor or an unrelated donor, and are administered to the patient following stimulation and expansion.
- compositions of the disclosure formulation of pharmaceutically-acceptable excipients and carrier solutions is well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including e.g., oral, parenteral, intravenous, intranasal, intradermal, subcutaneous and intramuscular administration and formulation.
- compositions disclosed herein may be delivered via oral administration to a subject.
- these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
- Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
- Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S. Pat. No. 5,466,468, specifically incorporated herein by reference in its entirety).
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils.
- polyol e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like
- suitable mixtures thereof e.g., vegetable oils
- vegetable oils e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like
- suitable mixtures thereof e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like
- vegetable oils e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like
- Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion
- isotonic agents for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- aqueous solution for parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
- a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure.
- one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion (see, e.g., Remington's Pharmaceutical Sciences, 15th Edition, pp.
- Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with the various other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- compositions disclosed herein may be formulated in a neutral or salt form.
- Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxy groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
- solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective for treatment of leprosy.
- the formulations are easily administered in a variety of dosage forms such as injectable solutions, drug-release capsules, and the like.
- carrier includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.
- carrier includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.
- the use of such media and agents for pharmaceutical active substances is well known to one of ordinary skill in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- phrases “pharmaceutically-acceptable” refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.
- the preparation of an aqueous composition that contains a protein as an active ingredient is well understood to one of ordinary skill in the art.
- such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared.
- the preparation can also be emulsified.
- compositions of the present disclosure may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles.
- Methods for delivering genes, polynucleotides, and peptide compositions directly to the lungs via nasal aerosol sprays has been described e.g., in U.S. Pat. Nos. 5,756,353 and 5,804,212 (each specifically incorporated herein by reference in its entirety).
- the delivery of drugs using intranasal microparticle resins Takenaga et al., 1998) and lysophosphatidyl-glycerol compounds (U.S. Pat. No.
- the delivery may occur by use of liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, for the introduction of compositions comprising a fusion polypeptide as describe herein into suitable host cells.
- the compositions of the present disclosure may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, a nanoparticle or the like.
- the formulation and use of such delivery vehicles can be carried out using known and conventional techniques.
- a pharmaceutical or immunogenic composition may, alternatively, contain an immunostimulant and a nucleic acid molecule, e.g., a DNA or RNA molecule encoding one or more of the polypeptides or fusion polypeptides as described above, such that a desired polypeptide is generated in situ.
- a nucleic acid molecule e.g., a DNA or RNA molecule encoding one or more of the polypeptides or fusion polypeptides as described above, such that a desired polypeptide is generated in situ.
- the DNA encoding the fusion protein may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal).
- Bacterial delivery systems involve the administration of a bacterium (such as Bacillus -Calmette-Guerrin) that expresses an immunogenic portion of the polypeptide on its cell surface.
- the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus.
- vaccinia or other pox virus, retrovirus, or adenovirus e.g., vaccinia or other pox virus, retrovirus, or adenovirus
- Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art.
- the DNA may also be “naked.” as described, for example, in Ulmer et al., Science 259:1745-1749 (1993) and reviewed by Cohen, Science 259: 1691-1692 (1993).
- the uptake of naked DNA may be increased by coating the DNA onto biodegradable beads,
- compositions and vaccines of the disclosure may be used, in certain embodiments, to induce protective immunity against M. leprae in a patient, such as a human or an armadillo, to prevent leprosy or diminish its severity.
- the compositions and vaccines may also be used to stimulate an immune response, which may be cellular and/or humoral, in a patient, for treating an individual already infected.
- the immune responses generated include a preferential Th1 immune response (i.e., a response characterized by the production of the cytokines interleukin-1, interleukin-2, interleukin-12 and/or interferon-y, as well as tumor necrosis factor-a).
- the immune response involves production of interleukin-12 and/or interleukin-2, or the stimulation of gamma delta T-cells.
- the response stimulated may include IL-12 production.
- Such responses may also be elicited in biological samples of PBMC or components thereof derived from M. leprae -infected or uninfected individuals.
- assays for any of the above cytokines, as well as other known cytokines may generally be performed using methods known to those of ordinary skill in the art, such as an enzyme-linked immunosorbent assay (ELISA).
- ELISA enzyme-linked immunosorbent assay
- fusion polypeptide administration for these purposes can be readily determined by a skilled artisan using available knowledge in the art and/or routine techniques. Routes and frequency of administration, as well as dosage, for the above aspects of the present disclosure may vary from individual to individual and may parallel those currently being used in immunization against other infections, including protozoan, viral and bacterial infections. For example, in one embodiment, between 1 and 12 doses of composition having a fusion polypeptide, which comprises M. leprae polypeptides or immunogenic/antigenic portions, fragments or variants thereof, are administered over a 1-year period. Booster vaccinations may be given periodically thereafter as needed or desired. Of course, alternate protocols may be appropriate for individual patients.
- a suitable dose is an amount of fusion polypeptide or DNA encoding such a peptide that, when administered as described above, is capable of eliciting an immune response in an immunized patient sufficient to protect the patient from leprosy caused by M. leprae .
- the amount of fusion polypeptide present in a dose ranges from about 100 ng to about 1 mg per kg of host, typically from about 101.1 g to about 100 ug.
- Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL.
- composition of the present invention is administered to a subject in the methods described herein.
- the composition can be, for example, in lyophilized form.
- the composition is administered in combination with an immunostimulant.
- the immunostimulant can be, for example, any of the immunostimulants described herein.
- the immunostimulant is GLA having any one of the structures described herein and is optionally formulated in an oil-in-water emulsion.
- the GLA is administered at a dose of from 2 ug to 20 ug per dose, or from about 1 ug to about 10 ug per dose or at about 5 ug per dose.
- a dose of from 2 ug to 20 ug per dose or from about 1 ug to about 10 ug per dose or at about 5 ug per dose.
- alternative dosage amounts are contemplated herein.
- this disclosure provides methods for stimulating an immune response against M. leprae in a mammal including the step of administering to a mammal in need thereof a composition of the present disclosure.
- the methods further include a step of administering to the mammal M. bovis BCG vaccine.
- M. bovis BCG vaccine was previously administered to the mammal.
- the method may involve stimulating an immune response in various populations of mammals, including, where the mammal has not been exposed to M. leprae , where the mammal has been exposed to M. leprae , where the mammal is a human healthy household contact of a human identified as being infected with M. leprae , where the mammal has been infected by M.
- compositions of the present disclosure can be administered, for example, prophylactically, post-exposure but prior to clinical symptoms, or post-exposure and after exhibition of clinical symptoms.
- it will be unknown whether or not the mammal to be treated has been exposed to M. leprae but the mammal will have been in a leprosy endemic region or in contact with a mammal having active leprosy.
- the disclosure provides methods for stimulating an immune response against a tuberculosis-causing mycobacterium in a mammal comprising administering to a mammal in need thereof a composition of the disclosure.
- the disclosure provides methods for treating an M. leprae infection in a mammal, including the step of administering to a mammal having an M. leprae infection a composition of the disclosure.
- the method may include multiple subsequent administrations of the composition.
- Identifying mammals having an M. leprae infection may be carried with methods known in the art.
- the World Health Organization (WHO) has established diagnostic criteria as the presence of one or more of the following key signs: appearance of hypopigmented or reddish lesion with hypoesthesia, presence of acid fast bacilli in lymph node smears and compatible skin lesion histopathology. Once diagnosed, leprosy is treatable and patients are operationally defined into one of two categories, paucibacillary (PB) or multibacillary (MB) for treatment purposes.
- PB paucibacillary
- MB multibacillary
- the Ridley-Jopling scale characterizes five forms of leprosy through the use of clinical, histopathological, and immunological methods: lepromatous leprosy (LL), borderline lepromatous (BL), mid-borderline (BB), borderline tuberculoid (BT), and tuberculoid leprosy (TT).
- lepromatous leprosy LL
- borderline lepromatous BL
- mid-borderline BB
- borderline tuberculoid BT
- tuberculoid leprosy TT.
- PB leprosy patients encompassing TT and a number of BT forms, are characterized as having one or few skin lesions and granulomatous dermatopathology with a low or absent bacterial index (BI).
- BI bacterial index
- TT patients demonstrate a specific cell-mediated immunity against M. leprae and have an absent, or low, BI. Control of bacterial growth by PB patients indicates that these individuals mount a strong, but not necessarily curative, immune response against M. leprae.
- the methods further include a step of administering to the mammal one or more chemotherapeutic agents.
- a “chemotherapeutic”. “chemotherapeutic agents” or “chemotherapy regime” is a drug or combination of drugs used to treat or in the treatment thereof of patients infected or exposed to M.
- leprae includes, but is not limited to, amikacin, aminosalicylic acid, capreomycin, clofazimine, cycloserine, dapsone, ethambutol, ethionamide, gatifloxacin, isoniazid (INH), kanamycin, linezolid, minocycline, pyrazinamide, rifamycins (i.e., rifampin, rifampicin, rifapentine and rifabutin), streptomycin, ofloxacin, ciprofloxacin, clarithromycin, azithromycin, PA824, and fluoroquinolones and other derivatives analogs or biosimilars in the art.
- amikacin aminosalicylic acid
- capreomycin clofazimine
- cycloserine dapsone
- ethambutol ethionamide
- gatifloxacin isoniazid
- the mammal is first administered one or more chemotherapeutic agents over a period of time and subsequently administered the composition. In other embodiments, the mammal is first administered the composition and subsequently administered one or more chemotherapeutic agents over a period of time. In other embodiments, administration of the one or more chemotherapeutic agents and the composition is concurrent.
- the method includes a step of administering to the mammal M. bovis BCG vaccine.
- M. bovis BCG vaccine was previously administered to the mammal.
- the mammal does not exhibit signs or symptoms of infection by M. leprae .
- the mammal has indeterminate or tuberculoid presentation.
- the mammal has paucibacillary leprosy.
- the mammal has multibacillary leprosy.
- the mammal has lepromatous leprosy.
- the mammal has borderline lepromatous leprosy.
- the mammal has mid-borderline leprosy.
- the mammal has borderline tuberculoid leprosy.
- the mammal has tuberculoid leprosy.
- the mammal is infected with a multidrug resistant M. leprae .
- the mammal is a human.
- a method for reducing the time course of chemotherapy against an M. leprae infection is provided.
- the time course of chemotherapy is shortened, for example, to no more than about 3 months, about 5 months, or about 7 months.
- a “chemotherapeutic”, “chemotherapeutic agents” or “chemotherapy regime” is a drug or combination of drugs used to treat or in the treatment thereof of patients infected or exposed to M. leprae and includes, but is not limited to, amikacin, aminosalicylic acid, capreomycin, clofazimine, cycloserine, dapsone, ethambutol, ethionamide, gatifloxacin, isoniazid (INH), kanamycin, linezolid, minocycline, pyrazinamide, rifamycins (i.e., rifampin, rifampicin, rifapentine and rifabutin), streptomycin, ofloxacin, ciprofloxacin, clarithromycin, azithromycin, PA824, and fluoroquinolones and other derivatives analogs or biosimilars in the art.
- amikacin aminosalicylic acid
- capreomycin
- the disclosure provides methods for preventing an M. leprae infection in a mammal, or preventing onset of clinical symptoms in a mammal that has been exposed to M. leprae or has been diagnosed with M. leprae but does not yet exhibit symptoms thereof, including the step of administering to a mammal having an M. leprae infection a composition of the disclosure.
- the method may include multiple subsequent administrations of the composition.
- the methods of treatment of the present disclosure may include the administration of the compositions of the disclosure either alone or in conjunction with other agents and, as such, the therapeutic vaccine may be one of a plurality of treatment components as part of a broader therapeutic treatment regime. Accordingly, the methods of the present disclosure advantageously improve the efficacy of a chemotherapy treatment regime for the treatment of M. leprae infection.
- kits for treatment of an M. leprae infection including a composition of the disclosure.
- this disclosure provides compounds and methods for detecting leprosy in individuals and in blood supplies.
- the individual is a mammal.
- the mammal is a human or armadillo.
- the fusion polypeptides, polypeptides, and antigens of the present disclosure can be used as effective diagnostic reagents for detecting and/or monitoring M. leprae infection in a patient.
- the compositions, fusion polypeptides, and polynucleotides of the disclosure may be used in in vitro and in vivo assays for detecting humoral antibodies or cell-mediated immunity against M. leprae for diagnosis of infection, monitoring of disease progression or test-of-cure evaluation.
- the fusion polypeptides and polynucleotides are useful diagnostic reagents for serodiagnosis and whole blood assay in patients having leprosy or in individuals exposed to M. leprae.
- the diagnostic methods and kits preferably employ a composition or fusion polypeptide as described herein, repeats of polypeptide fragments, or multimeric polypeptide fragments, including antigenic/immunogenic fragments.
- fusion polypeptides of the present disclosure may comprise two or more M. leprae antigen fragments.
- an illustrative fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 12.
- the diagnostic methods and kits preferably employ a fusion polypeptide comprising at least 1, at least 2, at least 3, or at least 4 immunogenic/antigenic portions or fragments of M. leprae polypeptides, variants or the like, optionally in combination with one or more other M. leprae antigens or non- M. leprae sequences, as described herein or obtainable in the art.
- the antigens or polypeptides may be used in essentially any assay format desired, e.g., as individual antigens assayed separately, as multiple antigens assays simultaneously (e.g., a fusion polypeptide), as antigens immobilized on a solid support such as an array, or the like.
- diagnostic kits for detecting M. leprae infection in a biological sample comprising (a) a polypeptide or a fusion polypeptide described herein or variants thereof as described herein, and (b) a detection reagent.
- diagnostic kits for detecting M. leprae infection in a biological sample comprising (a) antibodies or antigen binding fragments thereof that are specific for a polypeptide or a fusion polypeptides described herein or variants thereof as described herein, and (b) a detection reagent.
- methods for detecting the presence of M. leprae infection in a biological sample, comprising (a) contacting a biological sample with a polypeptide or a fusion polypeptide described herein or variants thereof described herein; and (b) detecting in the biological sample the presence of antibodies that bind to the fusion polypeptide.
- methods for detecting the presence of M. leprae infection in a biological sample, comprising (a) contacting a biological sample with at least 2 monoclonal antibodies that bind to a polypeptide or a polypeptide described herein or variants thereof described herein; and (b) detecting in the biological sample the presence of M. leprae proteins that bind to the monoclonal antibody.
- kits described herein may be used to detect all types of leprosy, depending on the particular combination of immunogenic portions of M. leprae antigens present in the fusion polypeptide.
- the assay involves the use of fusion polypeptide immobilized on a solid support to bind to and remove the antibody from the sample. The bound antibody may then be detected using a detection reagent that binds to the antibody/peptide complex and contains a detectable reporter group.
- Suitable detection reagents include, for example, antibodies that bind to the antibody/polypeptide complex and free polypeptide labeled with a reporter group (e.g., in a semi-competitive assay).
- Suitable reporter groups are also well known and include, for example, fluorescent labels, enzyme labels, radioisotopes, chemiluminescent labels, electrochemiluminescent labels, bioluminescent labels, polymers, polymer particles, metal particles, haptens, and dyes.
- a competitive assay may be utilized, in which an antibody that binds to a fusion polypeptide of the present disclosure labeled with a reporter group and allowed to bind to the immobilized fusion polypeptide after incubation of the fusion polypeptide with the sample.
- the extent to which components of the sample inhibit the binding of the labeled antibody to the fusion polypeptide is indicative of the reactivity of the sample with the immobilized fusion polypeptide.
- the solid support may be any material known to those of ordinary skill in the art to which the fusion polypeptide may be attached.
- the support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane.
- the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride.
- the support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Pat. No. 5,359,681.
- the fusion polypeptide may be bound to the solid support using a variety of techniques known to those in the art, which are amply described in the patent and scientific literature.
- the term “bound” refers to both non-covalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Binding by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the polypeptide, in a suitable buffer, with the solid support for a suitable amount of time.
- the contact time varies with temperature, but is typically between about 1 hour and 1 day.
- contacting a well of a plastic microtiter plate such as polystyrene or polyvinylchloride
- an amount of fusion polypeptide ranging from about 10 ng to about 1 pg, and preferably about 100 ng, is sufficient to bind an adequate amount of antigen.
- Nitrocellulose will bind approximately 100 pg of protein per 3 cm.
- Covalent attachment of fusion polypeptide to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the fusion polypeptide.
- a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the fusion polypeptide.
- the fusion polypeptide may be bound to a support having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the polypeptide (see, e.g., Pierce Immunotechnology Catalog and Handbook (1991) at A12-A13).
- the assay is an enzyme linked immunosorbent assay (ELISA).
- ELISA enzyme linked immunosorbent assay
- This assay may be performed by first contacting a fusion polypeptide of the present disclosure that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that antibodies to the M. leprae antigens of the fusion polypeptide within the sample are allowed to bind to the immobilized fusion polypeptide. Unbound sample is then removed from the immobilized fusion polypeptide and a detection reagent capable of binding to the immobilized antibody-polypeptide complex is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific detection reagent.
- the fusion polypeptide is immobilized on the support, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin (BSA) or Tween 20TM (Sigma Chemical Co., St. Louis, Mo.) may be employed.
- BSA bovine serum albumin
- Tween 20TM Sigma Chemical Co., St. Louis, Mo.
- the immobilized polypeptide is then incubated with the sample, and antibody (if present in the sample) is allowed to bind to the antigen.
- the sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation.
- PBS phosphate-buffered saline
- an appropriate contact time i.e., incubation time
- incubation time is that period of time that is sufficient to permit detection of the presence of antibody within a M.
- the contact time is sufficient to achieve a level of binding that is at least 95% of that achieved at equilibrium between bound and unbound antibody.
- the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.
- Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20TM.
- Detection reagent may then be added to the solid support.
- An appropriate detection reagent is any compound that binds to the immobilized antibody-polypeptide complex and that can be detected by any of a variety of means known to those in the art.
- the detection reagent contains a binding agent (such as, for example, Protein A. Protein G, immunoglobulin, lectin or free antigen) conjugated to a reporter group.
- Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups, colloidal gold and biotin.
- enzymes such as horseradish peroxidase
- substrates such as horseradish peroxidase
- cofactors such as horseradish peroxidase
- inhibitors such as horseradish peroxidase
- dyes such as horseradish peroxidase
- radionuclides such as luminescent groups
- luminescent groups such as horseradish peroxidase
- the detection reagent is then incubated with the immobilized antibody polypeptide complex for an amount of time sufficient to detect the bound antibody.
- An appropriate amount of time may generally be determined from the manufacturer's instructions or by assaying the level of binding that occurs over a period of time.
- Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group.
- the method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.
- the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value.
- the cut-off value is preferably the average mean signal obtained when the immobilized polypeptide is incubated with samples from an uninfected patient.
- a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive (i.e., reactive with the polypeptide).
- the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., Clinical Epidemiology: A Basic Science for Clinical Medicine, p.
- the cut-off value may be determined from a plot of pairs of true positive rates (i.e., sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result.
- the cut-off value on the plot that is the closest to the upper lefthand corner i.e., the value that encloses the largest area
- a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive.
- the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate.
- an assay is performed in a flow-through assay format, wherein the antigen is immobilized on a membrane such as nitrocellulose.
- a detection reagent e.g., protein A-colloidal gold
- a detection reagent then binds to the antibody-polypeptide complex as the solution containing the detection reagent flows through the membrane. The detection of bound detection reagent may then be performed as described above.
- an assay if performed in a strip test format, also known as a lateral flow format.
- a strip test format also known as a lateral flow format.
- one end of the membrane to which polypeptide is bound is immersed in a solution containing the sample.
- the sample migrates along the membrane through a region containing detection reagent and to the area of immobilized fusion polypeptide.
- Concentration of detection reagent at the fusion polypeptide indicates the presence of M. leprae antibodies in the sample.
- concentration of detection reagent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result.
- the amount of fusion polypeptide immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of antibodies that would be sufficient to generate a positive signal in an ELISA, as discussed above.
- the amount of fusion polypeptide immobilized on the membrane ranges from about 25 ng to about 1 fag, and more preferably from about 50 ng to about 500 ng.
- Such tests can typically be performed with a very small amount (e.g., one drop) of patient serum or blood. Lateral flow tests can operate as either competitive or sandwich assays.
- a fusion polypeptide of the disclosure is adapted for use in a dual path platform (DPP) assay.
- DPP dual path platform
- the assays discussed above may be used, in certain aspects of the disclosure, to specifically detect visceral leprosy.
- antibodies in the sample may be detected using a fusion polypeptide of the present disclosure, e.g., comprising an amino acid sequence of antigenic/immunogenic fragments or epitopes of M. leprae antigens.
- the M. leprae antigens are immobilized by adsorption to a solid support such as a well of a microtiter plate or a membrane, as described above, in roughly similar amounts such that the total amount of fusion polypeptide in contact with the support ranges from about 10 ng to about 100 pg.
- the remainder of the steps in the assay may generally be performed as described above.
- polypeptides described herein may be used in methods that detect all types of leprosy.
- immobilized fusion polypeptides may be used to purify antibodies that bind thereto.
- Such antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Land, Antibodies. A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988.
- an immunogen comprising a fusion polypeptide of the present disclosure is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep and goats). In this step, the polypeptide may serve as the immunogen without modification.
- a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin.
- a carrier protein such as bovine serum albumin or keyhole limpet hemocyanin.
- the immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically.
- Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.
- Monoclonal antibodies specific for the antigenic fusion polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, Eur. J. Immunol. 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed.
- the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells.
- a preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.
- Monoclonal antibodies may be isolated from the supematants of growing hybridoma colonies. In this process, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. One or more polypeptides may be used in the purification process in, for example, an affinity chromatography step.
- Monospecific antibodies that bind to a fusion polypeptide comprising two or more immunogenic portions of M. leprae antigens may be used, for example, to detect M. leprae infection in a biological sample using one of a variety of immunoassays, which may be direct or competitive. Briefly, in one direct assay format, a monospecific antibody may be immobilized on a solid support (as described above) and contacted with the sample to be tested. After removal of the unbound sample, a second monospecific antibody, which has been labeled with a reporter group, may be added and used to detect bound antigen. In an exemplary competitive assay, the sample may be combined with the monoclonal or polyclonal antibody, which has been labeled with a suitable reporter group.
- the mixture of sample and antibody may then be combined with polypeptide antigen immobilized on a suitable solid support.
- Antibody that has not bound to an antigen in the sample is allowed to bind to the immobilized antigen and the remainder of the sample and antibody is removed.
- the level of antibody bound to the solid support is inversely related to the level of antigen in the sample. Thus, a lower level of antibody bound to the solid support indicates the presence of M. leprae in the sample.
- Other formats for using monospecific antibodies to detect M. leprae in a sample will be apparent to those of ordinary skill in the art, and the above formats are provided solely for exemplary purposes.
- EC were healthy individuals who had never had tuberculosis, had no history of leprosy in the family, and were living in the leprosy endemic area. All donors had previously been immunized with BCG and all blood samples were obtained after informed consent and after local ethics committee approval.
- WBA whole blood assay
- the detection limit of the test was 0.05 IU/ml.
- a positive result was assigned as a concentration above an arbitrary cut-off point of 0.5 IU/ml.
- Spontaneous IFN ⁇ secretion was observed in WBA only for some TB patients, and in those cases, was subtracted to provide antigen-induced values.
- Antigen recognition by leprosy-affected individuals Replication and dissemination of M. leprae is limited in PB leprosy patients and most HHC, suggesting the potent cellular immune response they develop is associated with limited or localized disease. Antigens that are recognized by PB patients or HHC are potentially targets of an effective immune response against M. leprae .
- the analyses was expanded to include ethnically and geographically distinct populations (Table 1). While each of the individual antigens ML2028, ML2055 and ML2380 were recognized by over 50% PB patients and HHC, the combination of these antigens pushed the theoretical recognition to over 80%.
- mice and immunizations Wild type C57BL/6 (B6) mice were purchased from Charles River Laboratories (Wilmington, MA). Mice were immunized with recombinant protein formulated with saline, stable emulsion (SE), or glucopyranosyl lipid adjuvant (GLA)-SE, to provide a final protein concentration of 10 ⁇ g antigen and 20 ⁇ g GLA-SE. Mice were immunized up to 3 times by subcutaneous (s.c) injection of 0.1 ml volume at the base of the tail at 2 week intervals. Mice were maintained in specific pathogen-free conditions and all procedures were approved by the pertinent institutional animal care and use committees.
- s.c subcutaneous
- M. leprae bacilli live M. leprae bacilli (Thai-53 strain) were purified from the footpads of nu/nu mice at National Institute of Infectious Diseases. Mice were inoculated with 1 ⁇ 104 bacilli by s.c. injection into each foot pad. Foot pads were harvested 12 months later and the bacilli were enumerated by direct microscopic counting of acid-fast bacilli according to the method of Shepard and McRae or by RT-PCR of the M. leprae specific repetitive element (RLEP).
- RLEP RT-PCR of the M. leprae specific repetitive element
- Immunization with select antigens reduces M. leprae infection.
- mice were immunized with single antigens, or combinations of antigens, before infection with M. leprae .
- Immunization significantly decreased bacterial numbers ( FIGS. 1 A and 1 B ; p-values ⁇ 0.05). These data indicate that immunization with the selected antigens elicits protective responses in mice and warrant inclusion within a defined sub-unit vaccine against leprosy.
- ML89 Single 89kD fusion protein, designated ML89, was generated from the ML2028, ML2055 and ML2380 antigens, with the addition of ML2531 to stabilize expression.
- Mouse sera were prepared following collection of retro-orbital blood into microtainer serum collection tubes (VWR International, West Chester, PA) followed by centrifugation at 1200 rpm for 5 minutes. Each serum was then analyzed by antibody capture ELISA. Briefly, ELISA plates (Nunc, Rochester, NY) were coated with 1 ⁇ g/ml recombinant antigen in 0.1 M bicarbonate buffer and blocked with 1% BSA-PBS.
- Single cell suspensions were prepared by disrupting spleens between frosted slides. Red blood cells were removed by lysis in 1.66% NH 4 Cl solution, then mononuclear cells enumerated by Via Count assay with a PCA system (Guava Technologies, Hayward, CA). Single cell suspensions were cultured at 2 ⁇ 105 cells per well in duplicate in a 96-well plate (Corning Incorporated, Corning, NY) in RPMI-1640 supplemented with 5% heat-inactivated FCS and 50,000 Units penicillin/streptomycin (Invitrogen).
- bovis BCG vaccine is routinely used in leprosy-affected regions, we also examined the interplay of ML89 and BCG vaccination and determined if prior BCG immunization led to any interactions upon ML89 immunization.
- Mice were either primed with BCG or not, then immunized with ML89/GLA-SE. Subsequent analyses of the IFN ⁇ recall response to ML89 indicated similar responses in both immunization strategies ( FIG. 3 A ).
- mice immunized with ML89 also responded to lysate of BCG and, most importantly, to crude M. leprae antigens ( FIGS. 3 B and 3 D ). These data indicate that recognition of ML89 raises responses that recognize M. leprae that are not adversely affected by prior BCG immunization.
- M. leprae bacilli live M. leprae bacilli (Thai-53 strain) were purified from the footpads of nu/nu mice at National Institute of Infectious Diseases. Mice were inoculated with 1 ⁇ 104 bacilli by s.c. injection into each foot pad. Foot pads were harvested 12 months later and the bacilli were enumerated by direct microscopic counting of acid-fast bacilli according to the method of Shepard and McRae or by RT-PCR of the M. leprae specific repetitive element (RLEP).
- RLEP RT-PCR of the M. leprae specific repetitive element
- ML89-specific T cells reduced M. leprae viability during experimental infection.
- Mice were injected s.c. with ML89/GLA-SE at biweekly intervals, for a total of 3 immunizations.
- T cells were purified from the spleens of immunized mice and transferred by i.v. injection into athymic recipient mice.
- LEP-F1/GLA-SE immunization delayed the onset of motor nerve conduction abnormality among animals already incubating leprosy ( FIG. 5 B ). It is highly pertinent that LEP-F1/GLA-SE immunization, at a minimum, appears to be safe and induces no further neurological injury in armadillos.
- M. leprae is killed by MDT
- neurological injury continues to occur in patients and can be exacerbated during inflammatory reactional episodes.
- Some clinicians/researchers fear that immunization to boost inflammatory T cell responses will induce nerve-damaging reversal reactions.
- Live attenuated or killed mycobacteria vaccines have generally been well tolerated in patients and the incidence of reactions has not been dramatically altered versus unvaccinated groups, while more rapid bacterial clearance has occurred and has been accompanied by distinct signs of clinical improvement.
- Anecdotal reports, and now clinical evidence indicate that BCG immunization may however precipitate the onset of PB disease in some individuals, with speculation that infected but asymptomatic M. leprae -infected individuals are at greatest risk.
- a Phase I clinical trial will be performed.
- the proposed clinical trial is a first-in-man trial to establish an initial safety profile in mycobacterially naive healthy adults.
- the evaluation of vaccine-induced immunity will be based on the development of circulating antibody and T cell responses directed against the LEP-F1 antigen. Primary response will be assessed at Day 63. Responses at baseline and Day 35 will also be assessed. Each participant will be on study for 14 months. Serum will be collected on days 0, 35, and 63. These samples will be used to determine by IgG ELISA whether subjects have antibody responses to the LEP-F1 antigen at each of these time points. Measured antibody responses to LEP-F11 will be reported as normalized titers. Cellular immune response analysis of selected Th1 and Th2 cytokines specific to LEP-F1 will be assayed on days 0, 35, and 63 by whole blood assay. Cytokine concentrations will be quantified by ELISA or multiplex bead array.
- MULTISPECIES diacylglycerol 96% 85% WP_067924124.1 acyltransferase/mycolytransferase Ag85A [ Mycobacterium ] Diacylglycerol acyltransferase/ 100% 83% Q50397.1 mycolyltransferase Ag85B [ Mycobacterium scrofulaceum ] diacylglycerol acyltransferase/ 96% 85% WP_066954325.1 mycolyltransferase Ag85A [ Mycobacterium sp.
- type VII secretion protein EsxH 98% 68%
- WP_064281562.1 Mycobacterium iranicum
- low molecular weight protein 98% 72% CPR13219.1 antigen 7
- Cfp7 Mycobacterium bohemicum DSM 44277
- WP_066929865.1 Mycobacterium sp.
- type VII secretion protein EsxH 100% 71% WP_048893951.1
- Mycobacterium homeeshornense low molecular weight protein 100% 67% ABK67570.1 antigen 7 Cfp7
- Mycobacterium avium 104 hypothetical protein GuangZ0019_ 100% 67% EQM16518.1 4184 [ Mycobacterium tuberculosis GuangZ0019] type VII secretion protein EsxH 100% 69% WP_067330420.1 [ Mycobacterium sp. 1245111.1]
Abstract
Compositions and methods for preventing, treating and detecting leprosy are disclosed. The compositions generally comprise polypeptides comprising one or more Mycobacterium leprae antigens as well as polynucleotides encoding such polypeptides.
Description
- This application claims the benefit of U.S. patent application Ser. No. 16/333,596, filed Mar. 15, 2019, which claims the benefit of PCT Application No. PCT/US2017/051824, filed Sep. 15, 2017, which claims the benefit of U.S. Patent Application No. 62/396,074, filed Sep. 16, 2016, all of which are hereby incorporated by reference herein in their entirety, including all references and appendices cited therein, for all purposes, as if fully set forth herein.
- The content of the following submission of a Sequence Listing XML is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing with file name: 40-US-01_Sequence_Listing_ST26.XML, date created: Mar. 13, 2023, size: 19,983 bytes).
- The present disclosure relates generally to compositions and methods for preventing, treating and detecting leprosy in patients. More particularly, the disclosure relates to compositions and methods comprising Mycobacterium leprae antigens and fusion polypeptides, as well as polynucleotides encoding such antigens and fusion polypeptides.
- Leprosy (Hansen's disease) is an infectious peripheral neurological disorder caused by Mycobacterium leprae. Nerve involvement in leprosy patients can present as sensory and/or motor neuron damage and can advance to cause disability and disfigurement. Nerve damage likely involves a complicated interplay of both host immunity and mycobacterial infection-mediated events (1, 2). Although bacterial cure can be achieved by multidrug therapy (MDT), which the World Health Organization (WHO) provides free of charge for registered leprosy patients, leprosy remains as a public health problem in many regions. Declines in global incidence prompted by the introduction of MDT and drive toward ‘elimination’ as a global health problem by the year 2000 have now levelled off. More worryingly, it is widely believed that a large number of cases go unreported (Smith, 2015 #4604). Recent new case incidence rates indicate that transmission continues and the disease is slowly re-emerging in many regions that previously reported elimination.
- The current pursuit of preventative measures against leprosy involves provision of MDT for patients or chemoprophylaxis within high risk populations. These strategies, however, are limited. Unlike drug treatment, vaccines could be used to potentially provide active and sustained protection in both uninfected and infected individuals. Multibacillary (MB) leprosy patients present with many disseminated skin lesions and large bacterial burdens, indicating that the strong humoral immune responses that they classically exhibit are not protective. Replication and dissemination of M. leprae is limited in paucibacillary (PB) leprosy patients, however, suggesting the potent cellular immune response they develop is associated with limited or localized disease. In addition, despite presumed exposure to M. leprae, the vast majority of healthy household contacts (HHC) of MB patients appear to develop effective immunity. Understanding the targets of the immune response of these individuals is likely the key to generating an effective vaccine.
- By promoting a lasting adaptive immune response, a vaccine, unlike drug treatment, has the potential to provide active and sustained protection. The current standard—and only administered-vaccine against M. leprae is the BCG vaccine, originally developed for use in tuberculosis. The persistence of leprosy in countries where BCG is implemented suggests its effectiveness is limited. (Goulart I M, Clin Vaccine Immunol 2008; 15(1): 101-5.) The degree of protection afforded by BCG against leprosy has varied dramatically between studies. Systematic meta-analyses indicate that BCG has a wide-ranging protective efficacy with an average around 50% and protection appears to be better against the MB than PB forms. (Setia M S et al., Lancet Infect Dis 2006; 6(3): 162-70; Merle C S, Expert review of vaccines. 2010; 9(2): 209-22) Furthermore, BCG vaccination has been shown to precipitate paucibacillarv (PB) leprosy in some instances, negating its limited usefulness.
- M. leprae itself as an immunogen has been assessed in various trials, often to see if it can add to the protective effect of BCG. Large-scale studies in Venezuela, Malawi and India testing the use of killed M. leprae in combination with BCG have been largely inconclusive, with wide discrepancies in results. (Convit J et al., Lancet 1992; 339(8791): 446-50; Karonga Prevention Trial Group, Lancet 1996; 348(9019): 17-24) As a practical matter, production of a vaccine using killed M. leprae would be enormously constrained by the difficulties associated with mass production.
- Accordingly, there remains a significant need for compositions and vaccines that can effectively prevent, treat and/or diagnose leprosy in humans and other mammals. The present disclosure fulfills these needs and offers other related advantages.
- The present disclosure provides compositions, kits and methods for preventing, treating and detecting leprosy.
- In one aspect the disclosure provides compositions comprising at least two Mycobacterium leprae (M. leprae) antigens selected from the group consisting of ML2028, ML2055, and ML2380, or at least two M. leprae antigens each having at least 90% amino acid sequence identity to ML2028, ML2055, or ML2380. In some embodiments, the composition comprises ML2028 and ML2055; or an M. leprae antigen having at least 90% amino acid identity to ML2028 and an M. leprae antigen having at least 90% amino acid identity to ML2055. In some embodiments, the composition comprises ML2028 and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2028 and an M. leprae antigen having at least 90% amino acid identity to ML2380. In some embodiments, the composition comprises ML2055 and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2055 and an M. leprae antigen having at least 90% amino acid identity to ML2380. In some embodiments, the composition comprises ML2028, ML2055, and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2028, an M. leprae antigen having at least 90% amino acid identity to ML2055, and an M. leprae antigen having at least 90% amino acid identity to ML2380. In some embodiments, the composition further comprises ML2531 or a M. leprae antigen having at least 90% amino acid sequence identity to ML2531.
- In another aspect the disclosure provides fusion polypeptides comprising at least two Mycobacterium leprae (M. leprae) antigens selected from the group consisting of ML2028, ML2055, and ML2380, or at least two M. leprae antigens each having at least 90% amino acid sequence identity to ML2028, ML2055, or ML2380. In some embodiments, the fusion polypeptide comprises ML2028 and ML2055; or an M. leprae antigen having at least 90% amino acid identity to ML2028 and an M. leprae antigen having at least 90% amino acid identity to ML2055. In some embodiments, the fusion polypeptide comprises ML2028 and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2028 and an M. leprae antigen having at least 90% amino acid identity to ML2380. In some embodiments, the fusion polypeptide comprises ML2055 and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2055 and an M. leprae antigen having at least 90% amino acid identity to ML2380. In some embodiments, the fusion polypeptide comprises ML2028, ML2055, and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2028, an M. leprae antigen having at least 90% amino acid identity to ML2055, and an M. leprae antigen having at least 90% amino acid identity to ML2380. In some embodiments, the fusion polypeptide further comprises M. leprae antigen ML2531. In some embodiments, the fusion polypeptide comprises the sequence of SEQ ID NO: 12, or a sequence having 90% sequence identity thereto.
- In another aspect, the disclosure provides isolated polynucleotides encoding the fusion polypeptides of the disclosure.
- In another aspect, the disclosure provides compositions comprising a fusion polypeptide of the disclosure.
- In some embodiments of the above aspects, ML2028 comprises the sequence of SEQ ID NO: 2. In some embodiments, ML2028 comprises the sequence of SEQ ID NO: 4. In some embodiments, ML2055 comprises the sequence of SEQ ID NO: 6. In some embodiments, ML2380 comprises the sequence of SEQ ID NO: 8. In some embodiments, ML2531 comprises the sequence of SEQ ID NO: 10.
- In some embodiments of compositions of the disclosure, the composition further includes an immunostimulant. In some embodiments, the immunostimulant is selected from the group consisting of a CpG-containing oligonucleotide, synthetic lipid A, MPL™, 3D-MPL™, saponins, saponin mimetics, AGPs, Toll-like receptor agonists, or a combination thereof. In some embodiments, the immunostimulant is selected from the group consisting of a TLR4 agonist, a TLR7/8 agonist and a TLR9 agonist. In some embodiments, the immunostimulant is selected from the group consisting of GLA, CpG-containing oligonucleotide, imiquimod, gardiquimod and resiquimod.
- In some embodiments the immunostimulant is GLA, having the following structure:
- wherein R1, R3, R5 and R6 are C11-C20 alkyl; and R2 and R4 are C9-C20 alkyl. In some embodiments. R1, R3, R5 and W6 are C11-14 alkyl; and R2 and R4 are C12-15 alkyl. In some embodiments, R1, R3, W5 and W6 are C11 alkyl; and R2 and W4 are C13 alkyl. In some embodiments, R1, R3, R5 and R6 are C11 alkyl; and R2 and R14 are C9 alkyl.
- In some embodiments, the immunostimulant has the following structure:
- In some embodiments, the immunostimulant has the following structure:
- In another aspect, the disclosure provides methods for stimulating an immune response against M. leprae in a mammal comprising administering to a mammal in need thereof a composition of the disclosure. In some embodiments, the method further comprises administering to the mammal M. bovis BCG vaccine. In some embodiments, M. bovis BCG vaccine was previously administered to the mammal. In some embodiments, the mammal has not been exposed to M. leprae. In some embodiments, the mammal has been exposed to M. leprae. In some embodiments, the mammal is a human healthy household contact of a human identified as being infected with M. leprae. In some embodiments, the mammal has been infected by M. leprae. In some embodiments, the mammal exhibits signs or symptoms of infection by M. leprae.
- In another aspect, the disclosure provides methods for stimulating an immune response against a tuberculosis-causing mycobacterium in a mammal comprising administering to a mammal in need thereof a composition of the disclosure.
- In another aspect, the disclosure provides methods for treating an M. leprae infection in a mammal, the method comprising administering to a mammal having an M. leprae infection a composition of the disclosure. In some embodiments, the method further comprises administering to the mammal one or more chemotherapeutic agents. In some embodiments, the one or more chemotherapeutic agents comprise one or more agents selected from the group consisting of dapsone, rifampicin, clofazimine, ofloxacin, minocycline, gatifloxacin, linezolid, and PA 824. In some embodiments, the mammal is first administered one or more chemotherapeutic agents over a period of time and subsequently administered the composition. In some embodiments, the mammal is first administered the composition and subsequently administered one or more chemotherapeutic agents over a period of time. In some embodiments, administration of the one or more chemotherapeutic agents and the composition is concurrent. In some embodiments, the method further comprises administering the composition to the mammal one or more subsequent times. In some embodiments, the method further comprises administering to the mammal M. bovis BCG vaccine. In some embodiments, M. bovis BCG vaccine was previously administered to the mammal. In some embodiments, the mammal does not exhibit signs or symptoms of infection by M. leprae. In some embodiments, the mammal has indeterminate or tuberculoid presentation. In some embodiments, the mammal has paucibacillary leprosy. In some embodiments, the mammal has multibacillary leprosy. In some embodiments, the mammal has lepromatous leprosy. In some embodiments, the mammal has borderline lepromatous leprosy. In some embodiments, the mammal has mid-borderline leprosy. In some embodiments, the mammal has borderline tuberculoid leprosy. In some embodiments, the mammal has tuberculoid leprosy. In some embodiments, the mammal is infected with a multidrug resistant M. leprae.
- In another aspect, the disclosure provides methods for reducing the time course of chemotherapy against an M. leprae infection, the method comprising administering to a mammal having an M. leprae infection a composition of the disclosure in conjunction with the chemotherapy, where the composition induces an immune response against M. leprae, thereby providing for a reduced time course of the chemotherapy against an M. leprae infection. In some embodiments, the time course of chemotherapy is shortened to no more than about 3 months, about 5 months, or about 7 months.
- In some embodiments of the methods of the disclosure, the mammal is a human.
- In another aspect, the disclosure provides a method for detecting M. leprae infection in a biological sample, comprising: (a) contacting a biological sample with a polypeptide (including a fusion polypeptide) as described herein; and (b) detecting in the biological sample the presence of antibodies that bind to the fusion polypeptide, thereby detecting M. leprae infection in a biological sample. Any suitable biological sample type may be analyzed by the method, illustrative examples of which may include, for example, sera, blood, saliva, skin, and nasal secretion.
- In certain embodiments of the disclosed diagnostic methods, the polypeptide (including a fusion polypeptide) is bound to a solid support. Accordingly, the present disclosure further provides diagnostic reagents comprising a polypeptide (including a fusion polypeptide) as described herein, immobilized on a solid support.
- Diagnostic kits for detecting M. leprae infection in a biological sample are also provided, generally comprising a polypeptide (including a fusion polypeptide) as described herein and a detection reagent. It will be understood that the kit may employ a polypeptide (including a fusion polypeptide) of the disclosure in any of a variety of assay formats known in the art, including, for example, a lateral flow test strip assay, a dual path platform (DPP) assay and an ELISA assay. These kits and compositions of the disclosure can offer valuable point of care diagnostic information. Furthermore, the kits and compositions can also be advantageously used as test-of-cure kits for monitoring the status of infection in an infected individual over time and/or in response to treatment.
- Treatment kits for treating an M. leprae infection in a mammal are also provided, generally comprising a composition of the disclosure.
- It is to be understood that one, some, or all of the properties of the various embodiments described herein may be combined to form other embodiments of the present disclosure. These and other aspects of the present disclosure will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.
-
FIG. 1 : Immunization with recombinant antigens formulated in GLA-SE reduce M. leprae burden. Mice were injected s.c. with antigens/GLA-SE at biweekly intervals, for a total of 3 immunizations. One month after the last immunization mice were infected with 1×104 M. leprae in each foot, and bacterial burdens determined 12 months later. Results are shown as mean and SE. Mann-Whitney test was used to calculate p-values between each group; n=6 per group.FIG. 1A shows the antigens, ML2028, ML2055 and ML2380, administered individually compared to the sham treatment and heat-killed M. leprae.FIG. 1B shows the results of administering the antigens in combination.FIG. 1C shows the negative results from immunization with the antigens ML0276 and ML46F. -
FIG. 2 : Immunological recognition of each component is retained in chimeric fusion protein ML89. Mice were injected s.c. with antigens/GLA-SE at biweekly intervals, for a total of 3 immunizations. Serum and spleens were collected one month after the third immunization. InFIG. 2 , antigen-specific serum IgG, IgG1 and IgG2a titers in response to ML89 immunization were determined by ELISA for ML89 (FIG. 2A ), ML2028 (FIG. 2B ), ML2055 (FIG. 2C ), and ML2380 (FIG. 2D ). -
FIG. 3 : Prior BCG priming does not alter the induction of anti-M. leprae responses by ML89 immunization. Single cell suspensions were prepared from each spleen and cultured with 10 μg/ml protein. Culture supematants were collected and IFN γ content determined by ELISA. Results are shown as mean and SE; n=3 per group. Data are representative of two independent experiments. The results show recall response following ML89 immunization (with and without BCG priming) to the following antigens inFIGS. 3A-3E : ML89 (FIG. 3A ), BCG lysate (FIG. 3B ), purified protein derivative (PPD) (FIG. 3C ), M. leprae cell sonicate (MLCS) (FIG. 3D ), and cell wall antigen (CWA) (FIG. 3E ). -
FIG. 4 : Immunization with ML89/GLA-SE reduces M. leprae burden. Mice were injected s.c. with antigens/GLA-SE at biweekly intervals, for a total of 3 immunizations. One month after the last immunization mice were infected with 1×104 M. leprae in each foot, and bacterial burdens determined 12 months later. Results were generated in 2 independent laboratories and are shown as mean and SE. Mann-Whitney test was used to calculate p-values between each group; n=6 per group.FIG. 4A demonstrates an 85% reduction of M. leprae bacterial burden.FIG. 4B shows that repeated ML89 administration still protects against M. leprae growth. -
FIG. 5 : Immunization with ML89/GLA-SE delays M. leprae-induced nerve damage.FIG. 5A shows that untreated armadillos demonstrated early onset of defects, while onset in ML89-immunized armadillos was comparatively delayed.FIG. 5B shows that ML89-immunized armadillos had lower incidence of sustained nerve conduction defects, whereas BCG-immunized armadillos developed more rapid onset of severe damage relative to both control and ML-89 treated animals.FIG. 5C shows the proportion of animals displaying normal, borderline, and abnormal nerve conduction in control, BCG, and LepVax-treated armadillos. - SEQ ID NO: 1 is a nucleic acid sequence encoding the ML2028 antigen polypeptide of SEQ ID NO: 2.
- SEQ ID NO: 2 is an amino acid sequence of Mycobacterium leprae ML2028 antigen (diacylglycerol acyltransferase; NCBI Reference Sequence: WP_010908679.1).
- SEQ ID NO: 3 is a nucleic acid sequence encoding the ML202839-327 polypeptide of SEQ ID NO: 4.
- SEQ ID NO: 4 is an amino acid sequence of the mature chain without signal sequence of ML2028 antigen from Mycobacterium leprae (ML202839-327).
- SEQ ID NO: 5 is a nucleic acid sequence encoding the ML2055 antigen polypeptide of SEQ ID NO: 6.
- SEQ ID NO: 6 is an amino acid sequence of ML2055 antigen from Mycobacterium leprae (alanine and proline-rich secreted protein Apa; NCBI Reference Sequence: WP_010908692.1).
- SEQ ID NO: 7 is a nucleic acid sequence encoding the ML2380 antigen polypeptide of SEQ ID NO: 8.
- SEQ ID NO: 8 is an amino acid sequence of ML2380 antigen from Mycobacterium leprae (hypothetical protein; NCBI Reference Sequence: WP_010908863.1).
- SEQ ID NO: 9 is a nucleic acid sequence encoding the ML2531 antigen polypeptide of SEQ ID NO: 10.
- SEQ ID NO: 10 is an amino acid sequence of ML2531 antigen from Mycobacterium leprae (ESAT-6-like protein EsxR: NCBI Reference Sequence: WP_010908945.1).
- SEQ ID NO: 11 is a nucleic acid sequence encoding the LEP-F1 fusion polypeptide of SEQ ID NO: 12.
- SEQ ID NO: 12 is an amino acid sequence of the LEP-F1 fusion polypeptide.
- The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology, recombinant DNA, and chemistry, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Molecular Cloning A Laboratory Manual, 2nd Ed., Sambrook et al., ed., Cold Spring Harbor Laboratory Press: (1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al., U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); and in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Maryland (1989).
- As noted above, the present disclosure is generally directed to compositions and methods for preventing, treating and detecting leprosy. The compositions of the disclosure include, for example, polypeptides including fusion polypeptides that comprise various immunogenic portions of Mycobacterium leprae (M. leprae) proteins, wherein the portions and variants preferably retain substantially the same or similar immunogenic properties as a corresponding full length M. leprae protein. Immunization strategies using compositions of the disclosure can be applied to the in vivo protection against, for example, infection by M. leprae, which is the causative agent of leprosy in humans and armadillos. The present disclosure also contemplates, in other embodiments, using the polypeptides including fusion polypeptides described herein in methods of treating mammals having an M. leprae infection. The present disclosure also contemplates, in other embodiments, using the polypeptides including fusion polypeptides described herein in diagnostic applications, including, but not limited to, diagnosis and whole blood assays, preferably in a format amenable to providing rapid, point of care diagnostic results, such as a lateral flow assay or a dual path platform assay.
- M. Leprae Antigens and Fusion Polypeptides and Uses Therefor
- In a general aspect, the present disclosure provides M. leprae antigens, as described herein, including fusion polypeptides and compositions containing the same.
- In some embodiments the disclosure provides compositions comprising at least two Mycobacterium leprae (M. leprae) antigens selected from the group consisting of ML2028, ML2055, and ML2380, or at least two M. leprae antigens each having at least 90% amino acid sequence identity to ML2028, ML2055, or ML2380. In some embodiments, the composition comprises ML2028 and ML2055; or an M. leprae antigen having at least 90% amino acid identity to ML2028 and an M. leprae antigen having at least 90% amino acid identity to ML2055. In some embodiments, the composition comprises ML2028 and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2028 and an M. leprae antigen having at least 90% amino acid identity to ML2380. In some embodiments, the composition comprises ML2055 and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2055 and an M. leprae antigen having at least 90% amino acid identity to ML2380. In some embodiments, the composition comprises ML2028, ML2055, and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2028, an M. leprae antigen having at least 90% amino acid identity to ML2055, and an M. leprae antigen having at least 90% amino acid identity to ML2380. In some embodiments, the composition further comprises ML2531 or an M. leprae antigen having at least 90% amino acid sequence identity to ML2531.
- In some embodiments the disclosure provides fusion polypeptides comprising at least two Mycobacterium leprae (M. leprae) antigens selected from the group consisting of ML2028, ML2055, and ML2380, or at least two M. leprae antigens each having at least 90% amino acid sequence identity to ML2028, ML2055, or ML2380. In some embodiments, the fusion polypeptide comprises ML2028 and ML2055; or an M. leprae antigen having at least 90% amino acid identity to ML2028 and an M. leprae antigen having at least 90% amino acid identity to ML2055. In some embodiments, the fusion polypeptide comprises ML2028 and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2028 and an M. leprae antigen having at least 90% amino acid identity to ML2380. In some embodiments, the fusion polypeptide comprises ML2055 and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2055 and an M. leprae antigen having at least 90% amino acid identity to ML2380. In some embodiments, the fusion polypeptide comprises ML2028. ML2055, and ML2380; or an M. leprae antigen having at least 90% amino acid identity to ML2028, an M. leprae antigen having at least 90% amino acid identity to ML2055, and an M. leprae antigen having at least 90% amino acid identity to ML2380. In some embodiments, the fusion polypeptide further comprises M. leprae antigen ML2531. In some embodiments, the fusion polypeptide comprises the sequence of SEQ ID NO: 12, or a sequence having 90% sequence identity thereto.
- In some embodiments, compositions comprising antigens and fusion polypeptides described herein can generate an immune response or an effective immune response to M. leprae. The immune response may have one or more of the following characteristics: 1) a reduction in bacterial burden in immunized hosts upon challenge with an M. leprae infection; 2) secretion of IFNγ in vitro spleen cell cultures from mice immunized with the compositions of the disclosure upon incubation with the matched fusion polypeptide or individual antigens of the fusion polypeptide; 3) IFNγ secretion in vitro spleen cell cultures from mice immunized with the compositions of the disclosure following incubation with crude M. leprae, 4) generation of antigen-specific multifunctional Th1 cells, for example CD4 T cells that produce multiple cytokines indicative of a Th1 phenotype such as the combined production of IFNγ, TNF and IL-2 or IFNγ and TNF; or 5) improvement or enhancement of the immune recognition of one or more antigen(s), when presented in the context of a fusion polypeptide, as measured for example by the secretion of cytokines such γIFN, or the titer of presence of antibodies or cellular responses to the antigen. Methods for testing one or more of the above immune responses are known in the art and are described in detail in Examples.
- Different M. leprae antigens in the fusion polypeptides may be arranged in the fusion polypeptide in any order. For example, any particular polypeptide of the fusion polypeptide may be located towards the C-terminal end of the fusion polypeptide or the N-terminal end of the polypeptide or in the center of the fusion polypeptide {i.e., located in between at least two other polypeptides in the fusion polypeptide). Different M. leprae antigens may be linked by a linker sequence of any length (e.g., 2-20 amino acids).
- In one embodiment, the fusion polypeptide consists of four M. leprae antigens: ML2531 (ESAT-6-like protein EsxR), ML2380 (hypothetical protein), ML2055 (cell surface protein associated with virulence), and ML202839-327 (antigen 85B, mature chain without signal sequence). The full native sequence of ML2531, ML2380, ML2055 are present, while ML202839-327 represents the mature chain without the
signal sequence residues 1 through 38. - There is a two-residue linker sequence inserted between each of the antigens to improve expression and recovery. The resulting 831 amino acid fusion protein has a predicted molecular weight of 89,062 Da. The polynucleotide sequence encoding the fusion polypeptide is SEQ ID NO: 11, and the amino acid sequence of the fusion polypeptide is SEQ ID NO: 12. Such fusion polypeptide may be referred to as LEP-F1, ML89, or LepVax.
- A schematic of one embodiment of the fusion polypeptide is below.
-
ML2531 ML2380 ML2055 ML2028 39-327 10 kDa 17 kDa 30 kDa 31 kDa - As used herein, the term “polypeptide” or “protein” encompasses amino acid chains of any length, including full length proteins, wherein the amino acid residues are linked by covalent bonds. An antigen is a polypeptide comprising an immunogenic portion of a M. leprae polypeptide or protein and may consist solely of an immunogenic portion, may contain two or more immunogenic portions and/or may contain additional sequences. The additional sequences may be derived from a native M. leprae polypeptide or protein or may be heterologous, and such heterologous sequences may (but need not) be immunogenic.
- An “isolated polypeptide” is one that is removed from its original environment. For example, a naturally-occurring protein is isolated if it is separated from some or all of the coexisting materials in the natural system. Preferably, such polypeptides are at least about 90% pure, more preferably at least about 95% pure and most preferably at least about 99% pure. One of ordinary skill in the art would appreciate that antigenic polypeptide fragments could also be obtained from those already available in the art. Polypeptides of the disclosure, antigenic/immunogenic fragments thereof, and other variants may be prepared using conventional recombinant and/or synthetic techniques.
- The M. leprae antigens used in a fusion polypeptide of the present disclosure can be full length, substantially full length polypeptides, or variants thereof as described herein. Alternatively, a fusion polypeptide or composition of the disclosure can comprise or consist of immunogenic portions or fragments of a full length M. leprae polypeptide, or variants thereof.
- In certain embodiments, an immunogenic portion of a M. leprae polypeptide is a portion that is capable of eliciting an immune response (i.e., cellular and/or humoral) in a presently or previously M. leprae-infected patient (such as a human or a mammal (e.g., an armadillo)) and/or in cultures of spleen cells, lymph node cells or peripheral blood mononuclear cells (PBMC) isolated from presently or previously M. leprae-infected individuals. The cells in which a response is elicited may comprise a mixture of cell types or may contain isolated component cells (including, but not limited to, T-cells, NK cells, macrophages, monocytes and/or B cells). In a particular embodiment, immunogenic portions of a fusion polypeptide of the disclosure are capable of inducing T-cell proliferation and/or a predominantly Th1-type cytokine response (e.g., IL-2, IFN-γ, and/or TNFα production by T-cells and/or NK cells, and/or IL-12 production by monocytes, macrophages and/or B cells). Immunogenic portions of the polypeptides described herein may generally be identified using techniques known to those of ordinary skill in the art, including the representative methods summarized in Paul, Fundamental Immunology, 5th ed., Lippincott Williams & Wilkins, 2003 and references cited therein. Such techniques include screening fusion polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T cell lines or clones. As used herein, antisera and antibodies are “antigen-specific” if they specifically bind to an antigen (i.e., they react with the protein in an immunoassay, and do not react detectably with unrelated proteins). Such antisera and antibodies may be prepared as described herein and using well-known techniques.
- Immunogenic portions of an M. leprae polypeptide can be essentially any length; provided they retain one or more of the immunogenic regions that are responsible for or contribute to the in vivo protection provided against leprosy by one or more antigens of fusion polypeptides of the disclosure, as disclosed herein. In one embodiment, the ability of an immunogenic portion to react with antigen-specific antisera may be enhanced or unchanged, relative to the native protein, or may be diminished by less than 50%, and preferably less than 20%, relative to the native protein. Illustrative portions will generally be at least 10, 15, 25, 50, 150, 200, 250, 300, or 350 amino acids in length, or more, up to and including full length M. leprae polypeptide.
- In some embodiments, a M. leprae antigen described herein includes ML2028, ML2055, ML2380, and ML2531. In some embodiments, these M. leprae antigens include any naturally occurring variants.
- As would be recognized by the skilled artisan, a composition of the disclosure may also comprise one or more polypeptides that are immunologically reactive with T cells and/or antibodies generated against a polypeptide of the disclosure, particularly a polypeptide having an amino acid sequence disclosed herein, or to an immunogenic fragment or variant thereof. In a specific embodiment, the polypeptide is a fusion polypeptide, as described herein.
- As noted, in various embodiments of the present disclosure, fusion polypeptides generally comprise at least an immunogenic portion or variant of the M. leprae polypeptides described herein. In some instances, preferred immunogenic portions will be identified that have a level of immunogenic activity greater than that of the corresponding full-length polypeptide, e.g., having greater than about 100% or 150% or more immunogenic activity. In particular embodiments, the immunogenicity of the fill-length fusion polypeptide will have additive, or greater than additive immunogenicity contributed by of each of the antigenic/immunogenic portions contained therein.
- In another aspect, fusion polypeptides of the present disclosure may contain multiple copies of polypeptide fragments, repeats of polypeptide fragments, or multimeric polypeptide fragments, including antigenic/immunogenic fragments, such as M. leprae polypeptides comprising at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more contiguous fragments of aM leprae polypeptide, in any order, and including all lengths of a polypeptide composition set forth herein, or those encoded by a polynucleotide sequence set forth herein.
- In some embodiments, the ML2028 antigen comprises the sequence of SEQ ID NO: 2 or SEQ ID NO: 4, or a sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) to SEQ ID NO: 2 or to SEQ ID NO: 4. In some embodiments, the ML2055 antigen comprises the sequence of SEQ ID NO: 6, or a sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) to SEQ ID NO: 6. In some embodiments, the ML2380 antigen comprises the sequence of SEQ ID NO: 8, or a sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) to SEQ ID NO: 8. In some embodiments, the ML2531 antigen comprises the sequence of SEQ ID NO: 10, or a sequence having at least 90% identity (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) to SEQ ID NO: 10.
- In another aspect, the disclosure provides a fusion polypeptide comprising, consisting of, or consisting essentially of the amino acid sequence set forth in SEQ ID NO: 12, or a sequence having at least 90% identity thereto (e.g., at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity thereto).
- In yet another aspect, the present disclosure provides fusion polypeptides comprising one or more variants of the M. leprae antigens described herein. Polypeptide variants generally encompassed by the present disclosure will typically exhibit at least about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or more identity (determined as described below), along its length, to a polypeptide sequence set forth herein.
- In other related embodiments, a polypeptide “variant,” includes polypeptides that differ from a native protein in one or more substitutions, deletions, additions and/or insertions, such that the desired immunogenicity of the variant polypeptide is not substantially diminished relative to a native polypeptide.
- For example, certain variants of the disclosure include polypeptides of the disclosure that have been modified to replace one or more cysteine residues with alternative residues. Such polypeptides are referred to hereinafter as cysteine-modified polypeptides or cysteine-modified fusion polypeptides. Preferably, the modified polypeptides retain substantially the same or similar immunogenic properties as the corresponding unmodified polypeptides. In a more specific embodiment, cysteine residues are replaced with serine residues because of the similarity in the spatial arrangement of their respective side chains. However, it will be apparent to one skilled in the art that any amino acid that is incapable of interchain or intrachain disulfide bond formation can be used as a replacement for cysteine. When all or substantially all of the cysteine residues in a polypeptide or fusion polypeptide of this disclosure are replaced, the resulting cysteine-modified variant may be less prone to aggregation and thus easier to purify, more homogeneous, and/or obtainable in higher yields following purification.
- In one embodiment, the ability of a variant to react with antigen-specific antisera may be enhanced or unchanged, relative to the native protein, or may be diminished by less than 50%, and preferably less than 20%, relative to a corresponding native or control polypeptide. In a particular embodiment, a variant of an M. leprae polypeptide is one capable of providing protection against M. leprae infection.
- In particular embodiments, a fusion polypeptide of the present disclosure comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 or more substitutions, deletions, additions and/or insertions within a M. leprae polypeptide, where the fusion polypeptide is capable of providing protection against an M. leprae infection.
- In related embodiments, a fusion polypeptide of the present disclosure comprises at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 or more substitutions, deletions, additions and/or insertions within a M. leprae polypeptide, where the fusion polypeptide is capable of serodiagnosis of M. leprae.
- In many instances, a variant will contain conservative substitutions. A “conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. As described above, modifications may be made in the structure of the polynucleotides and polypeptides of the present disclosure and still obtain a functional molecule that encodes a variant or derivative polypeptide with desirable characteristics, e.g., with immunogenic characteristics. When it is desired to alter the amino acid sequence of a polypeptide to create an equivalent, or even an improved, immunogenic variant or portion of a polypeptide of the disclosure, one skilled in the art will typically change one or more of the codons of the encoding DNA sequence according to Table 1.
- For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of interactive binding capacity with structures such as, for example, antigen-binding regions of antibodies or binding sites on substrate molecules. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence, and, of course, its underlying DNA coding sequence, and nevertheless obtain a protein with like properties. It is thus contemplated that various changes may be made in the peptide sequences of the disclosed compositions, or corresponding DNA sequences which encode said peptides without appreciable loss of their biological utility or activity.
-
TABLE 1 Amino Acids Codons Alanine Ala A GCA GCC GCG GCU Cysteine Cys C UGC UGU Aspartic acid Asp D GAG GAU Glutamic acid Glu E GAA GAG Phenylalanine Phe F UUC UUU Glycine Gly G GGA GGC GGG GGU Histidine His H CAC CAU Isoleucine Ile I AUA AUC AUU Lysine Lys K AAA AAG Leucine Leu L UUA UUG CUA CUC CUG CUU Methionine Met M AUG Asparagine Asn N AAC AAU Proline Pro P CCA CCC CCG CCU Glutamine Gin Q CAA CAG Arginine Arg R AGA AGG CGA CGC CGG CGU Serine Ser S AGC AGU UCA UCC UCG UCU Threonine Thr T ACA ACC ACG ACU Valine Val V GUA GUC GUG GUU Tryptophan Trp W UGG Tyrosine Tyr Y UAC UAU - In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a protein is generally understood in the art (Kyte and Doolittle, 1982, incorporated herein by reference). It is accepted that the relative hydropathic character of the amino acid contributes to the secondary structure of the resultant protein, which in turn defines the interaction of the protein with other molecules, for example, enzymes, substrates, receptors, DNA, antibodies, antigens, and the like. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics (Kyte and Doolittle, 1982). These values are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (−0.4); threonine (−0.7); serine (−0.8); tryptophan (−0.9); tyrosine (−1.3); proline (−1.6); histidine (−3.2); glutamate (−3.5); glutamine (−3.5); aspartate (−3.5); asparagine (−3.5); lysine (−3.9); and arginine (−4.5).
- It is known in the art that certain amino acids may be substituted by other amino acids having a similar hydropathic index or score and still result in a protein with similar biological activity, i.e. still obtain a biological functionally equivalent protein. In making such changes, the substitution of amino acids whose hydropathic indices are within +2 is preferred, those within +1 are particularly preferred, and those within +0.5 are even more particularly preferred. It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity.
- As detailed in U.S. Pat. No. 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0±1); glutamate (+3.0±1) serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (−0.4); proline (−0.5±1); alanine (−0.5); histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine (−1.8); isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5); tryptophan (−3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein. In such changes, the substitution of amino acids whose hydrophilicity values are within ±2 is preferred, those within ±1 are particularly preferred, and those within ±0.5 are even more particularly preferred.
- As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine.
- Amino acid substitutions may further be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine and valine: glycine and alanine: asparagine and glutamine; and serine, threonine, phenylalanine and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gin, asn, ser, thr: (2) cys, ser, tyr, thr: (3) val, ile, leu, met, ala, phe: (4) lys, arg, his; and (5) phe, tyr, trp, his. A variant may also, or alternatively, contain nonconservative changes. In a preferred embodiment, variant polypeptides differ from a native sequence by substitution, deletion or addition of five amino acids or fewer. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure and hydropathic nature of the polypeptide.
- As noted above, polypeptides may comprise a signal (or leader) sequence at the N-terminal end of the protein, which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification or identification of the polypeptide (e.g., poly-Histidine tag (6XHis), GST, MBP, TAP/TAG, FLAG epitope, MYC epitope, V5 epitope, VSV-G epitope, etc.), or to enhance binding of the polypeptide to a solid support. For example, a polypeptide may be conjugated to an immunoglobulin Fc region.
- When comparing polynucleotide or polypeptide sequences, two sequences are said to be “identical” if the sequence of nucleotides or amino acids in the two sequences is the same when aligned for maximum correspondence, as described below. Comparisons between two sequences are typically performed by comparing the sequences over a comparison window to identify and compare local regions of sequence similarity. A “comparison window” as used herein, refers to a segment of at least about 20 contiguous positions, usually 30 to about 75, 40 to about 50, in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.
- Alignment of sequences for comparison may be conducted using, for example, the Megalign program in the Lasergene suite of bioinformatics software (DNASTAR, Inc., Madison, WI), using default parameters. This program embodies several alignment schemes described in the following references: Dayhoff, M. O. (1978) A model of evolutionary change in proteins—Matrices for detecting distant relationships. In Dayhoff, M. O. (ed.) Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, Washington DC Vol. 5, Suppl. 3, pp. 345-358: Hein J. (1990) Unified Approach to Alignment and Phylogenes pp. 626-″645 Methods in Enzymology vol. 183, Academic Press, Inc., San Diego, CA: Higgins, D. G. and Sharp, P. M. (1989) CABIOS 5:151-153: Myers, E. W. and Muller W. (1988) CABIOS 4: 11-17: Robinson, E. D. (1971) Comb. Theor 11:105: Santou, N. Nes, M. (1987) MoL Biol. Evol. 4:406-425: Sneath, P. H. A. and Sokal, R. R. (1973) Numerical Taxonomy—the Principles and Practice of Numerical Taxonomy, Freeman Press, San Francisco, CA; Wilbur, W. J. and Lipman, D. J. (1983) Proc. Natl. Acad., Sci. USA 80:726-730.
- Alternatively, alignment of sequences for comparison may be conducted by the local identity algorithm of Smith and Waterman (1981) Add. APL. Math 2:482, by the identity alignment algorithm of Needleman and Wunsch (1970) J. MoL Biol. 48:443, by the search for similarity methods of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. USA 85: 2444, by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.
- One example of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) Nucl. Acids Res. 25:3389-3402 and Altschul ct al. (1990) J. Mol. Biol. 215:403-410, respectively. BLAST and BLAST 2.0 can be used, for example with the parameters described herein, to determine percent sequence identity for the polynucleotides and polypeptides of the disclosure. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. In one illustrative example, cumulative scores can be calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix can be used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W. T and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915) alignments, (B) of 50, expectation (E) of 10, M=5, N=−4 and a comparison of both strands.
- Preferably, the “percentage of sequence identity” is determined by comparing two optimally aligned sequences over a window of comparison of at least 20 positions, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less, usually 5 to 15 percent, or 10 to 12 percent, as compared to the reference sequences (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid bases or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the reference sequence (i.e., the window size) and multiplying the results by 100 to yield the percentage of sequence identity.
- Therefore, as noted above, the present disclosure encompasses polynucleotide and polypeptide sequences having substantial identity to the sequences disclosed herein, for example those comprising at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence identity compared to a polynucleotide or polypeptide sequence of this disclosure (e.g., as set out in SEQ ID NOs: 1-12) using the methods described herein, (e.g., BLAST analysis using standard parameters, as described below). One skilled in this art will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like. Furthermore, it would be understood by of ordinary skill in the art that fusion polypeptides of the present disclosure may comprise at least 2, at least 3, or at least 4 or more antigenic/immunogenic portions or fragments of a polypeptide comprising at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher, sequence identity to a M. leprae polypeptide that is capable of providing protection against M. leprae infection, or serodiagnosis of M. leprae.
- In another aspect of the disclosure, fusion polypeptides are provided that comprise at least an immunogenic portion of a polypeptide and further comprise a heterologous fusion partner, as well as polynucleotides encoding such fusion polypeptides. For example, in one embodiment, a fusion polypeptide comprises one or more immunogenic portions or fragments of a M. leprae polypeptide and one or more additional immunogenic M. leprae sequences, which are joined via a peptide linkage into a single amino acid chain.
- In another embodiment, a fusion polypeptide may comprise multiple M. leprae antigenic portions. In some embodiments, at least one of the portions in the fusion polypeptide is from ML2028, ML2055, or ML2380. In some embodiments, an immunogenic portion is a portion of an antigen that reacts with blood samples from M. leprae-infected individuals (i.e. an epitope is specifically bound by one or more antibodies and/or T-cells present in such blood samples.
- In certain embodiments, a fusion polypeptide may further comprise at least one heterologous fusion partner having a sequence that assists in providing T helper epitopes (an immunological fusion partner), preferably T helper epitopes recognized by humans, or that assists in expressing the protein (an expression enhancer) at higher yields than the native recombinant protein. Certain preferred fusion partners include both immunological and expression-enhancing fusion partners. Other fusion partners may be selected so as to increase the solubility of the protein or to enable the protein to be targeted to desired intracellular compartments. Still further fusion partners include affinity tags, such as V5, 6XHIS, MYC, FLAG, and GST, which facilitate purification of the protein. It would be understood by one having ordinary skill in the art that those unrelated sequences may, but need not, be present in a fusion polypeptide used in accordance with the present disclosure. In another particular embodiment, an immunological fusion partner comprises an amino acid sequence derived from the protein known as LYTA, or a portion thereof (preferably a C-terminal portion). LYTA is derived from Streptococcus pneumoniae, which synthesizes an N-acetyl-L-alanine amidase known as amidase LYTA (encoded by the LytA gene; Gene 43:265-292 (1986)). LYTA is an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LYTA protein is responsible for the affinity to the choline or to some choline analogues such as DEAE. This property has been exploited for the development of E. coli C-LYTA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LYTA fragment at the amino terminus has been described (see Biotechnology 10:795-798 (1992)). Within a particular embodiment, a repeat portion of LYTA may be incorporated into a fusion protein. A repeat portion is found in the C-terminal region starting at residue 178. A more particular repeat portion incorporates residues 188-305.
- Fusion sequences may be joined directly (i.e., with no intervening amino acids) or may be joined by way of a linker sequence (e.g., Gly-Cys-Gly) that does not significantly diminish the immunogenic properties of the component polypeptides. The polypeptides forming the fusion protein are typically linked C-terminus to N-terminus, although they can also be linked C-terminus to C-terminus, N-terminus to N-terminus, or N-terminus to C-terminus. The polypeptides of the fusion protein can be in any order. Fusion polypeptides or fusion proteins can also include conservatively modified variants, polymorphic variants, alleles, mutants, subsequences, interspecies homologs, and immunogenic fragments of the antigens that make up the fusion protein.
- Fusion polypeptides may generally be prepared using standard techniques, including recombinant technology, chemical conjugation and the like. For example, DNA sequences encoding the polypeptide components of a fusion may be assembled separately, and ligated into an appropriate expression vector. The 3′ end of the DNA sequence encoding one polypeptide component is ligated, with or without a peptide linker, to the 5′ end of a DNA sequence encoding the second polypeptide component so that the reading frames of the sequences are in frame. This permits translation into a single fusion polypeptide that retains or in some cases exceeds the biological activity of the component polypeptides.
- A peptide linker sequence may be employed to separate the fusion components by a distance sufficient to ensure that each polypeptide folds into its desired secondary and/or tertiary structures. Such a peptide linker sequence may be incorporated into the fusion polypeptide using standard techniques well known in the art. Suitable peptide linker sequences may be chosen, for example, based on one or more of the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Certain preferred peptide linker sequences contain Gly. Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al., Gene 40:39-46, 1985; Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258-8262, 1986; U.S. Pat. Nos. 4,935,233 and 4,751,180. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.
- The ligated DNA sequences are operably linked to suitable transcriptional or translational regulatory elements. The regulatory elements responsible for expression of DNA are located only 5′ to the DNA sequence encoding the first polypeptides. Similarly, stop codons required to end translation and transcription termination signals are only present 3′ to the DNA sequence encoding the second polypeptide.
- In addition to recombinant fusion polypeptide expression, M. leprae polypeptides, immunogenic portions, variants and fusions thereof may be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain (Merrifield, J. Am. Chem. Soc. 85:2149-2146, 1963). Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division, Foster City, CA, and may be operated according to the manufacturer's instructions. Thus, for example, M. leprae antigens, or portions thereof, may be synthesized by this method.
- Recombinant polypeptides containing portions and/or variants of a native M. leprae polypeptide may be readily prepared from a DNA sequence encoding the antigen, using well known and established techniques. In particular embodiments, a fusion polypeptide comprising M. leprae antigens may be readily prepared from a DNA sequence encoding the cloned fused antigens. For example, supematants from suitable host/vector systems which secrete recombinant protein into culture media may be first concentrated using a commercially available filter. Following concentration, the concentrate may be applied to a suitable purification matrix such as an affinity matrix, a size exclusion chromatography matrix or an ion exchange resin.
- Alternatively, any of a variety of expression vectors known to those of ordinary skill in the art may be employed to express recombinant polypeptides of this disclosure. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a polynucleotide that encodes a recombinant polypeptide. Preferably, the host cells are E. coli, yeast, an insect cell line (such as Spodoptera or Trichoplusia) or a mammalian cell line, including (but not limited to) CHO, COS, HEK-293T and NS-1. The DNA sequences expressed in this manner may encode naturally occurring proteins, and fusion proteins comprising M. leprae antigens, such as those described herein, portions thereof, and repeats or other variants of such proteins. Expressed fusion polypeptides of this disclosure are generally isolated in substantially pure form. Preferably, the fusion polypeptides are isolated to a purity of at least 80% by weight, more preferably, to a purity of at least 95% by weight, and most preferably to a purity of at least 99% by weight. In general, such purification may be achieved using, for example, the standard techniques of ammonium sulfate fractionation. SDS-PAGE electrophoresis, and affinity chromatography.
- Regardless of the method of preparation, the polypeptides or fusion polypeptides produced as described above are preferably immunogenic. In certain embodiments, for example, the polypeptides (or immunogenic portions thereof) are capable of eliciting an immune response in cultures of lymph node cells and/or peripheral blood mononuclear cells (PBMC) isolated from presently or previously M. leprae—infected individuals. More specifically, in certain embodiments, the antigens, and immunogenic portions thereof, have the ability to induce T-cell proliferation and/or to elicit a dominantly Th1-type cytokine response (e.g., IL-2, IFN-γ, and/or TNF-α production by T-cells and/or NK cells; and/or IL-12 production by monocytes, macrophages and/or B cells) in cells isolated from presently or previously M. leprae-infected individuals. A M. leprae-infected individual may be afflicted with a form of leprosy (such as paucibacillary (PB), multibacillary (MB), lepromatous leprosy (LL), borderline lepromatous (BL), mid-borderline (BB), borderline tuberculoid (BT), or tuberculoid leprosy (Ti)) or may be asymptomatic. Such individuals may be identified using methods known to those of ordinary skill in the art. Individuals with leprosy may be identified based on clinical findings associated with, for example, at least one of the following: appearance of hypopigmented or reddish lesion with hypoesthesia, presence of acid fast bacilli in lymph node smears and compatible skin lesion histopathology. Asymptomatic individuals are infected individuals who have no signs or symptoms of the disease. Such individuals can be identified, for example, based on a positive serological test and/or skin test.
- The term “PBMC,” which refers to a preparation of nucleated cells consisting primarily of lymphocytes and monocytes that are present in peripheral blood, encompasses both mixtures of cells and preparations of one or more purified cell types. PBMC may be isolated by methods known to those in the art. For example, PBMC may be isolated by density centrifugation through, for example, Ficoll™ (Winthrop Laboratories, New York). Lymph node cultures may generally be prepared by immunizing BALB/c mice (e.g., in the rear foot pad) with M. leprae promastigotes emulsified in complete Freund's adjuvant. The draining lymph nodes may be excised following immunization and T-cells may be purified in an anti-mouse Ig column to remove the B cells, followed by a passage through a Sephadex G10 column to remove the macrophages. Similarly, lymph node cells may be isolated from a human following biopsy or surgical removal of a lymph node.
- The ability of a fusion polypeptide of the disclosure to induce a response in PBMC or lymph node cell cultures may be evaluated, for example, by contacting the cells with the polypeptide and measuring a suitable response. In general, the amount of polypeptide that is sufficient for the evaluation of about 2×105 cells ranges from about 10 ng to about 100 ug or 100 ng to about 50 ug, and preferably is about 1 ug, to 10 ug. The incubation of polypeptide (e.g., a fusion polypeptide) with cells is typically performed at 37° C. for about 1-3 days. Following incubation with polypeptide, the cells are assayed for an appropriate response. If the response is a proliferative response, any of a variety of techniques well known to those of ordinary skill in the art may be employed. For example, the cells may be exposed to a pulse of radioactive thymidine and the incorporation of label into cellular DNA measured. In general, a polypeptide that results in at least a three fold increase in proliferation above background (i.e., the proliferation observed for cells cultured without polypeptide) is considered to be able to induce proliferation.
- Alternatively, the response to be measured may be the secretion of one or more cytokines (such as interferon-y (IFN-γ), interleukin-4 (IL-4), interleukin-12 (p70 and/or p40), interleukin-2 (IL-2) and/or tumor necrosis factor-a (TNF-α)) or the change in the level of mRNA encoding one or more specific cytokines. For example, the secretion of interferon-y, interleukin-2, tumor necrosis factor-a and/or interleukin-12 is indicative of a Th1 response, which contributes to the protective effect against M. leprae. Assays for any of the above cytokines may generally be performed using methods known to those of ordinary skill in the art, such as an enzyme-linked immunosorbent assay (ELISA). Suitable antibodies for use in such assays may be obtained from a variety of sources such as Chemicon, Temucula, CA and PharMingen, San Diego, CA, and may generally be used according to the manufacturer's instructions. The level of mRNA encoding one or more specific cytokines may be evaluated by, for example, amplification by polymerase chain reaction (PCR). In general, a polypeptide that is able to induce, in a preparation of about 1-3×105 cells, the production of 30 pg/mL of IL-12, IL-4, IFN-γ, TNF-α or IL-12 p40, or 10 pg/mL of IL-12 p70, is considered able to stimulate production of a cytokine.
- Polynucleotide Compositions
- The present disclosure also provides isolated polynucleotides, particularly those encoding the polypeptide combinations and/or fusion polypeptides of the disclosure, as well as compositions comprising such polynucleotides. As used herein, the terms “DNA” and “polynucleotide” and “nucleic acid” refer to a DNA molecule that has been isolated free of total genomic DNA of a particular species. Therefore, a DNA segment encoding a polypeptide refers to a DNA segment that contains one or more coding sequences yet is substantially isolated away from, or purified free from, total genomic DNA of the species from which the DNA segment is obtained. Included within the terms “DNA segment” and “polynucleotide” are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phagemids, phage, viruses, and the like.
- As will be understood by those skilled in the art, the polynucleotide sequences of this disclosure can include genomic sequences, extra-genomic and plasmid-encoded sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, fusion polypeptides, peptides and the like. Such segments may be naturally isolated, recombinant, or modified synthetically by the hand of man.
- As will be recognized by the skilled artisan, polynucleotides may be single-stranded (coding or anti sense) or double-stranded, and may be DNA (genomic, cDNA or synthetic) or RNA molecules. Any polynucleotide may be further modified to increase stability in vivo. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends; the use of phosphorothioate or 2′ 0-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl- methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide of the present disclosure, and a polynucleotide may, but need not, be linked to other molecules and/or support materials.
- Polynucleotides may comprise a native sequence (i.e., an endogenous sequence that encodes a M. leprae antigen or a portion thereof) or may comprise a variant, or a biological or antigenic functional equivalent of such a sequence. In particular embodiments, polynucleotides may encode for two or more antigenic/immunogenic portions, fragments, or variants derived from the M. leprae antigens described herein. In some embodiments, polynucleotides of the present disclosure comprise a sequence encoding any of the immunogenic portions described herein. In some embodiments, the polynucleotide comprises the sequence of SEQ ID NO: 1, 3, 5, 7, 9, or 11. Of course, portions of these sequences and variant sequences sharing identity to these sequences may also be employed (e.g., those having at least about any of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% thereto).
- Polynucleotide variants may contain one or more substitutions, additions, deletions and/or insertions, as further described below, preferably such that the immunogenicity of the encoded polypeptide is not diminished, relative to the native protein. The effect on the immunogenicity of the encoded polypeptide may generally be assessed as described herein.
- For example, in certain embodiments, variants of the disclosure include cysteine-modified polynucleotides in which the cysteine-encoding codons are replaced with codons encoding other amino acids not capable of forming intrachain or interchain disulfide bonds. In more specific embodiments, some or all of the replacement codons encode serine because of the spatial similarity of the serine sidechain to the cysteine sidechain in the resulting polypeptide. In another specific embodiment, some or all of the replacement codons encode alanine. Illustrative methods of replacing cysteine and other codons within a polynucleotide are well known (e.g., U.S. Pat. No. 4,816,566, the contents of which are incorporated herein by reference, and Proc Natl Acad Sci 97 (15): 8530, 2000).
- The term “variants” also encompasses homologous genes of xenogenic origin.
- In additional embodiments, isolated polynucleotides of the present disclosure comprise various lengths of contiguous stretches of sequence identical to or complementary to the sequence encoding M. leprae polypeptides, such as those sequences disclosed herein. For example, polynucleotides are provided by this disclosure that comprise at least about 15, 20, 30, 40, 50, 75, 100, 150, 200, 300, 400, 500 or 1000 or more contiguous nucleotides of two or more of the sequences disclosed herein as well as all intermediate lengths there between. It will be readily understood that “intermediate lengths”, in this context, means any length between the quoted values, such as 16, 17, 18, 19, etc.; 21, 22, 23, etc.; 30, 31, 32, etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103, etc.; 150, 151, 152, 153, etc.; including all integers through 200-500; 500-1,000, and the like.
- The polynucleotides of the present disclosure, or fragments thereof, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a polynucleotide fragment of almost any length may be employed; with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol.
- Moreover, it will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present disclosure, for example polynucleotides that are optimized for human and/or primate codon selection. Further, alleles of the genes comprising the polynucleotide sequences provided herein are within the scope of the present disclosure. Alleles are endogenous genes that are altered as a result of one or more mutations, such as deletions, additions and/or substitutions of nucleotides. The resulting mRNA and protein may, but need not, have an altered structure or function. Alleles may be identified using standard techniques (such as hybridization, amplification and/or database sequence comparison).
- M. leprae polynucleotides and fusions thereof may be prepared, manipulated and/or expressed using any of a variety of well established techniques known and available in the art. In particular embodiments, fusions comprise two or more polynucleotide sequences encoding M. leprae polypeptides.
- For example, polynucleotide sequences or fragments thereof which encode polypeptides of the disclosure, or fusion proteins or functional equivalents thereof, may be used in recombinant DNA molecules to direct expression of a polypeptide in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences that encode substantially the same or a functionally equivalent amino acid sequence may be produced and these sequences may be used to clone and express a given polypeptide of the present disclosure.
- As will be understood by those of skill in the art, it may be advantageous in some instances to produce fusion polypeptide-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce a recombinant RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.
- Moreover, the polynucleotide sequences of the present disclosure can be engineered using methods generally known in the art in order to alter fusion polypeptide encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, expression and/or immunogenicity of the gene product.
- In order to express a desired fusion polypeptide comprising two or more antigenic/immunogenic fragments or portions of M. leprae polypeptides, a nucleotide sequence encoding the fusion polypeptide, or a functional equivalent, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding a polypeptide of interest and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook et al., Molecular Cloning, A Laboratory Manual (2001), and Ausubel et al., Current Protocols in Molecular Biology (January 2008, updated edition).
- A variety of expression vector/host systems are known and may be utilized to contain and express polynucleotide sequences. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast (such as Saccharomyces or Pichia) transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.
- The “control elements” or “regulatory sequences” present in an expression vector are those non-translated regions of the vector-enhancers, promoters, 5′ and 3′ untranslated regions—which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the PBLUESCRIPT phagemid (Stratagene, La Jolla, Calif.) or PSPORTI plasmid (Gibco BRL, Gaithersburg, Md.) and the like may be used. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are generally preferred. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding a polypeptide, vectors based on SV40 or EBV may be advantageously used with an appropriate selectable marker.
- In bacterial systems, a number of expression vectors may be selected depending upon the use intended for the expressed polypeptide. For example, when large quantities are needed, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional E. coli cloning and expression vectors such as PBLUESCRIPT (Stratagene), in which the sequence encoding the polypeptide of interest may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of B-galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke & Schuster, J. Biol. Chem. 264:5503 5509 (1989)); and the like, pGEX Vectors (Promega, Madison, Wis.) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.
- In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al., Methods Enzymol. 153:516-544 (1987).
- In cases where plant expression vectors are used, the expression of sequences encoding polypeptides may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, EMBO J. 6:307-311 (1987)). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi et EMBO J. 3:1671-1680 (1984); Broglie et al., Science 224:838-843 (1984); and Winter et al., Results Probl. Cell Differ. 17:85-105 (1991)). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, e.g., Hobbs in McGraw Hill, Yearbook of Science and Technology, pp. 191-196 (1992)).
- An insect system may also be used to express a polypeptide of interest. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding the polypeptide may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of the polypeptide-encoding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in which the polypeptide of interest may be expressed (Engelhard et al., Proc. Natl. Acad. Sci. U.S.A. 91:3224-3227 (1994)).
- In mammalian host cells, a number of viral-based expression systems are generally available. For example, in cases where an adenovirus is used as an expression vector, sequences encoding a polypeptide of the present disclosure may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing the polypeptide in infected host cells (Logan & Shenk, Proc. Natl. Acad. Sci. U.S.A. 81:3655-3659 (1984)). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.
- Specific initiation signals may also be used to achieve more efficient translation of sequences encoding a fusion polypeptide of interest. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding the polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, et al., Results ProbL Cell Differ. 20:125-162 (1994)).
- In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed fusion protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a “prepro” form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, HEK293, and W138, which have specific cellular machinery and characteristic mechanisms for such post-translational activities, may be chosen to ensure the correct modification and processing of the foreign protein.
- For long-term, high-yield production of recombinant proteins, stable expression is generally preferred. For example, cell lines which stably express a fusion polynucleotide of the present disclosure may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.
- Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223-232 (1977)) and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817-823 (1990)) genes which can be employed in tk- or aprt- cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler et al., Proc. Natl. Acad. Sci. U.S.A. 77:3567-70 (1980)); npt, which confers resistance to the aminoglycosides, neomycin and G-418 (Colbere-Garapin et al., J. Mol. Biol. 150:1-14 (1981)); and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, Proc. Natl. Acad. Sci. U.S.A. 85:8047-51 (1988)). The use of visible markers has gained popularity with such markers as anthocyanins, B-glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes et al., Methods MoL Biol. 55:121-131 (1995)).
- A variety of protocols for detecting and measuring the expression of polynucleotide-encoded products, using either polyclonal or monoclonal antibodies specific for the product are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). These and other assays are described, among other places, in Hampton et al., Serological Methods, a Laboratory Manual (1990) and Maddox et al., I Exp. Med. 158:1211-1216 (1983).
- A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide.
- Alternatively, the sequences, or any portions thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits. Suitable reporter molecules or labels, which may be used, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.
- Host cells transformed with a polynucleotide sequence of interest may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a recombinant cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides of the disclosure may be designed to contain signal sequences which direct secretion of the encoded polypeptide through a prokaryotic or eukaryotic cell membrane. Other recombinant constructions may be used to join sequences encoding a polypeptide of interest to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. In addition to recombinant production methods, fusion polypeptides of the disclosure, and fragments thereof, may be produced by direct peptide synthesis using solid-phase techniques (Merrifield, J. Am. Chem. Soc. 85:2149-2154 (1%3)). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431 A Peptide Synthesizer (Perkin Elmer). Alternatively, various fragments, for example, immunogenic fragments from M. leprae polypeptides, may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.
- In certain aspects, the polypeptides, antigens, polynucleotides, portions, variants, fusion polypeptides, etc., as described herein, are incorporated into pharmaceutical compositions or vaccines. Pharmaceutical compositions generally comprise one or more polypeptides, antigens, polynucleotides, portions, variants, fusion polypeptides, etc., as described herein, in combination with a physiologically acceptable carrier. Vaccines, also referred to as immunogenic compositions, generally comprise one or more of the polypeptides, antigens, polynucleotides, portions, variants, fusion proteins, etc., as described herein, in combination with an immunostimulant, such as an adjuvant. In particular embodiments, the compositions comprise fusion polypeptides containing M. leprae antigens (or portions or variants thereof) that are capable of providing protection against M. leprae. In some embodiments, the compositions comprise fusion polypeptides containing M. leprae antigens (or portions or variants thereof) that are capable of providing protection against a tuberculosis-causing Mycobacterium.
- An immunostimulant may be any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen. Examples of immunostimulants include adjuvants, biodegradable microspheres (e.g., polylactic galactide) and liposomes (into which the compound is incorporated; see, e.g., Fullerton, U.S. Pat. No. 4,235,877). Vaccine preparation is generally described in, for example. Powell & Newman, eds., Vaccine Design (the subunit and adjuvant approach) (1995).
- Any of a variety of immunostimulants may be employed in the vaccines of this disclosure. For example, an adjuvant may be included. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A (natural or synthetic), Bordatella pertussis or Mycobacterium species or Mycobacterium-derived proteins. Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, Mich.); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, N.J.); AS-2 and derivatives thereof (GlaxoSmithKline Beecham, Philadelphia, Pa.); CWS, TDM, LeIF, aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides; polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quit A. Cytokines, such as GM-CSF or interleukin-2, -7, or -12, may also be used as adjuvants.
- Certain embodiments of the present disclosure contemplate vaccine and pharmaceutical compositions that include one or more toll-like receptor agonists (TLR agonist). In more specific embodiments, for example, the compositions of the disclosure include Toll-like receptor agonists, such as TLR7 agonists and TLR7/8 agonists. In certain embodiments the TLR agonist is capable of delivering a biological signal by interacting with at least one TLR that is selected from TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8 and TLR-9.
- Toll-like receptors (TLR) include cell surface transmembrane receptors of the innate immune system that confer early-phase recognition capability to host cells for a variety of conserved microbial molecular structures such as may be present in or on a large number of infectious pathogens, (e.g., Armant et al., 2002 Genome Biol. 3(8): reviews 3011.1-3011.6; Fearon et al., 1996 Science 272:50; Medzhitov et al., 1997 Curr. Opin. Immunol. 9:4; Luster 2002 Curr. Opin. Immunol. 14:129; Lien et al. 2003 Nat. Immunol. 4:1162; Medzhitov, 2001 Nat. Rev. Immunol. 1:135; Takeda et al., 2003 Ann Rev Immunol. 21:335; Takeda et al. 2005 Inf Immunol. 17:1; Kaisho et al., 2004 Microbes Infect. 6:1388; Datta et al., 2003 J. Immunol. 170:4102).
- Induction of TLR-mediated signal transduction to potentiate the initiation of immune responses via the innate immune system may be effected by TLR agonists, which engage cell surface TLR or cytoplasmic TLR. For example, lipopolysaccharide (LPS) may be a TLR agonist through TLR2 or TLR4 (Tsan et al., 2004 J. Leuk. Biol. 76:514; Tsan et al., 2004 Am. J. Physiol. Cell Phsiol. 286: C739; Lin et al., 2005 Shock 24:206); poly(inosine-cytidine) (polyl:C) may be a TLR agonist through TLR3 (Salem et al., 2006 Vaccine 24:5119); CpG sequences (oligodeoxynucleotides containing unmethylated cytosine-guanosine or “CpG” dinucleotide motifs, e.g., CpG 7909, Cooper et al., 2005 AIDS 19:1473; CpG 10101 Bayes et al. Methods Find Exp Clin Pharnacol 27:193; Vollmer et al. Expert Opinion on Biological Therapy 5:673; Vollmer et al., 2004 Antimicrob. Agents Chemother. 48:2314; Deng et al., 2004 J. Immunol. 173:5148) may be TLR agonists through TLR9 (Andaloussi et a., 2006 Glia 54:526; Chen et al., 2006 J. Immunol. 177:2373); peptidoglycans may be TLR2 and/or TLR6 agonists (Soboll et al., 2006 Biol. Reprod. 75:131; Nakao et al., 2005 J. Immunol. 174:1566); 3M003 (4-amino-2-(ethoxymethyl)-a,a-dimethyl-617,8,9-tetrahydro-IH-imidazo[4,5] quinoline-1-ethanol hydrate, Mol. Wt. 318 Da from 3M Pharmaceuticals, St. Paul, MN, which is also a source of the related compounds 3M001 and 3M002; Gorden et al., 2005 J. Immunol. 174:1259) may be a TLR7 agonist (Johansen 2005 Clin. Exp. Allerg. 35:1591) and/or a TLR8 agonist (Johansen 2005); flagellin may be a TLR5 agonist (Feuillet et al., 2006 Proc. Nat. Acad. Sci. USA 103: 12487); and hepatitis C antigens may act as TLR agonists through TLR7 and/or TLR9 (Lee et al., 2006 Proc. Nat. Acad. Sci. USA 103:1828; Horsmans et al., 2005 Hepatol. 42:724). Other TLR agonists are known (e.g., Schirmbeck et al., 2003 J. Immunol. 171:5198) and may be used according to certain of the presently described embodiments.
- For example, and by way of background (see, e.g., U.S. Pat. No. 6,544,518) immunostimulatory oligonucleotides containing unmethylated CpG dinucleotides (“CpG”) are known as being adjuvants when administered by both systemic and mucosal routes (WO 96/02555, EP 468520, Davis et al., J. Immunol, 1998. 160(2): 870-876; McCluskie and Davis, J. Immunol., 1998, 161(9):4463-6). CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. The central role of the CG motif in immunostimulation was elucidated by Krieg, Nature 374, p546 1995. Detailed analysis has shown that the CG motif has to be in a certain sequence context, and that such sequences are common in bacterial DNA but are rare in vertebrate DNA. The immunostimulatory sequence is often: Purine. Purine, C, G, pyrimidine, pyrimidine: wherein the dinucleotide CG motif is not methylated, but other unmethylated CpG sequences are known to be immunostimulatory and may be used in certain embodiments of the present disclosure. CpG when formulated into vaccines, may be administered in free solution together with free antigen (WO 96/02555; McCluskie and Davis, supra) or covalently conjugated to an antigen (PCT Publication No. WO 98/16247), or formulated with a carrier such as aluminium hydroxide (e.g., Davis et al. supra, Brazolot-Millan et al., Proc.NatLAcad.Sci., USA, 1998, 95(26), 15553-8).
- Other illustrative oligonucleotides for use in compositions of the present disclosure will often contain two or more dinucleotide CpG motifs separated by at least three, more preferably at least six or more nucleotides. The oligonucleotides of the present disclosure are typically deoxynucleotides. In one embodiment the internucleotide in the oligonucleotide is phosphorodithioate, or more preferably a phosphorothioate bond, although phosphodiester and other intemucleotide bonds are within the scope of the disclosure including oligonucleotides with mixed internucleotide linkages. Methods for producing phosphorothioate oligonucleotides or phosphorodithioate are described in U.S. Pat. Nos. 5,666,153, 5,278,302 and WO95/26204.
- Other examples of oligonucleotides have sequences that are disclosed in the following publications; for certain herein disclosed embodiments the sequences preferably contain phosphorothioate modified intemucleotide linkages: CPG 7909: Cooper et al., “CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.” AIDS, 2005 Sep. 23; 19(14): 1473-9.
- CpG 10101: Bayes et al., “Gateways to clinical trials.” Methods Find. Exp. Clin.
- Pharmacol. 2005 April; 27(3): 193-219.
- Vollmer J., “Progress in drug development of immunostimula-tory CpG oligodeoxynucleotide ligands for TLR9.” Expert Opinion on Biological Therapy. 2005 May; 5(5): 673-682.
- Alternative CpG oligonucleotides may comprise variants of the preferred sequences described in the above-cited publications that differ in that they have inconsequential nucleotide sequence substitutions, insertions, deletions and/or additions thereto. The CpG oligonucleotides utilized in certain embodiments of the present disclosure may be synthesized by any method known in the art (e.g., EP 468520). Conveniently, such oligonucleotides may be synthesized utilizing an automated synthesizer. The oligonucleotides are typically deoxynucleotides. In a preferred embodiment the intemucleotide bond in the oligonucleotide is phosphorodithioate, or more preferably phosphorothioate bond, although phosphodiesters are also within the scope of the presently contemplated embodiments. Oligonucleotides comprising different internucleotide linkages are also contemplated, e.g., mixed phosphorothioate phophodiesters. Other internucleotide bonds which stabilize the oligonucleotide may also be used.
- In certain more specific embodiments the TLR agonist is selected from lipopolysaccharide, peptidoglycan, polyl: C, CpG, 3M003, flagellin, M. leprae homolog of eukaryotic ribosomal elongation and initiation factor 4a (LeIF) and at least one hepatitis C antigen.
- Still other illustrative adjuvants include imiquimod, gardiquimod and resiquimod (all available from Invivogen), and related compounds, which are known to act as TLR7/8 agonists. A compendium of adjuvants that may be useful in vaccines is provided by Vogel et al., Pharm Biotechnol 6:141 (1995), which is herein incorporated by reference.
- Compositions of the disclosure may also employ adjuvant systems designed to induce an immune response predominantly of the Th1 type. High levels of Th1-type cytokines (e.g., IFN-γ, TNF-a, IL-2 and IL-12) tend to favor the induction of cell mediated immune responses to an administered antigen. In contrast, high levels of Th2-type cytokines (e.g., IL-4, IL-5, IL-6 and IL-10) tend to favor the induction of humoral immune responses. Following application of a vaccine as provided herein, a patient will support an immune response that includes Th1- and Th2-type responses. Within a preferred embodiment, in which a response is predominantly of the Th1-type, the level of Th1-type cytokines will increase to a greater extent than the level of Th2-type cytokines. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mossman & Coffman, Ann. Rev. Immunol. 7:145-173 (1989).
- Certain adjuvants for use in eliciting a predominantly Th1-type response include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MPL™), together with an aluminum salt (U.S. Pat. Nos. 4,436,727; 4,877,611; 4,866,034; and 4,912,094). CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) also induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Pat. Nos. 6,008.200 and 5,856.462. Immunostimulatory DNA sequences are also described, for example, by Sato et al., Science 273:352 (1996). Another illustrative adjuvant comprises a saponin, such as Quil A, or derivatives thereof, including QS21 and QS7 (Aquila Biopharmaceuticals Inc., Framingham, Mass.); Escin; Digitonin; or Gypsophila or Chenopodium quinoa saponins. Other illustrative formulations include more than one saponin in the adjuvant combinations of the present disclosure, for example combinations of at least two of the following group comprising QS21, QS7, Quil A, 0-escin, or digitonin.
- In a particular embodiment, the adjuvant system includes the combination of a monophosphoryl lipid A and a saponin derivative, such as the combination of QS21 and 3D-MPL™ adjuvant, as described in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol, as described in WO 96/33739. Other formulations comprise an oil-in-water emulsion and tocopherol. Another adjuvant formulation employing QS21, 3D-MPL™ adjuvant and tocopherol in an oil-in-water emulsion is described in WO 95/17210.
- In certain preferred embodiments, the adjuvant used in the present disclosure is a glucopyranosyl lipid A (GLA) adjuvant, as described in U.S. Patent Application Publication No. 20080131466, the disclosure of which is incorporated herein by reference in its entirety. In one embodiment, the GLA adjuvant used in the context of the present disclosure has the following structure:
- where: R1, R3, R5 and R6 are C11-C20 alkyl, and R2 and R4 are C9-C20 alkyl.
- In a more specific embodiment, the GLA has the formula set forth above wherein R1, R3, R5 and R6 are C11-14 alkyl, and R2 and R4 are C12-15 alkyl.
- In a more specific embodiment, the GLA has the formula set forth above wherein R1, R3, R5 and R6 are C11 alkyl; and R2 and R4 are C13 alkyl.
- In a more specific embodiment, the GLA has the formula set forth above wherein R1, R3, R5 and R6 are C11 alkyl; and R2 and R4 are C9 alkyl.
- In certain embodiments, the adjuvant is a GLA adjuvant (e.g., synthetic) having the following structure:
- In certain embodiments of the above GLA structure, R1, R3, R5 and R6 are C11-C20 alkyl; and R2 and R4 are C9-C20 alkyl. In certain embodiments, R1, R3, R5 and R6 are C11 alkyl; and R2 and R4 are C9 alkyl.
- In certain embodiments, the adjuvant is a synthetic GLA adjuvant having the following structure:
- In certain embodiments of the above GLA structure, R1, R3, R5 and R6 are C11-C20 alkyl; and R2 and R4 are C9-C20 alkyl. In certain embodiments. R1, R3, R5 and R6 are C11 alkyl; and R2 and R4 are C9 alkyl.
- In certain embodiments, the adjuvant is a synthetic GLA adjuvant having the following structure:
- In certain embodiments of the above GLA structure. R1, R3, R5 and R6 are C11-C20 alkyl; and R2 and R4 are C11-C20 alkyl. In certain embodiments. R1, R3, R5 and R6 are C11 alkyl; and R2 and R4 are C9 alkyl.
- In certain embodiments, the adjuvant is a synthetic GLA adjuvant having the following structure:
- In certain embodiments, the adjuvant is a synthetic GLA adjuvant having the following structure:
- In certain embodiments, the adjuvant is a synthetic GLA adjuvant having the following structure:
- In certain embodiments, the adjuvant is GLA-SE having the following structure:
- In certain embodiments, the adjuvant is GLA-SE having the following structure:
- The skilled artisan will understand that, in any of the embodiments described herein, the GLA adjuvant may be in a salt form, e.g., an ammonium salt.
- GLA-SE refers to a stable oil-in-water emulsion comprising GLA formulated in squalene oil and other excipients including, for example, dimyristoyl phosphatidyl choline (DPMC). In some preferred embodiments, 20 ug/ml GLA is formulated in 4% squalene oil. Methods of making GLA-SE are known in the art, see for example, Misquith et al., Colloids and Surfaces B: Biointerfaces 113(2014) 312-319; Fox et al., Vaccine 31(2013) 1633-1640, Van Hoeven et al., Nature Scientific Reports 7:46426.
- Another enhanced adjuvant system involves the combination of a CpG-containing oligonucleotide and a saponin derivative as disclosed in WO 00/09159.
- Other illustrative adjuvants include Montanide ISA 720 (Seppic, France), SAF (Chiron, Calif, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (e.g., SBAS-2, AS2′, AS2,″ SBAS-4, or SBAS6, available from SmithKline Beecham, Rixensart, Belgium), Detox, RC-529 (Corixa, Hamilton, Mont.) and other aminoalkyl glucosaminide 4-phosphates (AGPs), such as those described in pending U.S. patent application Ser. Nos. 08/853,826 and 09/074,720, the disclosures of which are incorporated herein by reference in their entireties, and polyoxyethylene ether adjuvants such as those described in WO 99/52549A1.
- The vaccine and pharmaceutical compositions of the disclosure may be formulated using any of a variety of well known procedures. In certain embodiments, the vaccine or pharmaceutical compositions are prepared as stable emulsions (e.g., oil-in-water emulsions) or as aqueous solutions.
- Compositions of the disclosure may also, or alternatively, comprise T cells specific for fusion polypeptide comprising immunogenic/antigenic portions or fragments of M. leprae antigens or variants thereof, described herein. Such cells may generally be prepared in vitro or ex vivo, using standard procedures. For example, T cells may be isolated from bone marrow, peripheral blood, or a fraction of bone marrow or peripheral blood of a patient. Alternatively, T cells may be derived from related or unrelated humans, non-human mammals, cell lines or cultures.
- T cells may be stimulated with a fusion polypeptide comprising M. leprae polypeptides or immunogenic portions or variants thereof, polynucleotide encoding such a fusion polypeptide, and/or an antigen presenting cell (APC) that expresses such a fusion polypeptide. Such stimulation is performed under conditions and for a time sufficient to permit the generation of T cells that are specific for the polypeptide. In certain embodiments, the polypeptide or polynucleotide is present within a delivery vehicle, such as a microsphere, to facilitate the generation of specific T cells.
- T cells are considered to be specific for a fusion polypeptide of the disclosure if the T cells specifically proliferate, secrete cytokines or kill target cells coated with the fusion polypeptide or expressing a gene encoding the fusion polypeptide. T cell specificity may be evaluated using any of a variety of standard techniques. For example, within a chromium release assay or proliferation assay, a stimulation index of more than two fold increase in lysis and/or proliferation, compared to negative controls, indicates T cell specificity. Such assays may be performed, for example, as described in Chen et al., Cancer Res. 54:1065-1070 (1994)).
- Alternatively, detection of the proliferation of T cells may be accomplished by a variety of known techniques. For example, T cell proliferation can be detected by measuring an increased rate of DNA synthesis (e.g., by pulse-labeling cultures of T cells with tritiated thymidine and measuring the amount of tritiated thymidine incorporated into DNA). Contact with a polypeptide of the disclosure (100 ng/ml-1001.1 g/ml, preferably 200 ng/ml-251.1 g/ml) for 3-7 days should result in at least a two fold increase in proliferation of the T cells. Contact as described above for 2-3 hours should result in activation of the T cells, as measured using standard cytokine assays in which a two fold increase in the level of cytokine release (e.g., TNF or IFN-γ) is indicative of T cell activation (see Coligan et al., Current Protocols in Immunology, vol. 1 (1998)). T cells that have been activated in response to a polypeptide, polynucleotide or polypeptide-expressing APC may be CD4+ and/or CD8+. Protein-specific T cells may be expanded using standard techniques. Within preferred embodiments, the T cells are derived from a patient, a related donor or an unrelated donor, and are administered to the patient following stimulation and expansion.
- In the compositions of the disclosure, formulation of pharmaceutically-acceptable excipients and carrier solutions is well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including e.g., oral, parenteral, intravenous, intranasal, intradermal, subcutaneous and intramuscular administration and formulation.
- In certain applications, the compositions disclosed herein may be delivered via oral administration to a subject. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft-shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
- In certain circumstances it will be desirable to deliver the compositions disclosed herein parenterally, intravenously, intramuscularly, or even intraperitoneally as described, for example, in U.S. Pat. Nos. 5,543,158; 5,641,515 and 5,399,363 (each specifically incorporated herein by reference in its entirety). Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S. Pat. No. 5,466,468, specifically incorporated herein by reference in its entirety). In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be facilitated by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this connection, a sterile aqueous medium that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion (see, e.g., Remington's Pharmaceutical Sciences, 15th Edition, pp. 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, and the general safety and purity standards as required by FDA Office of Biologics standards.
- Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with the various other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- The compositions disclosed herein may be formulated in a neutral or salt form. Pharmaceutically-acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxy groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective for treatment of leprosy. The formulations are easily administered in a variety of dosage forms such as injectable solutions, drug-release capsules, and the like.
- As used herein, “carrier” includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known to one of ordinary skill in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
- The phrase “pharmaceutically-acceptable” refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human. The preparation of an aqueous composition that contains a protein as an active ingredient is well understood to one of ordinary skill in the art. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified.
- In certain embodiments, the compositions of the present disclosure may be delivered by intranasal sprays, inhalation, and/or other aerosol delivery vehicles. Methods for delivering genes, polynucleotides, and peptide compositions directly to the lungs via nasal aerosol sprays has been described e.g., in U.S. Pat. Nos. 5,756,353 and 5,804,212 (each specifically incorporated herein by reference in its entirety). Likewise, the delivery of drugs using intranasal microparticle resins (Takenaga et al., 1998) and lysophosphatidyl-glycerol compounds (U.S. Pat. No. 5,725,871, specifically incorporated herein by reference in its entirety) are also well-known in the pharmaceutical arts. Likewise, transmucosal drug delivery in the form of a polytetrafluoroethylene support matrix is described in U.S. Pat. No. 5,780,045 (specifically incorporated herein by reference in its entirety).
- In certain embodiments, the delivery may occur by use of liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, and the like, for the introduction of compositions comprising a fusion polypeptide as describe herein into suitable host cells. In particular, the compositions of the present disclosure may be formulated for delivery either encapsulated in a lipid particle, a liposome, a vesicle, a nanosphere, a nanoparticle or the like. The formulation and use of such delivery vehicles can be carried out using known and conventional techniques.
- A pharmaceutical or immunogenic composition may, alternatively, contain an immunostimulant and a nucleic acid molecule, e.g., a DNA or RNA molecule encoding one or more of the polypeptides or fusion polypeptides as described above, such that a desired polypeptide is generated in situ. In such compositions, the DNA encoding the fusion protein may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as Bacillus-Calmette-Guerrin) that expresses an immunogenic portion of the polypeptide on its cell surface. In a particular embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be “naked.” as described, for example, in Ulmer et al., Science 259:1745-1749 (1993) and reviewed by Cohen, Science 259: 1691-1692 (1993). The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.
- The pharmaceutical compositions and vaccines of the disclosure may be used, in certain embodiments, to induce protective immunity against M. leprae in a patient, such as a human or an armadillo, to prevent leprosy or diminish its severity. The compositions and vaccines may also be used to stimulate an immune response, which may be cellular and/or humoral, in a patient, for treating an individual already infected. In one embodiment, for M. Leprae-infected patients, the immune responses generated include a preferential Th1 immune response (i.e., a response characterized by the production of the cytokines interleukin-1, interleukin-2, interleukin-12 and/or interferon-y, as well as tumor necrosis factor-a). In another embodiment, for uninfected patients, the immune response involves production of interleukin-12 and/or interleukin-2, or the stimulation of gamma delta T-cells. In either category of patient, the response stimulated may include IL-12 production. Such responses may also be elicited in biological samples of PBMC or components thereof derived from M. leprae-infected or uninfected individuals. As noted above, assays for any of the above cytokines, as well as other known cytokines, may generally be performed using methods known to those of ordinary skill in the art, such as an enzyme-linked immunosorbent assay (ELISA).
- Appropriate doses and methods of fusion polypeptide administration for these purposes can be readily determined by a skilled artisan using available knowledge in the art and/or routine techniques. Routes and frequency of administration, as well as dosage, for the above aspects of the present disclosure may vary from individual to individual and may parallel those currently being used in immunization against other infections, including protozoan, viral and bacterial infections. For example, in one embodiment, between 1 and 12 doses of composition having a fusion polypeptide, which comprises M. leprae polypeptides or immunogenic/antigenic portions, fragments or variants thereof, are administered over a 1-year period. Booster vaccinations may be given periodically thereafter as needed or desired. Of course, alternate protocols may be appropriate for individual patients. In a particular embodiment, a suitable dose is an amount of fusion polypeptide or DNA encoding such a peptide that, when administered as described above, is capable of eliciting an immune response in an immunized patient sufficient to protect the patient from leprosy caused by M. leprae. In general, the amount of fusion polypeptide present in a dose (or produced in situ by the DNA in a dose) ranges from about 100 ng to about 1 mg per kg of host, typically from about 101.1 g to about 100 ug. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 mL to about 5 mL. In some aspects, from 1 ug to about 20 ug per dose or from about 1 ug to about 10 ug per dose of a composition of the present invention is administered to a subject in the methods described herein. If so desired, the composition can be, for example, in lyophilized form. In some aspects, the composition is administered in combination with an immunostimulant. The immunostimulant can be, for example, any of the immunostimulants described herein. In some aspects, the immunostimulant is GLA having any one of the structures described herein and is optionally formulated in an oil-in-water emulsion. In some aspects, the GLA is administered at a dose of from 2 ug to 20 ug per dose, or from about 1 ug to about 10 ug per dose or at about 5 ug per dose. The skilled artisan will appreciate that alternative dosage amounts are contemplated herein.
- In another aspect, this disclosure provides methods for stimulating an immune response against M. leprae in a mammal including the step of administering to a mammal in need thereof a composition of the present disclosure. In some embodiments, the methods further include a step of administering to the mammal M. bovis BCG vaccine. In other embodiments M. bovis BCG vaccine was previously administered to the mammal. The method may involve stimulating an immune response in various populations of mammals, including, where the mammal has not been exposed to M. leprae, where the mammal has been exposed to M. leprae, where the mammal is a human healthy household contact of a human identified as being infected with M. leprae, where the mammal has been infected by M. leprae, and where the mammal exhibits signs or symptoms of infection by M. leprae. The compositions of the present disclosure can be administered, for example, prophylactically, post-exposure but prior to clinical symptoms, or post-exposure and after exhibition of clinical symptoms. In some aspects, it will be unknown whether or not the mammal to be treated has been exposed to M. leprae but the mammal will have been in a leprosy endemic region or in contact with a mammal having active leprosy.
- In another aspect, the disclosure provides methods for stimulating an immune response against a tuberculosis-causing mycobacterium in a mammal comprising administering to a mammal in need thereof a composition of the disclosure.
- In another aspect, the disclosure provides methods for treating an M. leprae infection in a mammal, including the step of administering to a mammal having an M. leprae infection a composition of the disclosure. The method may include multiple subsequent administrations of the composition.
- Identifying mammals having an M. leprae infection may be carried with methods known in the art. The World Health Organization (WHO) has established diagnostic criteria as the presence of one or more of the following key signs: appearance of hypopigmented or reddish lesion with hypoesthesia, presence of acid fast bacilli in lymph node smears and compatible skin lesion histopathology. Once diagnosed, leprosy is treatable and patients are operationally defined into one of two categories, paucibacillary (PB) or multibacillary (MB) for treatment purposes. The Ridley-Jopling scale characterizes five forms of leprosy through the use of clinical, histopathological, and immunological methods: lepromatous leprosy (LL), borderline lepromatous (BL), mid-borderline (BB), borderline tuberculoid (BT), and tuberculoid leprosy (TT). {Ridley D S et al., Int J Lepr Other Mycobact Dis 1966; 34(3): 255-73; Scollard D M Int. J Lepr Other Mycobact Dis 2004; 72(2): 166-8.} A pure neural leprosy presentation, which is PB, also exists. PB leprosy patients, encompassing TT and a number of BT forms, are characterized as having one or few skin lesions and granulomatous dermatopathology with a low or absent bacterial index (BI). At the extreme PB pole, TT patients demonstrate a specific cell-mediated immunity against M. leprae and have an absent, or low, BI. Control of bacterial growth by PB patients indicates that these individuals mount a strong, but not necessarily curative, immune response against M. leprae.
- In some embodiments, the methods further include a step of administering to the mammal one or more chemotherapeutic agents. A “chemotherapeutic”. “chemotherapeutic agents” or “chemotherapy regime” is a drug or combination of drugs used to treat or in the treatment thereof of patients infected or exposed to M. leprae and includes, but is not limited to, amikacin, aminosalicylic acid, capreomycin, clofazimine, cycloserine, dapsone, ethambutol, ethionamide, gatifloxacin, isoniazid (INH), kanamycin, linezolid, minocycline, pyrazinamide, rifamycins (i.e., rifampin, rifampicin, rifapentine and rifabutin), streptomycin, ofloxacin, ciprofloxacin, clarithromycin, azithromycin, PA824, and fluoroquinolones and other derivatives analogs or biosimilars in the art.
- In some embodiments, the mammal is first administered one or more chemotherapeutic agents over a period of time and subsequently administered the composition. In other embodiments, the mammal is first administered the composition and subsequently administered one or more chemotherapeutic agents over a period of time. In other embodiments, administration of the one or more chemotherapeutic agents and the composition is concurrent.
- In some embodiments, the method includes a step of administering to the mammal M. bovis BCG vaccine. In other embodiments, M. bovis BCG vaccine was previously administered to the mammal.
- The method may be practiced on various groups of mammals. In some embodiments, the mammal does not exhibit signs or symptoms of infection by M. leprae. In some embodiments, the mammal has indeterminate or tuberculoid presentation. In some embodiments, the mammal has paucibacillary leprosy. In some embodiments, the mammal has multibacillary leprosy. In some embodiments, the mammal has lepromatous leprosy. In some embodiments, the mammal has borderline lepromatous leprosy. In some embodiments, the mammal has mid-borderline leprosy. In some embodiments, the mammal has borderline tuberculoid leprosy. In some embodiments, the mammal has tuberculoid leprosy. In some embodiments, the mammal is infected with a multidrug resistant M. leprae. In some embodiments, the mammal is a human.
- In another aspect, a method for reducing the time course of chemotherapy against an M. leprae infection is provided. The time course of chemotherapy is shortened, for example, to no more than about 3 months, about 5 months, or about 7 months.
- A “chemotherapeutic”, “chemotherapeutic agents” or “chemotherapy regime” is a drug or combination of drugs used to treat or in the treatment thereof of patients infected or exposed to M. leprae and includes, but is not limited to, amikacin, aminosalicylic acid, capreomycin, clofazimine, cycloserine, dapsone, ethambutol, ethionamide, gatifloxacin, isoniazid (INH), kanamycin, linezolid, minocycline, pyrazinamide, rifamycins (i.e., rifampin, rifampicin, rifapentine and rifabutin), streptomycin, ofloxacin, ciprofloxacin, clarithromycin, azithromycin, PA824, and fluoroquinolones and other derivatives analogs or biosimilars in the art.
- In another aspect, the disclosure provides methods for preventing an M. leprae infection in a mammal, or preventing onset of clinical symptoms in a mammal that has been exposed to M. leprae or has been diagnosed with M. leprae but does not yet exhibit symptoms thereof, including the step of administering to a mammal having an M. leprae infection a composition of the disclosure. The method may include multiple subsequent administrations of the composition.
- It will also be understood that the methods of treatment of the present disclosure may include the administration of the compositions of the disclosure either alone or in conjunction with other agents and, as such, the therapeutic vaccine may be one of a plurality of treatment components as part of a broader therapeutic treatment regime. Accordingly, the methods of the present disclosure advantageously improve the efficacy of a chemotherapy treatment regime for the treatment of M. leprae infection.
- In another aspect, the present disclosure provides kits for treatment of an M. leprae infection including a composition of the disclosure.
- Diagnostic Compositions, Methods and Kits
- In another aspect, this disclosure provides compounds and methods for detecting leprosy in individuals and in blood supplies. In particular embodiments, the individual is a mammal. In more particular embodiments, the mammal is a human or armadillo.
- For example, the fusion polypeptides, polypeptides, and antigens of the present disclosure can be used as effective diagnostic reagents for detecting and/or monitoring M. leprae infection in a patient. For example, the compositions, fusion polypeptides, and polynucleotides of the disclosure may be used in in vitro and in vivo assays for detecting humoral antibodies or cell-mediated immunity against M. leprae for diagnosis of infection, monitoring of disease progression or test-of-cure evaluation. In particular embodiments, the fusion polypeptides and polynucleotides are useful diagnostic reagents for serodiagnosis and whole blood assay in patients having leprosy or in individuals exposed to M. leprae.
- In one aspect, the diagnostic methods and kits preferably employ a composition or fusion polypeptide as described herein, repeats of polypeptide fragments, or multimeric polypeptide fragments, including antigenic/immunogenic fragments. In another more specific aspect, fusion polypeptides of the present disclosure may comprise two or more M. leprae antigen fragments. In a more particular embodiment, an illustrative fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 12. In another embodiment, the diagnostic methods and kits preferably employ a fusion polypeptide comprising at least 1, at least 2, at least 3, or at least 4 immunogenic/antigenic portions or fragments of M. leprae polypeptides, variants or the like, optionally in combination with one or more other M. leprae antigens or non-M. leprae sequences, as described herein or obtainable in the art.
- The antigens or polypeptides may be used in essentially any assay format desired, e.g., as individual antigens assayed separately, as multiple antigens assays simultaneously (e.g., a fusion polypeptide), as antigens immobilized on a solid support such as an array, or the like.
- In one embodiment, there are provided diagnostic kits for detecting M. leprae infection in a biological sample, comprising (a) a polypeptide or a fusion polypeptide described herein or variants thereof as described herein, and (b) a detection reagent.
- In another embodiment, there are provided diagnostic kits for detecting M. leprae infection in a biological sample, comprising (a) antibodies or antigen binding fragments thereof that are specific for a polypeptide or a fusion polypeptides described herein or variants thereof as described herein, and (b) a detection reagent.
- In another embodiment, methods are provided for detecting the presence of M. leprae infection in a biological sample, comprising (a) contacting a biological sample with a polypeptide or a fusion polypeptide described herein or variants thereof described herein; and (b) detecting in the biological sample the presence of antibodies that bind to the fusion polypeptide.
- In another embodiment, methods are provided for detecting the presence of M. leprae infection in a biological sample, comprising (a) contacting a biological sample with at least 2 monoclonal antibodies that bind to a polypeptide or a polypeptide described herein or variants thereof described herein; and (b) detecting in the biological sample the presence of M. leprae proteins that bind to the monoclonal antibody.
- One of ordinary skill in the art would recognize that the methods and kits described herein may be used to detect all types of leprosy, depending on the particular combination of immunogenic portions of M. leprae antigens present in the fusion polypeptide.
- There are a variety of assay formats known to those of ordinary skill in the art for using a fusion polypeptide to detect antibodies in a sample. See, e.g., Harlow and Lane, Antibodies. A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988, which is incorporated herein by reference. In one embodiment, the assay involves the use of fusion polypeptide immobilized on a solid support to bind to and remove the antibody from the sample. The bound antibody may then be detected using a detection reagent that binds to the antibody/peptide complex and contains a detectable reporter group. Suitable detection reagents are well known and include, for example, antibodies that bind to the antibody/polypeptide complex and free polypeptide labeled with a reporter group (e.g., in a semi-competitive assay). Suitable reporter groups are also well known and include, for example, fluorescent labels, enzyme labels, radioisotopes, chemiluminescent labels, electrochemiluminescent labels, bioluminescent labels, polymers, polymer particles, metal particles, haptens, and dyes. Alternatively, a competitive assay may be utilized, in which an antibody that binds to a fusion polypeptide of the present disclosure labeled with a reporter group and allowed to bind to the immobilized fusion polypeptide after incubation of the fusion polypeptide with the sample. The extent to which components of the sample inhibit the binding of the labeled antibody to the fusion polypeptide is indicative of the reactivity of the sample with the immobilized fusion polypeptide.
- The solid support may be any material known to those of ordinary skill in the art to which the fusion polypeptide may be attached. For example, the support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Pat. No. 5,359,681.
- The fusion polypeptide may be bound to the solid support using a variety of techniques known to those in the art, which are amply described in the patent and scientific literature. In the context of the present disclosure, the term “bound” refers to both non-covalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Binding by adsorption to a well in a microtiter plate or to a membrane is preferred. In such cases, adsorption may be achieved by contacting the polypeptide, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of fusion polypeptide ranging from about 10 ng to about 1 pg, and preferably about 100 ng, is sufficient to bind an adequate amount of antigen. Nitrocellulose will bind approximately 100 pg of protein per 3 cm.
- Covalent attachment of fusion polypeptide to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the fusion polypeptide. For example, the fusion polypeptide may be bound to a support having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the polypeptide (see, e.g., Pierce Immunotechnology Catalog and Handbook (1991) at A12-A13).
- In certain embodiments, the assay is an enzyme linked immunosorbent assay (ELISA). This assay may be performed by first contacting a fusion polypeptide of the present disclosure that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that antibodies to the M. leprae antigens of the fusion polypeptide within the sample are allowed to bind to the immobilized fusion polypeptide. Unbound sample is then removed from the immobilized fusion polypeptide and a detection reagent capable of binding to the immobilized antibody-polypeptide complex is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific detection reagent.
- Once the fusion polypeptide is immobilized on the support, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin (BSA) or
Tween 20™ (Sigma Chemical Co., St. Louis, Mo.) may be employed. The immobilized polypeptide is then incubated with the sample, and antibody (if present in the sample) is allowed to bind to the antigen. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time (i.e., incubation time) is that period of time that is sufficient to permit detection of the presence of antibody within a M. leprae-infected sample. Preferably, the contact time is sufficient to achieve a level of binding that is at least 95% of that achieved at equilibrium between bound and unbound antibody. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient. - Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1
% Tween 20™. Detection reagent may then be added to the solid support. An appropriate detection reagent is any compound that binds to the immobilized antibody-polypeptide complex and that can be detected by any of a variety of means known to those in the art. Preferably, the detection reagent contains a binding agent (such as, for example, Protein A. Protein G, immunoglobulin, lectin or free antigen) conjugated to a reporter group. Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups, colloidal gold and biotin. The conjugation of binding agent to reporter group may be achieved using standard methods known to those of ordinary skill in the art. Common binding agents may also be purchased conjugated to a variety of reporter groups from many sources (e.g., Zymed Laboratories, San Francisco, Calif, and Pierce, Rockford, Ill.). - The detection reagent is then incubated with the immobilized antibody polypeptide complex for an amount of time sufficient to detect the bound antibody. An appropriate amount of time may generally be determined from the manufacturer's instructions or by assaying the level of binding that occurs over a period of time. Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.
- To determine the presence or absence of anti-M. leprae antibodies in the sample, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one embodiment, the cut-off value is preferably the average mean signal obtained when the immobilized polypeptide is incubated with samples from an uninfected patient. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive (i.e., reactive with the polypeptide). In an alternate embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., Clinical Epidemiology: A Basic Science for Clinical Medicine, p. 106-7 (Little Brown and Co., 1985). Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (i.e., sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper lefthand corner (i.e., the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate.
- In other embodiments, an assay is performed in a flow-through assay format, wherein the antigen is immobilized on a membrane such as nitrocellulose. In the flow-through test, antibodies within the sample bind to the immobilized polypeptide as the sample passes through the membrane. A detection reagent (e.g., protein A-colloidal gold) then binds to the antibody-polypeptide complex as the solution containing the detection reagent flows through the membrane. The detection of bound detection reagent may then be performed as described above.
- In other embodiments, an assay if performed in a strip test format, also known as a lateral flow format. Here, one end of the membrane to which polypeptide is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing detection reagent and to the area of immobilized fusion polypeptide. Concentration of detection reagent at the fusion polypeptide indicates the presence of M. leprae antibodies in the sample. Typically, the concentration of detection reagent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of fusion polypeptide immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of antibodies that would be sufficient to generate a positive signal in an ELISA, as discussed above. Preferably, the amount of fusion polypeptide immobilized on the membrane ranges from about 25 ng to about 1 fag, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount (e.g., one drop) of patient serum or blood. Lateral flow tests can operate as either competitive or sandwich assays.
- In still other embodiments, a fusion polypeptide of the disclosure is adapted for use in a dual path platform (DPP) assay. Such assays are described, for example, in U.S. Pat. No. 7,189,522, the contents of which are incorporated herein by reference.
- Of course, numerous other assay protocols exist that are suitable for use with the fusion polypeptides of the present disclosure. It will be understood that the above descriptions are intended to be exemplary only.
- The assays discussed above may be used, in certain aspects of the disclosure, to specifically detect visceral leprosy. In this aspect, antibodies in the sample may be detected using a fusion polypeptide of the present disclosure, e.g., comprising an amino acid sequence of antigenic/immunogenic fragments or epitopes of M. leprae antigens. Preferably, the M. leprae antigens are immobilized by adsorption to a solid support such as a well of a microtiter plate or a membrane, as described above, in roughly similar amounts such that the total amount of fusion polypeptide in contact with the support ranges from about 10 ng to about 100 pg. The remainder of the steps in the assay may generally be performed as described above. It will be readily apparent to those of ordinary skill in the art that, by combining polypeptides described herein with other polypeptides that can detect cutaneous and mucosal leprosy, the polypeptides disclosed herein may be used in methods that detect all types of leprosy.
- In another aspect of this disclosure, immobilized fusion polypeptides may be used to purify antibodies that bind thereto. Such antibodies may be prepared by any of a variety of techniques known to those of ordinary skill in the art. See, e.g., Harlow and Land, Antibodies. A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1988. In one such technique, an immunogen comprising a fusion polypeptide of the present disclosure is initially injected into any of a wide variety of mammals (e.g., mice, rats, rabbits, sheep and goats). In this step, the polypeptide may serve as the immunogen without modification. Alternatively, particularly for relatively short polypeptides, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as bovine serum albumin or keyhole limpet hemocyanin. The immunogen is injected into the animal host, preferably according to a predetermined schedule incorporating one or more booster immunizations, and the animals are bled periodically. Polyclonal antibodies specific for the polypeptide may then be purified from such antisera by, for example, affinity chromatography using the polypeptide coupled to a suitable solid support.
- Monoclonal antibodies specific for the antigenic fusion polypeptide of interest may be prepared, for example, using the technique of Kohler and Milstein, Eur. J. Immunol. 6:511-519, 1976, and improvements thereto. Briefly, these methods involve the preparation of immortal cell lines capable of producing antibodies having the desired specificity (i.e., reactivity with the polypeptide of interest). Such cell lines may be produced, for example, from spleen cells obtained from an animal immunized as described above. The spleen cells are then immortalized by, for example, fusion with a myeloma cell fusion partner, preferably one that is syngeneic with the immunized animal. A variety of fusion techniques may be employed. For example, the spleen cells and myeloma cells may be combined with a nonionic detergent for a few minutes and then plated at low density on a selective medium that supports the growth of hybrid cells, but not myeloma cells. A preferred selection technique uses HAT (hypoxanthine, aminopterin, thymidine) selection. After a sufficient time, usually about 1 to 2 weeks, colonies of hybrids are observed. Single colonies are selected and tested for binding activity against the polypeptide. Hybridomas having high reactivity and specificity are preferred.
- Monoclonal antibodies may be isolated from the supematants of growing hybridoma colonies. In this process, various techniques may be employed to enhance the yield, such as injection of the hybridoma cell line into the peritoneal cavity of a suitable vertebrate host, such as a mouse. Monoclonal antibodies may then be harvested from the ascites fluid or the blood. Contaminants may be removed from the antibodies by conventional techniques, such as chromatography, gel filtration, precipitation, and extraction. One or more polypeptides may be used in the purification process in, for example, an affinity chromatography step.
- Monospecific antibodies that bind to a fusion polypeptide comprising two or more immunogenic portions of M. leprae antigens may be used, for example, to detect M. leprae infection in a biological sample using one of a variety of immunoassays, which may be direct or competitive. Briefly, in one direct assay format, a monospecific antibody may be immobilized on a solid support (as described above) and contacted with the sample to be tested. After removal of the unbound sample, a second monospecific antibody, which has been labeled with a reporter group, may be added and used to detect bound antigen. In an exemplary competitive assay, the sample may be combined with the monoclonal or polyclonal antibody, which has been labeled with a suitable reporter group. The mixture of sample and antibody may then be combined with polypeptide antigen immobilized on a suitable solid support. Antibody that has not bound to an antigen in the sample is allowed to bind to the immobilized antigen and the remainder of the sample and antibody is removed. The level of antibody bound to the solid support is inversely related to the level of antigen in the sample. Thus, a lower level of antibody bound to the solid support indicates the presence of M. leprae in the sample. Other formats for using monospecific antibodies to detect M. leprae in a sample will be apparent to those of ordinary skill in the art, and the above formats are provided solely for exemplary purposes.
- As used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a polypeptide” optionally includes two or more polypeptides, and the like.
- It is understood that aspect and embodiments of the disclosure described herein include “comprising,” “consisting,” and “consisting essentially of aspects and embodiments.
- The various embodiments described above can be combined to provide further embodiments. All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet, are incorporated herein by reference, in their entirety. Aspects of the embodiments can be modified, if necessary to employ concepts of the various patents, applications and publications to provide yet further embodiments.
- Antigen Recognition in Leprosy Patient Samples.
- Subjects and samples. Recently diagnosed and previously untreated leprosy patients and endemic controls (EC) were recruited at Centra de Referencia em Diagnostico e Terapeutica and Hospital Anuar Auad, Goiania, Goias State, Brazil. Leprosy patients were categorized as paucibacillary (PB) by clinical, bacilloscopic and histological observations (bacterial index, skin lesions, nerve involvement and histopathology) carried out by qualified personnel. Blood was obtained from tuberculosis patients (Mycobacterium tuberculosis sputum-positive, HIV-negative individuals with clinically confirmed pulmonary tuberculosis) who were undergoing treatment. EC were healthy individuals who had never had tuberculosis, had no history of leprosy in the family, and were living in the leprosy endemic area. All donors had previously been immunized with BCG and all blood samples were obtained after informed consent and after local ethics committee approval.
- Determining reactivity by 24 hour whole blood assay (WBA). WBA were performed with venous undiluted heparinized whole blood (Greiner). Within 2 hours of collection, blood was added to each well of a 24-well plate (450 μl/well: Sigma, St. Louis, MO) and incubated with antigens at 37° C., 5% CO2. For each assay, stimulations were conducted with 10 μg/ml of recombinant protein and 1 μg/ml PHA (Sigma). After 24 hours, plasma was collected and stored at −20° C. IFNγ content within the plasma was determined by ELISA, used according to the manufacturer's instructions (QuantiFERON CMI Cellestis, Camegie, Australia). The detection limit of the test was 0.05 IU/ml. For data interpretation, a positive result was assigned as a concentration above an arbitrary cut-off point of 0.5 IU/ml. Spontaneous IFNγ secretion was observed in WBA only for some TB patients, and in those cases, was subtracted to provide antigen-induced values.
- Antigen recognition by leprosy-affected individuals. Replication and dissemination of M. leprae is limited in PB leprosy patients and most HHC, suggesting the potent cellular immune response they develop is associated with limited or localized disease. Antigens that are recognized by PB patients or HHC are potentially targets of an effective immune response against M. leprae. To further the antigen selection scheme, the analyses was expanded to include ethnically and geographically distinct populations (Table 1). While each of the individual antigens ML2028, ML2055 and ML2380 were recognized by over 50% PB patients and HHC, the combination of these antigens pushed the theoretical recognition to over 80%.
- Table 1. Percent responders above 50 pg/ml IFNγ in WBA. Whole blood from PB and HHC was cultured for 24 hours in the presence of antigen and IFNγ content in the plasma was measured by ELISA. Data were generated with cohorts from Brazil and the Philippines.
-
TABLE 1 Percent responders above 50 pg/mL IFNγ in WBA #Posi- #Nega- % Posi- tive tive tive Total Re- Re- Re- Antigens # sponders sponders sponders observed ML2028 129 77 52 59.7 ML2025 130 90 40 69.2 ML2380 68 45 23 66.2 theoretical ML2028 + ML2055 70 51 19 72.9 ML2028 + ML2380 32 26 6 81.3 ML2055 + ML2380 32 27 5 84.4 ML2028 + 32 27 5 84.4 ML2055 + ML2380 - Mice and immunizations. Wild type C57BL/6 (B6) mice were purchased from Charles River Laboratories (Wilmington, MA). Mice were immunized with recombinant protein formulated with saline, stable emulsion (SE), or glucopyranosyl lipid adjuvant (GLA)-SE, to provide a final protein concentration of 10 μg antigen and 20 μg GLA-SE. Mice were immunized up to 3 times by subcutaneous (s.c) injection of 0.1 ml volume at the base of the tail at 2 week intervals. Mice were maintained in specific pathogen-free conditions and all procedures were approved by the pertinent institutional animal care and use committees.
- Immunization with Select Antigens Reduces M. Leprae Infection.
- Determination of bacterial burden. To assess M. leprae growth, live M. leprae bacilli (Thai-53 strain) were purified from the footpads of nu/nu mice at National Institute of Infectious Diseases. Mice were inoculated with 1×104 bacilli by s.c. injection into each foot pad. Foot pads were harvested 12 months later and the bacilli were enumerated by direct microscopic counting of acid-fast bacilli according to the method of Shepard and McRae or by RT-PCR of the M. leprae specific repetitive element (RLEP).
- Immunization with select antigens reduces M. leprae infection. To investigate if immunization with the recognized antigens could limit M. leprae infection, mice were immunized with single antigens, or combinations of antigens, before infection with M. leprae. Immunization significantly decreased bacterial numbers (
FIGS. 1A and 1B ; p-values<0.05). These data indicate that immunization with the selected antigens elicits protective responses in mice and warrant inclusion within a defined sub-unit vaccine against leprosy. - Generation of ML89 Fusion Protein A single 89kD fusion protein, designated ML89, was generated from the ML2028, ML2055 and ML2380 antigens, with the addition of ML2531 to stabilize expression.
- Immune recognition of chimeric fusion protein ML89.
- Antibody responses. Mouse sera were prepared following collection of retro-orbital blood into microtainer serum collection tubes (VWR International, West Chester, PA) followed by centrifugation at 1200 rpm for 5 minutes. Each serum was then analyzed by antibody capture ELISA. Briefly, ELISA plates (Nunc, Rochester, NY) were coated with 1 μg/ml recombinant antigen in 0.1 M bicarbonate buffer and blocked with 1% BSA-PBS. Then, in consecutive order and following washes in PBS/
Tween® 20, serially diluted serum samples, anti-mouse IgG, IgG1 or IgG2c-HRP (all Southern Biotech, Birmingham, AL) and ABTS-H2O2 (Kirkegaard and Perry Laboratories, Gaithersburg, MD) were added to the plates. Plates were analyzed at 405 nm (ELX808, Bio-Tek Instruments Inc, Winooski, VT). Endpoint titer was determined as the last dilution to render a positive response, determined as 2 times the mean optical density of the replicates derived from sera from unimmunized mice in Prism software (GraphPad Software, La Jolla, CA). - Antigen stimulation and cytokine responses. Single cell suspensions were prepared by disrupting spleens between frosted slides. Red blood cells were removed by lysis in 1.66% NH4Cl solution, then mononuclear cells enumerated by Via Count assay with a PCA system (Guava Technologies, Hayward, CA). Single cell suspensions were cultured at 2×105 cells per well in duplicate in a 96-well plate (Corning Incorporated, Corning, NY) in RPMI-1640 supplemented with 5% heat-inactivated FCS and 50,000 Units penicillin/streptomycin (Invitrogen). Cells were cultured in the presence of 10 μg/ml antigen for 72-96 hours, after which culture supematants were harvested and cytokine content assessed. Cytokine concentrations within culture supematants were determined by single cytokine ELISA or multiple cytokine luminex assays. ELIS A kits for determination of mouse IFNγ. IL-5, IL-13 and TNF-α were performed according to manufacturer's instructions (eBioscience, San Diego, CA) and optical density was determined using an ELx808 plate reader.
- Immune recognition of chimeric fusion protein ML89. Combining multiple antigens into a single fusion protein is now commonly used to provide a more consistent production process whilst also increasing the proportion of the population that is likely to respond. We therefore created a single 89kD fusion protein, designated ML89, consisting of the ML2028, ML2055 and ML2380 antigens, with the addition of ML2531 to stabilize expression. When mice were immunized with the ML89 they raised antibodies against each individual component (
FIGS. 2B-2D ), indicating that antigenicity was retained. Given that the M. bovis BCG vaccine is routinely used in leprosy-affected regions, we also examined the interplay of ML89 and BCG vaccination and determined if prior BCG immunization led to any interactions upon ML89 immunization. Mice were either primed with BCG or not, then immunized with ML89/GLA-SE. Subsequent analyses of the IFNγ recall response to ML89 indicated similar responses in both immunization strategies (FIG. 3A ). Furthermore, mice immunized with ML89 also responded to lysate of BCG and, most importantly, to crude M. leprae antigens (FIGS. 3B and 3D ). These data indicate that recognition of ML89 raises responses that recognize M. leprae that are not adversely affected by prior BCG immunization. - Immunization with ML89/GLA-SE reduces M. leprae burdens.
- Determination of bacterial burden. To assess M. leprae growth, live M. leprae bacilli (Thai-53 strain) were purified from the footpads of nu/nu mice at National Institute of Infectious Diseases. Mice were inoculated with 1×104 bacilli by s.c. injection into each foot pad. Foot pads were harvested 12 months later and the bacilli were enumerated by direct microscopic counting of acid-fast bacilli according to the method of Shepard and McRae or by RT-PCR of the M. leprae specific repetitive element (RLEP).
- Immunization with ML89/GLA-SE reduces M. leprae burdens. We hypothesized that immunization with the ML89 antigen would limit bacterial growth, and evaluated the ability of the ML89/GLA-SE vaccine candidate to protect against experimental M. leprae infection using the BALB/c mouse footpad model. Immunized mice were infected with M. leprae in the footpad and bacilli numbers assessed months later. The vaccine decreased bacterial numbers by 85% when compared with mice injected with GLA-SE adjuvant alone (
FIG. 4A ; p-values<0.05). Immunization with ML89/GLA-SE elicited protection equivalent to the mixture of its individual components, and could provide protection when injected 2 or 3 times (FIG. 4B ; p-values<0.05). Taken together, the data indicated that the defined subunit ML89/GLA-SE vaccine induces responses that control of M. leprae infection. - Immunization with ML89/GLA-SE reduced lymphadenopathy induced by M. leprae infection. Mice were injected s.c. with ML89/GLA-SE at biweekly intervals, for a total of 3 immunizations. One month after the last immunization mice were infected with 1×106 M. leprae in each ear, and DLN cell numbers determined 16 weeks later. Results are shown as mean and SE (n=5 per group). Student's t-test was used to calculate p-values between each group.
- ML89-specific T cells reduced M. leprae viability during experimental infection. Mice were injected s.c. with ML89/GLA-SE at biweekly intervals, for a total of 3 immunizations. One month after the last immunization T cells were purified from the spleens of immunized mice and transferred by i.v. injection into athymic recipient mice. Recipient mice were infected with 1×104 M. leprae in each foot, and bacilli numbers and viability determined 1 month later. Results are shown as mean and SE. Mann-Whitney test was used to calculate p-values between each group: n=6 per group.
- Immunization with ML89/GLA-SE delays motor nerve function impairment
- The manifestation of leprosy in nine-banded armadillo (Dasypus novemcinctus), the only other natural host of M. leprae, is strikingly similar to humans. Most significantly, armadillos develop extensive nerve involvement during experimental M. leprae infection and can exhibit many classic clinical signs such as foot ulcers, skin lesions and even blindness. Armadillos are an abundant source of leprotic neurologic fibers and they have already provided some important insights into the demyelinating neuropathy involved in leprosy. Marked inflammation can be observed on histopathological inspection of infected armadillo nerves and a functional deficit can be demonstrated in leprotic nerves using electrophysiology. Importantly, among the unique attributes of experimental infection in armadillos are a controlled and known infection status, and functional recapitulation of leprosy as seen in humans but with a compressed time until disease emergence.
- Immunization with ML89/GLA-SE delays motor nerve function impairment. Given that the hallmark of leprosy is nerve damage, the vaccine was evaluated in nine-banded armadillos that develop the nerve involvement and functional perturbations seen in humans. To mimic a situation that may commonly arise in leprosy hyper-endemic regions, namely asymptomatic M. leprae infection, armadillos were infected prior to immunization then monitored for motor nerve conduction abnormality. Untreated armadillos began to show nerve conduction deficits as early as 4 months after inoculation, and all armadillos had had at least some measurable deficit by 12 months (
FIG. 5A ). Many animals that exhibited conduction deficits one month demonstrated a return to normal measurements the next. To account for these fluctuations, an animal demonstrating 3 consecutive months with abnormal readings was defined as exhibiting a sustained deficit. The variable nature of M. leprae infection in these outbred animals became apparent using this parameter, with sustained nerve conduction deficits occurring 6-22 months after infection and 2 of 12 (17%) infected armadillos not actually demonstrating persistent alterations (FIG. 5B ). Interestingly. BCG immunization of already infected animals led to precipitation of nerve damage. While onset of conduction deficits in BCG vaccinated armadillos occurred at the same time as control untreated animals (FIG. 5 a ), sustained conduction deficits were more rapidly observed in BCG vaccinated armadillos than control untreated animals (FIG. 5 b ). The extent of the dissemination was significant enough that 27% (3 of 11) of the BCG immunized armadillos had to be removed from the study. Sustained conduction deficits were also more rapidly observed in BCG vaccinated armadillos than control untreated animals. In stark contrast, LEP-F1/GLA-SE immunization delayed the onset of motor nerve conduction abnormality among animals already incubating leprosy (FIG. 5B ). It is highly pertinent that LEP-F1/GLA-SE immunization, at a minimum, appears to be safe and induces no further neurological injury in armadillos. -
TIME OF GROUP ID SACRIFICE COMMENT BCG 11I203 12 months 11I302 12 months 11I1903 10 months 12M41 19 months ID93 11J201 32 months Not due dissemination 11J301 23 months 11J901 13 months 12O68 23 months - Statistics. For human data, the Mann Whitney U test was applied for comparison between two groups. The non-parametric Kruskal-Wallis analysis of variance test was used to compare the IFNγ levels among all groups. The p-values for mouse studies resulting in normally distributed data including 2 groups were determined using the Student's t-test. Where more than 2 groups were compared, p-values were attained by ANOVA analyses. Data were log-transformed for non-normal data sets prior to analysis. Statistics were generated using MS Excel (Microsoft Corporation, Redmond, WA) or Prism software (GraphPad Software, Inc., La Jolla, CA). Statistical significance was considered as p-values were <0.05.
- Despite the positive impact that WHO-MDT has had on the global prevalence of leprosy, there are many indications that further efforts are required to prevent the re-emergence of leprosy and continue efforts toward eradication. Targeting vaccination to at-risk populations, amongst which many individuals may already be infected with M. leprae, appears a tenable long lasting strategy. Many countries re-immunize leprosy patients and their close contacts with the Mycobacterium bovis BCG vaccine developed against tuberculosis. Immunization with BCG does afford some protection, although meta-analyses of clinical trials estimated its ability to prevent leprosy to be modest (26% and 41%, respectively) (Setia et al., Lancet Infect. Dt. 2006:6(3): 162-170; Merle et al. Expert Review of Vaccines. 2010; 9(2):209-22.)
- The persistence of leprosy in regions with good BCG coverage indicates that additional strategies are required.
- Although M. leprae is killed by MDT, neurological injury continues to occur in patients and can be exacerbated during inflammatory reactional episodes. Some clinicians/researchers fear that immunization to boost inflammatory T cell responses will induce nerve-damaging reversal reactions. Live attenuated or killed mycobacteria vaccines have generally been well tolerated in patients and the incidence of reactions has not been dramatically altered versus unvaccinated groups, while more rapid bacterial clearance has occurred and has been accompanied by distinct signs of clinical improvement. Anecdotal reports, and now clinical evidence, indicate that BCG immunization may however precipitate the onset of PB disease in some individuals, with speculation that infected but asymptomatic M. leprae-infected individuals are at greatest risk. To date, however, the effect of vaccination on M. leprae-associated neuropathy has not been investigated in a controlled system. The data demonstrated that BCG vaccination precipitates nerve damage in M. leprae-infected armadillos, supporting that hypothesis that infected individuals are at risk of disease precipitation if vaccinated with BCG.
- Thus, it was surprising that the data indicated that LEP-F1/GLA-SE immunization was safe but also delayed nerve damage in animals infected with high doses of M. leprae.
- As would be recognized by the skilled artisan, these and other changes can be made to the embodiments of the disclosure in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled.
- GLP Repeated Dose Toxicity Study In Rabbits
- A study to determine the potential toxicity of LEP-F1+GLA-SE in New Zealand White rabbits when given every 14 days via IM injection for 6 weeks as well as to determine if delayed toxicity and/or recovery occurred after a 4 week recovery period was performed. Systemic exposure was evaluated by anti-LEP-F1 antibody analysis. Forty animals were divided into two groups and received either saline or LEP-F1 (20 ug)+GLA-SE (20 ug). The animals were dosed by IM Injection on
Days - Phase I Open Label Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1+GLA-SE in Healthy Adult Subjects
- To evaluate the safety and tolerability of 2 ug LEP-
F1+ 5 ug GLA-SE and 10 ug LEP-F1+ 5 ug GLA-SE following IM administration onstudy days 0, 28, and 56 and to assess the immunogenicity of 2 ug LEP-F1+ 5 ug GLA-SE and 10 ug LEP-F1+ 5 ug GLA-SE by evaluating T cell responses to LEP-F1 at specified time points, a Phase I clinical trial will be performed. The proposed clinical trial is a first-in-man trial to establish an initial safety profile in mycobacterially naive healthy adults. The evaluation of vaccine-induced immunity will be based on the development of circulating antibody and T cell responses directed against the LEP-F1 antigen. Primary response will be assessed at Day 63. Responses at baseline and Day 35 will also be assessed. Each participant will be on study for 14 months. Serum will be collected ondays 0, 35, and 63. These samples will be used to determine by IgG ELISA whether subjects have antibody responses to the LEP-F1 antigen at each of these time points. Measured antibody responses to LEP-F11 will be reported as normalized titers. Cellular immune response analysis of selected Th1 and Th2 cytokines specific to LEP-F1 will be assayed ondays 0, 35, and 63 by whole blood assay. Cytokine concentrations will be quantified by ELISA or multiplex bead array. - It is anticipated that adverse events will be generally mild, transient and typical of immunizations given by the IM. route. It is expected that subjects receiving LEP-F1+GLA-SE will have robust levels of antigen specific IgG antibodies and will display antigen-specific CD4+ T cell responses.
-
SEQUENCES SEQ ID NO: 1 Polynucleotide Encoding ML2028 Antigen ATGATTGACGTGAGCGGGAAGATCCGAGCCTGGGGGCGCTGGCTTTTGGTGGGTGCAGCTGCGACT CTGCCGAGCCTAATCAGCCTTGCTGGCGGAGCGGCGACCGCAAGCGCGTTCTCACGACCAGGCCTA CCCGTCGAGTACCTACAGGTGCCGTCGGAGGCGATGGGGCGCAGCACAAGGTGCAGTTTCAAAAC GGCGGAAACGGCTCTCCGGCGGTGTATCTGCTGGATGGTTTGCGTGCGCAGGACGACTATAACGGC TGGGACATCAACACCTCCGCATTCGAGTGGTACTATCAGTCGGGACTCTCGGTCGTGATGCCGGTCG GTGGGCAATCCAGCTTCTACAGCGACTGGTACAGCCCAGCGTGCGGCAAGGCAGGTTGCACGACC TACAAGTGGGAAACATTCCTTACTAGCGAGCTGCCTAAATGGCTATCCGCCAATAGGAGTGTCAA ATCCACCGGCAGCGCCGTGGTCGGCCTCTCGATGGCCGGTTCCTCGGCCCTAATACTGGCAGCTTA TCACCCCGATCAGTTCATCTATGCTGGCTCGTTGTCGGCGCTGATGGACTOCTCCCAGGGGATAGA ACCCCAGCTAATCGGCTTGGCGATGGGTGATGCTGGTGGCTACAAGGCCGCGGACATGTGGGGAC CACCAAATGACCCGGCCTGGCAACGAAACGACCCCATTCTGCAGGCTGGGAAGCTGGTCGCCAAC AACACCCACCTATGGGTTTACTGTGGTAACGGCACACCGTCAGAGTTGGGTGGAACCAACGTACC CGCGGAATTCCTGGAGAACTTCGTGCACGGCAGCAACCTAAAGTTCCAGGACGCCTACAACGGTG CTGGTGGCCACAACGCTGTGTTCAACCTCAATGCCGACGGAACGCACAGCTGGGAGTACTGGGGA GCCCAGCTCAACGCCATGAAGCCCGACCTACAGAACACCTTGATGGCTGTACCCCGCAGCGGT SEQ ID NO: 2 Amino Acid Sequence of ML2028 Antigen from Mycobacterium leprae (diacylglycerol acyltransferase; NCBI Reference Sequence: WP_010908679.1) MIDVSGKIRAWGRWLLVGAAATLPSLISLAGGAATASAFSRPGLPVEYLQVPSEAMGRSIKVQFQNGGN GSPAVYLLDGLRAQDDYNGWDINTSAFEWYYQSGLSVVMPVGGQSSFYSDWYSPACGKAGCTTYKW ETFLTSELPKWLSANRSVKSTGSAVVGLSMAGSSALILAAYHPDQFIYAGSLSALMDSSQGIEPQLIGLA MGDAGGYKAADMWGPPNDPAWQRNDPILQAGKLVANNTHLWVYCGNGTPSELGGTNVPAEFLENFV HGSNLKFQDAYNGAGGHNAVFNLNADGTHSWEYWGAQLNAMKPDLQNTLMAVPRSG SEQ ID NO: 3 Polynucleotide Encoding ML202839-327 TTCTCACGACCAGGCCTACCCGTCGAGTACCTACAGGTGCCGTCGGAGGCGATGGGGCGCAGCATC AAGGTGCAGTTTCAAAACGGCGGAAACGGCTCTCCGGCGGTGTATCTGCTGGATGGTTTGCGTGCG CAGGACGACTATAACGGCTGGGACATCAACACCTCCGCATTCGAGTGGTACTATCAGTCGGGACTCT CGGTCGTGATGCCGGTCGGTGGGCAATCCAGCTTCTACAGCGACTGGTACAGCCCAGCGTGCGGCA AGGCAGGTTGCACGACCTACAAGTGGGAAACATTCCTTACTAGCGAGCTGCCTAAATGGCTATCCGC CAATAGGAGTGTCAAATCCACCGGCAGCGCCGTGGTCGGCCTCTCGATGGCCGGTTCCTCGGCCCT AATACTGGCAGCTTATCACCCCGATCAGTTCATCTATGCTGGCTCGTTGTCGGCGCTGATGGACTCCT CCCAGGGGATAGAACCCCAGCTAATCGGCTTGGCGATGGGTGATGCTGGTGGCTACAAGGCCGCGG ACATGTGGGGACCACCAAATGACCCGGCCTGGCAACGAAACGACCCCATTCTGCAGGCTGGGAAG CTGGTCGCCAACAACACCCACCTATGGGTTTACTGTGGTAACGGCACACCGTCAGAGTTGGGTGGA ACCAACGTACCCGCGGAATTCCTGGAGAACTTCGTGCACGGCAGCAACCTAAAGTTCCAGGACGCC TACAACGGTGCTGGTGGCCACAACGCTGTGTTCAACCTCAATGCCGACGGAACGCACAGCTGGGA GTACTGGGGAGCCCAGCTCAACGCCATGAAGCCCGACCTACAGAACACCTTGATGGCTGTACCCCG CAGCGGT SEQ ID NO: 4 Amino Acid Sequence of Residues 39-327 of ML2028 antigen (ML202839-327) FSRPGLPVEYLQVPSEAMGRSIKVQFQNGGNGSPAVYLLDGLRAQDDYNGWDINTSAFEWYYQSGLSV VMPVGGQSSFYSDWYSPACGKAGCTTYKWETFLTSELPKWLSANRSVKSTGSAVVGLSMAGSSALILA AYHPDQFIYAGSLSALMDSSQGIEPQLIGLAMGDAGGYKAADMWGPPNDPAWQRNDPILQAGKLVAN NTHLWVYCGNGTPSELGGTNVPAEFLENFVHGSNLKFQDAYNGAGGHNAVFNLNADGTHSWEYWGA QLNAMKPDLQNTLMAVPRSG SEQ ID NO: 5 Polynucleotide Encoding ML2055 Antigen ATGAATCAGGTTGACCTGGACTCGACACATCGCAAAGGATTGTGGGCGATACTGGCGATTGCCGTG GTGGCCAGCGCCAGTGCCTTTACGATGCCGTTGCCTGCGGCCGCCAACGCCGATCCCGCGCCCCTG CCGCCATCGACGGCTACGGCAGCTCCCTCACCTGCGCAGGAGATCATTACACCCCTTCCAGGCGCCC CTGTCTCGTCCGAAGCCCAACCGGGTGATCCCAATGCGCCGTCGCTCGATCCGAATGCACCATACCC ACTTGCAGTCGATCCCAACGCCGGCCGAATCACCAACGCTGTCGGTGGATTTAGCTTCGTCCTTCCT GCCGGTTGGGTGGAGTCAGAGGCTTCACATCTTGACTACGGTTCGGTGCTGCTCAGCAAAGCCATC GAGCAGCCGCCCGTGCTTGGTCAGCCGACGGTGGTCGCTACCGACACCCGTATAGTGCTCGGCCGG CTGGACCAAAAGCTCTACGCCAGTGCCGAAGCCGACAACATTAAGGCCGCGGTCCGACTGGGCTC GGATATGGGTGAGTTCTACCTGCCATACCCCGGTACGCGGATCAACCAAGAAACCATTCCGCTCCAC GCCAACGGGATAGCTGGAAGCGCCTCCTACTACGAGGTCAAATTCAGCGATCCCAATAAGCCAATTG GCCAAATATGTACGAGCGTAGTCGGCTCGCCAGCGGCGAGTACCCCTGACGTGGGGCCCTCGCAGC GTTGGTTTGTGGTATGGCTCGGAACCTCGAATAACCCGGTGGACAAGGGCGCAGCCAAAGAGCTGG CTGAGTCTATCCGGTCAGAGATGGCTCCGATCCCGGCGTCGGTTTCCGCTCCGGCACCTGTTGGA SEQ ID NO: 6 Amino Acid Sequence of ML2055 Antigen from Mycobacterium leprae (alanine and proline-rich secreted protein Apa; NCBI Reference Sequence: WP_010908692.1) MNQVDLDSTHRKGLWAILAIAVVASASAFTMPLPAAANADPAPLPPSTATAAPSPAQEIITPLPGAPVSSE AQPGDPNAPSLDPNAPYPLAVDPNAGRITNAVGGFSFVLPAGWVESEASHLDYGSVLLSKAIEQPPVLG QPTVVATDTRIVLGRLDQKLYASAEADNIKAAVRLGSDMGEFYLPYPGTRINQETIPLHANGIAGSASYY EVKFSDPNKPIGQICTSVVGSPAASTPDVGPSQRWFVVWLGTSNNPVDKGAAKELAESIRSEMAPIPASV SAPAPVG SEQ ID NO: 7 Polynucleotide Encoding ML2380 Antigen ATGTCTCGGCTGAGCACCAGCCTATGTAAAGGTGCTGTTTTTCTCGTTTTCGGTATCATTCCTGTGGC ATTTCCGACGACCGCCGTTGCCGATGGTTCCACGGAGGATTTTCCGATCCCCCGCAGGCAAATCGCC ACCACCTGTGATGCAGAGCAGTATTTGGCGGCCGTCAGGGATACCAGCCCGATCTACTACCAGCGGT ACATGATCGATATGCACAACAAGCCGACTGACATCCAGCAGGCCGCGGTCAATCGTATCCATTGGTT CTATTCCTTGAGCCCCACCGACCGTAGGCAGTATTCCGAGGACACCGCTACAAACGTCTACTACGAG CAGATGGCCACGCATTGGGGAAACTGGGCGAAGATTTTCTTCAATAACAAGGGCGTTGTCGCCAAA GCCACCGAGGTTTGCAACCAGTACCAGGCCGGAGACATGTCGGTGTGGAACTGGCCG SEQ ID NO: 8 Amino Acid Sequence of ML2380 Antigen from Mycobacterium leprae (hypothetical protein; NCBI Reference Sequence: WP_010908863.1) MSRLSTSLCKGAVFLVFGIIPVAFPTTAVADGSTEDFPIPRRQIATTCDAEQYLAAVRDTSPIYYQRYMIDM HNKPTDIQQAAVNRIHWFYSLSPTDRRQYSEDTATNVYYEQMATHWGNWAKIFFNNKGVVAKATEVC NQYQAGDMSVWNWP SEQ ID NO: 9 Polynucleotide Encoding ML2531 Antigen ATGACACAGATTATGTACAACTACCCGGCAATGTTGGACCACGCCGGGAATATGTCAGCCTGCGCCG GCGCTTTGCAGGGGGGGGCATCGACATCGCTGCCGAGCAAGCTGCGTTGCAAGCTTGCTGGGGGG GCGATACTGGGATTAGTTATCAGGCCTGGCAGGTGCAGTGGAACCAGGCCACGGAAGAGATGGTGC GTGCCTACCATGCAATGGCCAACACTCACCAAAACAACACTTTGGCTATGCTCACCCGCGACCAAG CTGAAGCCGCCAAATGGGGCGGC SEQ ID NO: 10 Amino Acid Sequence of ML2531 Antigen from Mycobacterium leprae (ESAT-6-like protein EsxR; NCBI Reference Sequence: WP_010908945.1) MTQIMYNYPAMLDHAGNMSACAGALQGVGIDIAAEQAALQACWGGDTGISYQAWQVQWNQATEEM VRAYHAMANTHQNNTLAMLTRDQAEAAKWGG SEQ ID NO: 11 Polynucleotide Encoding the LEP-F1 Fusion Polypeptide ATGACACAGATTATGTACAACTACCCGGCAATGTTGGACCACGCCGGGAATATGTCAGCCTGCGCCG GCGCTTTGCAGGGGGTGGGCATCGACATCGCTGCCGAGCAAGCTGCGTTGCAAGCTTGCTGGGGGG GCGATACTGGGATTAGTTATCAGGCCTGGCAGGTGCAGTGGAACCAGGCCACGGAAGAGATGGTGC GTGCCTACCATGCAATGGCCAACACTCACCAAAACAACACTTTGGCTATGCTCACCCGCGACCAAG CTGAAGCCGCCAAATGGGGCGGCGGATCCATGTCTCGGCTGAGCACCAGCCTATGTAAAGGTGCTG TTTTTCTCGTTTTCGGTATCATTCCTGTGGCATTTCCGACGACCGCCGTTGCCGATGGTTCCACGGAG GATTTTCCGATCCCCCGCAGGCAAATCGCCACCACCTGTGATGCAGAGCAGTATTTGGCGGCCGTCA GGGATACCAGCCCGATCTACTACCAGCGGTACATGATCGATATGCACAACAAGCCGACTGACATCCA GCAGGCCGCGGTCAATCGTATCCATTGGTTCTATTCCTTGAGCCCCACCGACCGTAGGCAGTATTCCG AGGACACCGCTACAAACGTCTACTACGAGCAGATGGCCACGCATTGGGGAAACTGGGCGAAGATTT TCTTCAATAACAAGGGCGTTGTCGCCAAAGCCACCGAGGTTTGCAACCAGTACCAGGCCGGAGACA TGTCGGTGTGGAACTGGCCGGAGCTCATGAATCAGGTTGACCTGGACTCGACACATCGCAAAGGAT TGTGGGCGATACTGGCGATTGCCGTGGTGGCCAGCGCCAGTGCCTTTACGATGCCGTTGCCTGCGGC CGCCAACGCCGATCCCGCGCCCCTGCCGCCATCGACGGCTACGGCAGCTCCCTCACCTGCGCAGGA GATCATTACACCCCTTCCAGGCGCCCCTGTCTCGTCCGAAGCCCAACCGGGTGATCCCAATGCGCCG TCGCTCGATCCGAATGCACCATACCCACTTGCAGTCGATCCCAACGCCGGCCGAATCACCAACGCTG TCGGTGGATTTAGCTTCGTCCTTCCTGCCGGTTGGGTGGAGTCAGAGGCTTCACATCTTGACTACGG TTCGGTGCTGCTCAGCAAAGCCATCGAGCAGCCGCCCGTGCTTGGTCAGCCGACGGTGGTCGCTAC CGACACCCGTATAGTGCTCGGCCGGCTGGACCAAAAGCTCTACGCCAGTGCCGAAGCCGACAACAT TAAGGCCGCGGTCCGACTGGGCTCGGATATGGGTGAGTTCTACCTGCCATACCCCGGTACGCGGATC AACCAAGAAACCATTCCGCTCCACGCCAACGGGATAGCTGGAAGCGCCTCCTACTACGAGGTCAAA TTCAGCGATCCCAATAAGCCAATTGGCCAAATATGTACGAGCGTAGTCGGCTCGCCAGCGGCGAGTA CCCCTGACGTGGGGCCCTCGCAGCGTTGGTTTGTGGTATGGCTCGGAACCTCGAATAACCCGGTGG ACAAGGGCGCAGCCAAAGAGCTGGCTGAGTCTATCCGGTCAGAGATGGCTCCGATCCCGGCGTCGG TTTCCGCTCCGGCACCTGTTGGAGTCGACTTCTCACGACCAGGCCTACCCGTCGAGTACCTACAGGT GCCGTCGGAGGCGATGGGGCGCAGCATCAAGGTGCAGTTTCAAAACGGCGGAAACGGCTCTCCGG CGGTGTATCTGCTGGATGGTTTGCGTGCGCAGGACGACTATAACGGCTGGGACATCAACACCTCCGC ATTCGAGTGGTACTATCAGTCGGGACTCTCGGTCGTGATGCCGGTCGGTGGGCAATCCAGCTTCTAC AGCGACTGGTACAGCCCAGCGTGCGGCAAGGCAGGTTGCACGACCTACAAGTGGGAAACATTCCT TACTAGCGAGCTGCCTAAATGGCTATCCGCCAATAGGAGTGTCAAATCCACCGGCAGCGCCGTGGTC GGCCTCTCGATGGCCGGTTCCTCGGCCCTAATACTGGCAGCTTATCACCCCGATCAGTTCATCTATGC TGGCTCGTTGTCGGCGCTGATGGACTCCTCCCAGGGGATAGAACCCCAGCTAATCGGCTTGGCGATG GGTGATGCTGGTGGCTACAAGGCCGCGGACATGTGGGGACCACCAAATGACCCGGCCTGGCAACG AAACGACCCCATTCTGCAGGCTGGGAAGCTGGTCGCCAACAACACCCACCTATGGGTTTACTGTGG TAACGGCACACCGTCAGAGTTGGGTGGAACCAACGTACCCGCGGAATTCCTGGAGAACTTCGTGCA CGGCAGCAACCTAAAGTTCCAGGACGCCTACAACGGTGCTGGTGGCCACAACGCTGTGTTCAACCT CAATGCCGACGGAACGCACAGCTGGGAGTACTGGGGAGCCCAGCTCAACGCCATGAAGCCCGACC TACAGAACACCTTGATGGCTGTACCCCGCAGCGGT SEQ ID NO: 12 Amino Acid Sequence of the LEP-F1 Fusion Polypeptide MTQIMYNYPAMLDHAGNMSACAGALQGVGIDIAAEQAALQACWGGDTGISYQAWQVQWNQATEEM VRAYHAMANTHQNNTLAMLTRDQAEAAKWGGGSMSRLSTSLCKGAVFLVFGIIPVAFPTTAVADGSTE DFPIPRRQIATTCDAEQYLAAVRDTSPIYYQRYMIDMHNKPTDIQQAAVNRIHWFYSL SPTDRRQYSEDT ATNVYYEQMATHWGNWAKIFFNNKGVVAKATEVCNQYQAGDMSVWNWPELMNQVDLDSTHRKGL WAILAIAVVASASAFTMPLPAAANADPAPLPPSTATAAPSPAQEIITPLPGAPVSSEAQPGDPNAPSLDPNA PYPLAVDPNAGRITNAVGGFSFVLPAGWVESEASHLDYGSVLLSKAIEQPPVLGQPTVVATDTRIVLGRL DQKLYASAEADNIKAAVRLGSDMGEFYLPYPGTRINQETIPLHANGIAGSASYYEVKFSDPNKPIGQICT SVVGSPAASTPDVGPSQRWFVVWLGTSNNPVDKGAAKELAESIRSEMAPIPASVSAPAPVGVDFSRPGL PVEYLQVPSEAMGRSIKVQFQNGGNGSPAVYLLDGLRAQDDYNGWDINTSAFEWYYQSGLSVVMPVG GQSSFYSDWYSPACGKAGCTTYKWETFLTSELPKWLSANRSVKSTGSAVVGLSMAGSSALILAAYHPD QFIYAGSLSALMDSSQGIEPQLIGLAMGDAGGYKAADMWGPPNDPAWQRNDPILQAGKLVANNTHLW VYCGNGTPSELGGTNVPAEFLENFVHGSNLKFQDAYNGAGGHNAVFNLNADGTHSWEYWGAQLNAM KPDLQNTLMAVPRSG -
TABLE 2 Results of alignment of ML2028 amino acid sequence with other species NAME Cover Identity Accession diacylglycerol acyltransferase 100% 94% WP_045843560.1 [Mycobacterium lepromatosis] diacylglycerol acyltransferase/ 100% 88% WP_047314133.1 mycolyltransferase Ag85A [Mycobacterium haemophilum] diacylglycerol acyltransferase/ 100% 84% WP_068052084.1 mycolyltransferase Ag85A [Mycobacterium sp. E342] diacylglycerol acyltransferase/ 100% 84% WP_067276075.1 mycolyltransferase Ag85A [Mycobacterium scrofulaceum] diacylglycerol acyltransferase/ 100% 83% WP_068078824.1 mycolyltransferase Ag85A [Mycobacterium sp. E1747 diacylglycerol acyltransferase 100% 84% WP_046185518.1 [Mycobacterium nebraskense] diacylglycerol acyltransferase/ 96% 85% WP_068048723.1 mycolyltransferase Ag85A [Mycobacterium sp. E2733] MULTISPECIES: diacylglycerol 96% 85% WP_067924124.1 acyltransferase/mycolytransferase Ag85A [Mycobacterium] Diacylglycerol acyltransferase/ 100% 83% Q50397.1 mycolyltransferase Ag85B [Mycobacterium scrofulaceum] diacylglycerol acyltransferase/ 96% 85% WP_066954325.1 mycolyltransferase Ag85A [Mycobacterium sp. 852002- 53434_SCH5985345] diacylglycerol acyltransferase/ 98% 83% WP_068023768.1 mycolyltransferase Ag85A [Mycobacterium szulgai] diacylglycerol acyltransferase/ 100% 83% WP_067099382.1 mycolyltransferase Ag85A [Mycobacterium sp. 852002- 40037_SCH5390672] diacylglycerol acyltransferase/ 98% 84% WP_065159015.1 mycolyltransferaseAg85A [Mycobacterium asiaticum] diacylglycerol acyltransferase/ 100% 82% WP_062899503.1 mycolyltransferaseAg85A [Mycobacterium avium] MULTISPECIES: hypothetical 100% 82% WP_003876576.1 protein [Mycobacterium avium complex (MAC)] diacylglycerol acyltransferase/ 98% 84% WP_065044249.1 mycolyltransferase Ag85A [Mycobacterium gordonae] hypothetical protein 98% 82% WP_012394484.1 [Mycobacterium marinum] secreted antigen 85-B 97% 82% BAV41604.1 [Mycobacterium ulcerans subsp. shinshuense] hypothetical protein 100% 81% WP_010949276.1 [Mycobacterium avium] antigen 85-B [Mycobacterium 96% 83% CQD16344.1 europaeum] hypothetical protein 98% 82% WP_007771267.1 [Mycobacterium colombiense] diacylglycerol acyltransferase 98% 82% WP_043954940.1 [Mycobacterium indicus pranii] diacylglycerol acyltransferase/ 100% 81% WP_068288134.1 mycolyltransferase Ag85A [Mycobacterium sp. E2462] diacylglycerol acyltransferase 98% 81% WP_036426578.1 [Mycobacterium sp. 012931] 85B protein [ Mycobacterium 100% 81% AAM21939.1 avium subsp. paratuberculosis] diacylglycerol acyltransferase/ 96% 82% WP_064934819.1 mycolyltransferase Ag85A [Mycobacterium intracellulare] secreted antigen 85-B FbpB 98% 81% ABL05230.1 [Mycobacterium ulcerans Agy99] diacylglycerol acyltransferase 98% 86% WP_036402954.1 [Mycobacterium kansasii] Esterase [Mycobacterium 97% 81% EPQ47622.1 sp. 012931] diacylglycerol acyltransferase/ 98% 81% WP_067934350.1 mycolyltransferase Ag85A [Mycobacterium sp. E2479] diacylglycerol acyltransferase 98% 85% WP_036418777.1 [Mycobacterium gastri] diacylglycerol acyltransferase/ 98% 81% WP_064951422.1 mycolyltransferaseAg85A [Mycobacterium colombiense] diacylglycerol acyltransferase/ 98% 83% WP_055380413.1 mycolyltransferaseAg85A Mycobacterium tuberculosis] esterase, putative, antigen 85-B 98% 83% AAK46207.1 [Mycobacterium tuberculosis CDC1551] diacylglycerol acyltransferase/ 100% 82% WP_066912698.1 mycolyltransferase Ag85A [Mycobacterium interjectum] antigen 85-B [Mycobacterium 97% 86% ETZ99389.1 kansasii 824] antigen 85-B [ Mycobacterium 100% 81% CPR05988.1 bohemicum DSM 44277] diacylglycerol acyltransferase/ 98% 83% WP_047713277.1 mycolyltransferase Ag85A [Mycobacterium bovis] -
TABLE 3 Results of alignment of ML2055 amino acid sequence with other species Name Cover Identity Accession alanine and proline-rich 96% 85% WP_045843569.1 secreted protein Apa [Mycobacterium lepromatosis] alanine and proline-rich 94% 61% AIR16824.1 secreted protein Apa [Mycobacterium kansasii 662] alanine and proline-rich 94% 74% WP_047317005.1 secreted protein Apa [Mycobacterium haemophilum] hypothetical protein 94% 63% WP_065145552.1 [Mycobacterium asiaticum] alanine and proline-rich 94% 68% WP_031695336.1 secreted protein Apa [Mycobacterium tuberculosis] hypothetical protein 94% 61% WP_065165242.1 [Mycobacterium gordonae] hypothetical protein 94% 62% WP_068156628.1 [Mycobacterium szulgai] hypothetical protein 94% 65% WP_055369424.1 [Mycobacterium tuberculosis] hypothetical protein 94% 66% WP_067743767.1 [Mycobacterium sp. 852014- 50255_SCH5639931] alanine and proline rich 60% 80% BAV41641.1 secreted protein [Mycobacterium ulcerans subsp. shinshuense] alanine and proline rich 60% 80% WP_015355514.1 secreted protein Apa [Mycobacterium liflandii] alanine and proline-rich 94% 64% WP_044081122.1 secreted protein Apa [Mycobacterium canettii] alanine and proline rich 60% 80% WP_020725275.1 secreted protein [Mycobacterium marinum] alanine and proline-rich 60% 79% WP_036417094.1 secreted protein Apa [Mycobacterium gastri] hypothetical protein 94% 58% WP_067409357.1 [Mycobacterium sp. 1423905.2] hypothetical protein 94% 66% WP_066933007.1 [Mycobacterium sp. 1554424.7] hypothetical protein 94% 65% WP_024456921.1 [Mycobacterium bovis] hypothetical protein 94% 64% WP_068079301.1 [Mycobacterium sp. E1747] fibronectin attachment protein 94% 65% WP_015293251.1 [Mycobacterium canettii] -
TABLE 4 Results of alignment of ML2380 amino acid sequence with other species Name Cover Identity Accession hypothetical protein 100% 89% WP_045843787.1 [Mycobacterium lepromatosis] hypothetical protein 100% 87% WP_047313676.1 [Mycobacterium haemophilum] hypothetical protein 99% 74% WP_065144676.1 [Mycobacterium asiaticum] MULTISPECIES: hypothetical 88% 73% WP_051128635.1 protein [Mycobacterium] hypothetical protein 94% 71% WP_064985021.1 [Mycobacterium mucogenicum] hypothetical protein TL10_07350 92% 68% KIU17456.1 [Mycobacterium llatzerense] hypothetical protein 100% 65% WP_040542321.1 [Mycobacterium vaccae] hypothetical protein 99% 65% WP_048631131.1 [Mycobacterium aurum] hypothetical protein 99% 67% WP_060999962.1 [Mycobacterium mucogenicum] hypothetical protein 100% 64% WP_067953437.1 [Mycobacterium sp. NAZ190054] hypothetical protein 95% 68% KMO66863.1 MCHLDSM_07340 [Mycobacterium chlorophenolicum] hypothetical protein 82% 75% WP_048421400.1 [Mycobacterium chubuense] hypothetical protein 82% 74% WP_057150842.1 [Mycobacterium sp. Soil538] hypothetical protein 96% 64% WP_024447804.1 [Mycobacterium iranicum] hypothetical protein 99% 65% WP_068289290.1 [Mycobacterium sp. E2462] hypothetical protein 99% 61% WP_011894296.1 [Mycobacterium gilvum] hypothetical protein 83% 75% WP_036470504.1 [Mycobacterium neoaurum] hypothetical protein BN971_ 99% 66% CPR11699.1 02987 [Mycobacterium bohemicum DSM 44277] hypothetical protein 93% 65% WP_029115183.1 [Mycobacterium sp. URHB0044] bypothetical protein 99% 66% WP_031705761.1 [Mycobacterium tuberculosis] hypothetical protein 99% 66% WP_015289054.1 [Mycobacterium canettii] hypothetical protein 99% 66% WP_067256445.1 [Mycobacterium sp. 852002- 10029_SCHS224772] hypothetical protein 99% 66% WP_003910126.1 [Mycobacterium africanum] hypothetical protein MT047] 99% 66% AAK44694.1 [Mycobacterium tuberculosis CDC1551] hypothetical protein 99% 65% WP_066959997.1 [Mycobacterium sp. 852002- 50816_SCH5313054-b] hypothetical protein 95% 66% WP_036421759.1 [Mycobacterium sp. 360MFTsu5.1] hypothetical protein 83% 75% WP_036462037.1 [Mycobacterium sp. UNCCL9] hypothetical protein 99% 65% CQD10070.1 BN000_02058 [Mycobacterium europaeum] hypothetical protein 99% 66% WP_067933987.1 [Mycobacterium sp. E2479] hypothetical protein 99% 66% WP_036457021.1 [Mycobacterium marinum] hypothetical protein 99% 65% WP_066917676.1 [Mycobacterium interjectum] hypothetical protein 99% 65% WP_068277017.1 [Mycobacterium sp. E787] hypothetical protein 99% 66% WP_064950639.1 [Mycobacterium colombiense] hypothetical protein 82% 71% WP_067990334.1 [Mycobacterium sp. YC-RL4] hypothetical protein 79% 73% WP_043414089.1 [Mycobacterium rufum] hypothetical protein 99% 66% WP_067171319.1 [Mycobacterium sp. 1165549.7] hypothetical protein 99% 65% WP_067109731.1 [Mycobacterium sp. 852002- 51057_SCH5723018] hypothetical protein 99% 64% WP_068061777.1 [Mycobacterium sp. E342] hypothetical protein 79% 72% WP_066835136.1 [Mycobacterium sp. 852013- 51886_SCH5428379] hypothetical protein 99% 66% WP_067837577.1 [Mycobacterium sp. E3078] hypothetical protein 99% 65% WP_068227057.1 [Mycobacterium sp. E3198] hypothetical protein 99% 65% WP_067009291.1 [Mycobacterium sp. 1081908.1] hypothetical protein SHTP_ 99% 65% BAV42346.1 3308 [Mycobacterium ulcerans subsp. shinsbuense] hypothetical protein 99% 66% WP_067344501.1 [Mycobacterium sp. 1245852.3] bypothetical protein 99% 64% WP_067871707.1 [Mycobacterium sp. E2699] hypothetical protein 99% 66% WP_036466491.1 [Mycobacterium triplex] hypothetical protein 98% 61% WP_036340591.1 [Mycobacterium aromaticivorans] hypothetical protein 99% 65% WP_067151627.1 [Mycobacterium sp. 1245805.9] conserved secreted protein 99% 66% ABL03953.1 [Mycobacterium ulcerans Agy99] hypothetical protein 87% 65% WP_011778329.1 [Mycobacterium vanbaalenii] hypothetical protein 87% 64% WP_036367359.1 [Mycobacterium austroafricanum] bypothetical protein 99% 65% WP_066930932.1 [Mycobacterium sp. 1554424.7] hypothetical protein 99% 64% WP_067282166.1 [Mycobacterium scrofulaceum] hypothetical protein 99% 66% WP_025737008.1 [Mycobacterium genavense] hypothetical protein 99% 66% WP_067122709.1 [Mycobacterium sp. 852002- 51971_SCH5477799-a] -
TABLE 5 Results of alignment of ML253.1 amino acid sequence with other species Name Cover Identity Accession type VII secretion protein EsxH 100% 88% WP_045843896.1 [Mycobacterium lepromatosis] type VII secretion protein EsxH 100% 74% WP_047315908.1 [Mycobacterium haemophilum] type VII secretion protein EsxH 100% 74% WP_036351589.1 [Mycobacterium asiaticum] ESAT-6-like protein EsxH 100% 72% WP_003902934.1 [Mycobacterium tuberculosis] type VII secretion protein EsxH 100% 73% WP_055580201.1 [Mycobacterium gordonae] type VII secretion protein EsxH 100% 72% WP_062541000.1 [Mycobacterium celatum] MULTISPECIES: type VII 100% 70% WP_068070284.1 secretion protein EsxH [Mycobacterium] EsaT-6 like protein EsxH 98% 76% AEF34288.1 [Mycobacterium sinense] low molecular weight protein 100% 71% EFP48790.1 antigen 7 esxH [Mycobacterium tuberculosis SUMu010] type VII secretion protein EsxH 100% 71% WP_065012511.1 [Mycobacterium kyorinense] ESAT-6-like protein EsxH 100% 70% WP_003910092.1 [Mycobacterium africanum] type VII secretion protein EsxH 98% 73% WP_047318399.1 [Mycobacterium heraklionense] ESAT-6-like protein EsxH 100% 70% WP_015288927.1 [Mycobacterium canettii] ESAT-6-like protein EsxH 98% 72% WP_011740245.1 [Mycobacterium marinum] type VII secretion protein EsxH 98% 72% WP_067972689.1 [Mycobacterium sp. 8WA6] type VII secretion protein EsxH 98% 74% WP_068918824.1 [Mycobacterium sp. djl-10] 10 kDa antigen [ Mycobacterium 100% 69% EPQ44287.1 sp. 012931] type VII secretion protein EsxH 100% 72% WP_068102777.1 [Mycobacterium sp. E2327] ESAT-6-like protein EsxH 98% 71% WP_011891324.1 [Mycobacterium gilvum] type VII secretion protein EsxH 100% 71% WP_061558056.1 [Mycobacterium simiae] type VII secretion protein EsxH 98% 72% WP_066851115.1 [Mycobacterium sp. 1274756.6] type VII secretion protein EsxH 98% 72% WP_024443849.1 [Mycobacterium sp. UM_WGJ] type VII secretion protein EsxH 100% 70% WP_046187146.1 [Mycobacterium nebraskense] EsaT-6 like protein EsxH 100% 68% ABL03785.1 [Mycobacterium ulcerans Agy99] type VII secretion protein EsxH 100% 71% WP_067013661.1 [Mycobacterium sp. 1081908.1] type VII secretion protein EsxH 100% 68% WP_063467440.1 [Mycobacterium kansasii] type VII secretion protein EsxH 100% 69% WP_067104747.1 [Mycobacterium sp. 852002- 40037_SCH5390672] type VII secretion protein EsxH 100% 70% WP_068138018.1 [Mycobacterium sp. E796] type VII secretion protein EsxH 100% 70% WP_068040952.1 [Mycobacterium sp. E2733] type VII secretion protein EsxH 100% 68% WP_066998456.1 [Mycobacterium sp. 1465703.0] type VII secretion protein EsxH 100% 71% WP_067116855.1 [Mycobacterium sp. 852002- 51057_SCH5723018] type VII secretion protein EsxH 100% 68% WP_067413879.1 [Mycobacterium sp. 1423905.2] type VII secretion protein EsxH 98% 68% WP_064281562.1 [Mycobacterium iranicum] low molecular weight protein 98% 72% CPR13219.1 antigen 7 Cfp7 [Mycobacteriumbohemicum DSM 44277] type VII secretion protein EsxH 100% 70% WP_066929865.1 [Mycobacterium sp. 1554424.7] type VII secretion protein EsxH 100% 71% WP_048893951.1 [Mycobacterium heckeshornense] low molecular weight protein 100% 67% ABK67570.1 antigen 7 Cfp7 [Mycobacteriumavium 104] hypothetical protein GuangZ0019_ 100% 67% EQM16518.1 4184 [Mycobacterium tuberculosis GuangZ0019] type VII secretion protein EsxH 100% 69% WP_067330420.1 [Mycobacterium sp. 1245111.1]
Claims (32)
1. A method for stimulating an immune response in a mammal comprising administering to a mammal in need thereof a fusion polypeptide comprising Mycobacterium leprae (M. leprae) antigens ML2028, ML2055, and ML2380, or M. leprae antigens having at least 90% amino acid sequence identity to ML2028, ML2055, and ML2380.
2. The method of claim 1 , wherein the fusion polypeptide further comprises M. leprae antigen ML2531 or an M. leprae antigen having at least 90% amino acid sequence identify to ML2531.
3. The method of claim 1 , further comprising administering to the mammal M. bovis BCG vaccine.
4. The method of claim 1 , wherein M. bovis BCG vaccine was previously administered to the mammal.
5. (canceled)
6. (canceled)
7. The method of claim 1 , wherein the mammal is a human healthy household contact of a human identified as being infected with M. leprae, the mammal has been infected by M. leprae, or the mammal exhibits signs or symptoms of infection by M. leprae.
8. (canceled)
9. (canceled)
10. The method of claim 1 , wherein from 1 ug to about 20 ug or from 1 ug to about 10 ug of the composition is administered to the mammal per dose.
11. (canceled)
12. (canceled)
13. A method for treating or reducing the time course of chemotherapy against a Mycobacterium leprae (M. leprae) infection in a mammal, the method comprising administering to a mammal having an M. leprae infection a fusion polypeptide comprising M. leprae antigens ML2028, ML2055, and ML2380, or M. leprae antigens having at least 90% amino acid sequence identity to ML2028, ML2055, and ML2380.
14. The method of claim 13 , wherein the fusion polypeptide further comprises M. leprae antigen ML2531 or an M. leprae antigen having at least 90% amino acid sequence identify to ML2531.
15. The method of claim 13 , further comprising administering to the mammal one or more chemotherapeutic agents.
16. The method of claim 15 , wherein the one or more chemotherapeutic agents comprise one or more agents selected from the group consisting of dapsone, rifampicin, clofazimine, ofloxacin, minocycline, gatifloxacin, linezolid, and PA 824.
17. The method of claim 15 , wherein: (i) the mammal is first administered one or more chemotherapeutic agents over a period of time and subsequently administered the composition, (ii) the mammal is first administered the composition and subsequently administered one or more chemotherapeutic agents over a period of time; (iii) administration of the one or more chemotherapeutic agents and the composition is concurrent.
18. (canceled)
19. (canceled)
20. The method of claim 13 , further comprising administering the composition to the mammal one or more subsequent times.
21. The method of claim 13 , further comprising administering to the mammal M. bovis BCG vaccine.
22. The method of claim 13 , wherein M. bovis BCG vaccine was previously administered to the mammal.
23-29. (canceled)
30. The method of claim 13 , wherein the mammal is infected with a multidrug resistant M. leprae.
31-33. (canceled)
34. The method of claim 13 , wherein the time course of chemotherapy is shortened to no more than about 3 months, about 5 months, or about 7 months.
35. (canceled)
36. The method of claim 13 , wherein from 1 ug to about 20 ug or from 1 ug to about 10 ug of the composition is administered to the mammal per dose.
37. The method of claim 13 , further comprising administering the immunostimulant GLA is administered to the mammal.
38. A method for detecting Mycobacterium leprae (M. leprae) infection in a biological sample, comprising:
(a) contacting a biological sample with a fusion polypeptide comprising M. leprae antigens ML2028, ML2055, and ML2380, or M. leprae antigens having at least 90% amino acid sequence identity to ML2028, ML2055, and ML2380; and
(b) detecting in the biological sample the presence of antibodies that bind to the fusion polypeptide, thereby detecting M. leprae infection in a biological sample.
39. The method of claim 38 , wherein the fusion polypeptide further comprises M. leprae antigen ML2531 or an M. leprae antigen having at least 90% amino acid sequence identify to ML2531.
40-46. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/190,934 US20230381292A1 (en) | 2016-09-16 | 2023-03-27 | Vaccines Comprising Mycobacterium Leprae Polypeptides for the Prevention, Treatment, and Diagnosis of Leprosy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662396074P | 2016-09-16 | 2016-09-16 | |
PCT/US2017/051824 WO2018053294A1 (en) | 2016-09-16 | 2017-09-15 | Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy |
US201916333596A | 2019-03-15 | 2019-03-15 | |
US18/190,934 US20230381292A1 (en) | 2016-09-16 | 2023-03-27 | Vaccines Comprising Mycobacterium Leprae Polypeptides for the Prevention, Treatment, and Diagnosis of Leprosy |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/051824 Continuation WO2018053294A1 (en) | 2016-09-16 | 2017-09-15 | Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy |
US16/333,596 Continuation US11801290B2 (en) | 2016-09-16 | 2017-09-15 | Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230381292A1 true US20230381292A1 (en) | 2023-11-30 |
Family
ID=60083421
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/333,596 Active 2040-06-01 US11801290B2 (en) | 2016-09-16 | 2017-09-15 | Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy |
US18/190,934 Pending US20230381292A1 (en) | 2016-09-16 | 2023-03-27 | Vaccines Comprising Mycobacterium Leprae Polypeptides for the Prevention, Treatment, and Diagnosis of Leprosy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/333,596 Active 2040-06-01 US11801290B2 (en) | 2016-09-16 | 2017-09-15 | Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy |
Country Status (6)
Country | Link |
---|---|
US (2) | US11801290B2 (en) |
BR (1) | BR112019004913B1 (en) |
CA (1) | CA3036218A1 (en) |
MX (2) | MX2019003035A (en) |
PH (1) | PH12019500496A1 (en) |
WO (1) | WO2018053294A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019003035A (en) | 2016-09-16 | 2019-09-13 | Infectious Disease Res Inst | Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy. |
CN109750054B (en) * | 2019-02-21 | 2021-07-02 | 华中农业大学 | Mycoplasma bovis protein gene MbovGdpp and application thereof |
US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
GB2605538A (en) | 2020-03-23 | 2022-10-05 | Hdt Bio Corp | Compositions and methods for delivery of RNA |
CA3173408A1 (en) | 2020-12-23 | 2022-06-30 | Access To Advanced Health Institute | Solanesol vaccine adjuvants and methods of preparing same |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4816566A (en) | 1983-06-01 | 1989-03-28 | Hoffmann-La Roche, Inc. | Polypeptides having interferon activity |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5350681A (en) | 1986-08-18 | 1994-09-27 | The Coca-Cola Company | Enzymatic membrane method for the synthesis and separation of peptides |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
DE69312487T2 (en) | 1992-05-18 | 1997-11-27 | Minnesota Mining & Mfg | DEVICE FOR TRANSMUCOSAL DELIVERY OF ACTIVE SUBSTANCES |
ES2143716T3 (en) | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | VACCINE COMPOSITION CONTAINING ADJUVANTS. |
US5359681A (en) | 1993-01-11 | 1994-10-25 | University Of Washington | Fiber optic sensor and methods and apparatus relating thereto |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US6583266B1 (en) * | 1993-08-19 | 2003-06-24 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to mycobacterium tuberculosis and leprae for diagnostics and therapeutics |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
DE69535905D1 (en) | 1994-07-15 | 2009-02-26 | Coley Pharm Group Inc | Immunomodulatory oligonucleotides |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
ATE292980T1 (en) | 1996-10-11 | 2005-04-15 | Univ California | IMMUNO-STIMULATING OLIGONUCLEOTIDE CONJUGATES |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6355257B1 (en) | 1997-05-08 | 2002-03-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
AU773204C (en) | 1998-08-10 | 2005-05-19 | Antigenics Llc | Compositions of CPG and saponin adjuvants and methods thereof |
PL203951B1 (en) | 1999-04-19 | 2009-11-30 | Smithkline Beecham Biolog | Vaccines |
US7472098B2 (en) | 2000-02-14 | 2008-12-30 | Ubs Financial Services, Inc. | System and method for execution of trades made pursuant to stock option and purchase plans |
CN1277843C (en) * | 2001-02-22 | 2006-10-04 | 巴斯德研究院 | Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
US7189522B2 (en) | 2005-03-11 | 2007-03-13 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
PL2484375T3 (en) | 2006-09-26 | 2018-09-28 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
HUP0700552A2 (en) | 2007-08-27 | 2009-03-30 | Janos Dr Feher | Method and composition inhibiting inflammation |
CN101969976A (en) | 2008-01-11 | 2011-02-09 | 美国政府健康与人类服务部秘书处 | Polypeptide vaccine and vaccination strategy against mycobacterium |
WO2011013097A2 (en) | 2009-07-29 | 2011-02-03 | Bernd Helmut Adam Rehm | Polymer particles and uses thereof |
WO2014009438A2 (en) * | 2012-07-10 | 2014-01-16 | Transgene Sa | Mycobacterial antigen vaccine |
MX2019003035A (en) | 2016-09-16 | 2019-09-13 | Infectious Disease Res Inst | Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy. |
-
2017
- 2017-09-15 MX MX2019003035A patent/MX2019003035A/en unknown
- 2017-09-15 BR BR112019004913-4A patent/BR112019004913B1/en active IP Right Grant
- 2017-09-15 CA CA3036218A patent/CA3036218A1/en active Pending
- 2017-09-15 US US16/333,596 patent/US11801290B2/en active Active
- 2017-09-15 WO PCT/US2017/051824 patent/WO2018053294A1/en active Application Filing
-
2019
- 2019-03-07 PH PH12019500496A patent/PH12019500496A1/en unknown
- 2019-03-15 MX MX2023004973A patent/MX2023004973A/en unknown
-
2023
- 2023-03-27 US US18/190,934 patent/US20230381292A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PH12019500496A1 (en) | 2019-05-27 |
US20200338180A1 (en) | 2020-10-29 |
US11801290B2 (en) | 2023-10-31 |
WO2018053294A1 (en) | 2018-03-22 |
BR112019004913A2 (en) | 2019-06-04 |
MX2019003035A (en) | 2019-09-13 |
CA3036218A1 (en) | 2018-03-22 |
MX2023004973A (en) | 2023-05-12 |
BR112019004913B1 (en) | 2022-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230381292A1 (en) | Vaccines Comprising Mycobacterium Leprae Polypeptides for the Prevention, Treatment, and Diagnosis of Leprosy | |
EP2300051B1 (en) | Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis | |
EP2637687B1 (en) | Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis | |
US8911746B2 (en) | Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis | |
EP2978447B1 (en) | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis | |
EP2291394B1 (en) | Fusion proteins and their use in the diagnosis and treatment of leishmaniasis | |
EP3199176A1 (en) | Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof | |
US20210253650A1 (en) | Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections | |
WO2012057904A1 (en) | Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity | |
EP2879701B1 (en) | Compositions and methods for treating an active mycobacterium tuberculosis infection | |
US20160158329A1 (en) | Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INFECTIOUS DISEASE RESEARCH INSTITUTE, WASHINGTON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:REED, STEVEN G.;DUTHIE, MALCOLM S.;SIGNING DATES FROM 20020313 TO 20031105;REEL/FRAME:063190/0334 Owner name: ACCESS TO ADVANCED HEALTH INSTITUTE, WASHINGTON Free format text: CHANGE OF NAME;ASSIGNOR:INFECTIOUS DISEASE RESEARCH INSTITUTE;REEL/FRAME:063190/0246 Effective date: 20220308 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |